Valuation models for Australian biotechnology companies by Jens, P
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Valuation Models for Australian Biotechnology Companies 
 
 
 
 
 
 
 
 
Paul Justin Jens 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
2007 
 
 
 
RMIT 
 
 i
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Valuation Models for Australian Biotechnology Companies 
 
 
 
A thesis submitted in fulfilment of the requirements for the degree of 
Doctorate in Philosophy 
 
 
 
 
 
 
Paul Justin Jens 
B.Eng. (hons), B.Com., M.Fin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
School of Economics Finance and Marketing 
Business Portfolio 
RMIT University 
March 2007 
 
 ii
DECLARATION 
I certify that except where due acknowledgement has been made, the work is that of the 
author alone; the work has not been submitted previously, in whole or in part, to qualify 
for any other academic award; the content of the thesis is the result of work which has 
been carried out since the official commencement date of the approved research 
program; and, any editorial work, paid or unpaid, carried out by a third party is 
acknowledged. 
 
 
 
 
 
Paul Justin Jens 
 
20 March 2007 
 iii
TABLE OF CONTENTS 
Declaration .............................................................................................................. ii 
Table of Contents......................................................................................................... iii 
List of Figures and Tables..........................................................................................viii 
List of Figures ....................................................................................................viii 
List of Tables ........................................................................................................ x 
Acknowledgements...................................................................................................... xi 
Abstract ...........................................................................................................xiii 
Chapter 1 Introduction ........................................................................................... 1 
1.1 Thesis Motivation...................................................................................... 1 
1.2 Research Aims and Questions.................................................................... 2 
1.3 Significance and Innovation....................................................................... 3 
1.4 Structure of This Thesis ............................................................................. 5 
Chapter 2 Literature Review .................................................................................. 7 
2.1 Introduction ............................................................................................... 7 
2.2 The Australian Biotechnology Sector......................................................... 8 
2.2.1 Evolution of a Sector........................................................................ 11 
2.2.1.1 International Biotechnology ......................................................... 11 
2.2.1.2 Australian Biotechnology............................................................. 13 
i Victoria............................................................................................ 15 
ii NSW................................................................................................ 16 
iii Queensland ...................................................................................... 16 
iv Western Australia ............................................................................ 17 
v South Australia ................................................................................ 18 
vi Australian Capital Territory ............................................................. 18 
vii Tasmania...................................................................................... 18 
2.2.2 Funding ........................................................................................... 19 
2.2.3 Government Support ........................................................................ 23 
2.2.4 Listed Companies ............................................................................ 24 
2.2.5 Australia as a Global Competitor ..................................................... 26 
2.3 IPOs ........................................................................................................ 27 
 iv
2.3.1 Information Asymmetry................................................................... 28 
2.3.2 Uncertainty ...................................................................................... 28 
2.3.3 Signalling Hypothesis ...................................................................... 30 
2.3.4 Entrepreneurial Wealth .................................................................... 30 
2.3.5 Sentiment......................................................................................... 31 
2.3.6 Australian Observations ................................................................... 32 
2.3.7 IPO Underpricing in the Biotechnology Context .............................. 34 
2.4 Valuation................................................................................................. 36 
2.4.1 Discounted Cash Flow ..................................................................... 37 
2.4.1.1 Methodological Summary ............................................................ 38 
2.4.1.2 Limitations................................................................................... 38 
2.4.1.3 Discounted Cash Flow Methodological Extensions ...................... 39 
i Non-constant discount rate............................................................... 40 
ii Probability weighted decision tree.................................................... 40 
iii Monte Carlo scenario testing............................................................ 41 
2.4.2 Real Options Valuation .................................................................... 41 
2.4.2.1 Methodological Summary ............................................................ 43 
i Binomial Decision Tree ................................................................... 43 
ii Binomial Lattice .............................................................................. 43 
iii Black Scholes .................................................................................. 44 
2.4.2.2 Limitations................................................................................... 44 
2.5 Conclusion .............................................................................................. 45 
Chapter 3 Methodology ....................................................................................... 47 
3.1 Introduction ............................................................................................. 47 
3.2 Research Aims and Questions.................................................................. 47 
3.3 Research Design ...................................................................................... 48 
3.3.1 Multi-Method Research ................................................................... 48 
3.3.2 Research Structure ........................................................................... 50 
3.4 Qualitative Sector Investigation ............................................................... 52 
3.4.1 Interview schedule ........................................................................... 52 
3.4.2 Ethical Considerations ..................................................................... 53 
3.4.3 Invitation process & participant information .................................... 54 
3.4.4 Data Analysis................................................................................... 55 
3.5 Quantitative Review of Initial Public Offerings ....................................... 58 
3.6 Quantitative Review of Valuation Methodologies .................................... 59 
 v
3.7 Conclusion .............................................................................................. 61 
Chapter 4 The Australian Experience in Practice.................................................. 63 
4.1 Introduction ............................................................................................. 63 
4.2 Capital Raising and Availability .............................................................. 64 
4.2.1 Pre IPO............................................................................................ 65 
4.2.1.1 Start-up phase .............................................................................. 65 
4.2.1.2 Subsequent funding – Venture Capital.......................................... 67 
4.2.2 IPO .................................................................................................. 69 
4.2.3 Life after IPO................................................................................... 70 
4.2.3.1 News Flow................................................................................... 70 
4.2.3.2 Secondary Market ........................................................................ 71 
4.2.3.3 The Investment Community ......................................................... 71 
i Superannuation Investment .............................................................. 73 
ii Institutional Investors....................................................................... 73 
4.2.4 An International Comparison ........................................................... 74 
4.2.4.1 Foreign Listings ........................................................................... 75 
4.3 Business Model ....................................................................................... 76 
4.3.1 The Biotechnology Value Chain ...................................................... 77 
4.3.1.1 Evolution ..................................................................................... 79 
i Expansion through Specialisation..................................................... 80 
ii Business Evolution and Value Capture............................................. 81 
4.3.1.2 Sustainability ............................................................................... 83 
4.3.2 A Response to the Funding Environment ......................................... 84 
4.3.2.1 Product Focused Companies ........................................................ 86 
4.3.2.2 Technology Platform Companies ................................................. 87 
4.3.2.3 Virtual Companies ....................................................................... 88 
4.3.3 Management .................................................................................... 89 
4.3.4 External Relationships ..................................................................... 91 
4.3.4.1 Academia ..................................................................................... 92 
4.3.4.2 Big Pharma .................................................................................. 94 
4.4 Valuation................................................................................................. 96 
4.4.1 Current Application ......................................................................... 97 
4.4.1.1 Drivers of Value......................................................................... 100 
4.4.1.2 Assessment of Opportunities ...................................................... 101 
4.5 Australia as a Global Competitor: Challenges and Opportunities ........... 101 
 vi
4.6 Conclusion ............................................................................................ 105 
Chapter 5 Money Left and Underpricing in Australian Biotechnology IPOs....... 108 
5.1 Introduction ........................................................................................... 108 
5.2 Base Models .......................................................................................... 110 
5.2.1 Data ............................................................................................... 110 
5.2.2 Results ........................................................................................... 114 
5.2.2.1 Money Left Model ..................................................................... 117 
5.2.2.2 Underpricing Model................................................................... 120 
5.2.2.3 Log Capital Raised Model.......................................................... 120 
5.2.3 Discussion ..................................................................................... 122 
5.3 Sentiment Augmentation ....................................................................... 124 
5.3.1 Data ............................................................................................... 125 
5.3.2 Results and Discussion................................................................... 127 
5.4 Conclusion ............................................................................................ 129 
Chapter 6 Critical Evaluation of Contemporary Valuation Methodologies.......... 131 
6.1 Introduction ........................................................................................... 131 
6.2 Alternative Valuation Methods .............................................................. 132 
6.2.1 Discounted Cash Flow ................................................................... 132 
6.2.2 Expected Discounted Cash Flow .................................................... 133 
6.2.3 Binomial Option Valuation ............................................................ 137 
6.2.4 Binomial Lattice Option Valuation................................................. 140 
6.3 Model input assumptions ....................................................................... 143 
6.3.1 Population Sampling Distributions ................................................. 143 
6.3.2 Inputs Range Specification............................................................. 145 
6.3.2.1 Research and Development Costs............................................... 146 
6.3.2.2 Research and Development Time ............................................... 147 
6.3.2.3 Research and Development Success Probabilities....................... 148 
6.3.2.4 Salvage Values........................................................................... 148 
6.3.2.5 Commercialisation Cash flows ................................................... 149 
6.3.2.6 Discount Rate............................................................................. 151 
6.3.2.7 The Risk Free Rate and Inflation................................................ 152 
6.4 Valuation and the Product Development Cycle ...................................... 152 
6.4.1 Scenario Analysis Prior to Commencement of Clinical Trials ........ 155 
6.4.2 Scenario Analysis Prior to Commencement of Stage 2 Clinical Trials ..
 ...................................................................................................... 157 
 vii
6.4.3 Scenario Analysis Prior to Commencement of Stage 3 Clinical Trials ..
 ...................................................................................................... 159 
6.4.4 Scenario Analysis Prior to Regulatory Registration ........................ 160 
6.4.5 Value Accretion at the 25th Percentile ............................................ 162 
6.5 Valuation Model Sensitivities ................................................................ 162 
6.5.1 Development Time......................................................................... 164 
6.5.2 Development Costs ........................................................................ 172 
6.5.3 Salvage Values .............................................................................. 178 
6.5.4 Commercialisation Cash Flows ...................................................... 185 
6.5.5 Discount Rate ................................................................................ 194 
6.5.6 Development Risk.......................................................................... 198 
6.6 Valuation Methodology Choice Implications ......................................... 204 
6.6.1 Management .................................................................................. 204 
6.6.2 Investors ........................................................................................ 205 
6.7 Conclusion ............................................................................................ 206 
Chapter 7 Conclusion......................................................................................... 209 
7.1 Introduction ........................................................................................... 209 
7.2 Summary of Thesis ................................................................................ 209 
7.3 Key Contributions of Thesis .................................................................. 211 
7.4 Directions For Future Research.............................................................. 213 
References .......................................................................................................... 215 
Appendices  .......................................................................................................... 225 
 
 
 
 viii
LIST OF FIGURES AND TABLES 
LIST OF FIGURES 
Figure 2-1 Australian Biotechnology Companies by Sub-sector .................................... 9 
Figure 2-2 International Biotechnology Industry Comparison ..................................... 12 
Figure 2-3 International Comparison of Biotechnology Market Capitalisations ........... 13 
Figure 2-4 Asia Pacific Biotechnology Industry Comparison ...................................... 14 
Figure 2-5 Number of Publicly Listed and Unlisted Biotechnology Firms by State...... 15 
Figure 2-6 Australia vs. US Biotechnology Life Cycle Funding Comparison .............. 20 
Figure 2-7 Allocated and Unallocated Australian Venture Capital............................... 21 
Figure 2-8 Allocation of Australian VC funding by Investee Activity ......................... 22 
Figure 2-9 Benchmarking Australia's International Pharmaceutical Investment ........... 23 
Figure 2-10 State by State Distribution of Biotechnology Related Grants for 2006...... 24 
Figure 2-11 Weekly ASX All Ordinaries and Health Index levels ............................... 25 
Figure 3-1 Research Staging & Focus ......................................................................... 50 
Figure 3-2 Research Structure..................................................................................... 51 
Figure 3-3 NVivo Coding Theme Tree........................................................................ 57 
Figure 4-1 Biotechnology Value Chain & Development Success Rates....................... 77 
Figure 4-2 Decreasing Pharmaceutical R&D Productivity ........................................... 82 
Figure 4-3 Public Sector Funding Initiatives to the Australian Biotechnology Industry93 
Figure 4-4 The capital raising challenge to industry sustainability............................. 103 
Figure 4-5 The Virtuous Circle ................................................................................. 104 
Figure 6-1 eDCF Project Example Illustration of Cash Flows ................................... 134 
Figure 6-2 Typical Drug Development Decision Tree ............................................... 135 
Figure 6-3 Drug Development and Commercialisation Decision Tree ....................... 135 
Figure 6-4 Simple Real Option Example ................................................................... 138 
Figure 6-5 Binomial Lattice Valuation Framework ................................................... 141 
Figure 6-6 Comparison of BetaPERT, Normal and Triangular Distribution Probability 
Mass Functions ................................................................................................ 145 
Figure 6-7 Revenue Forecast as a % of Peak Annual Revenue Estimates................... 150 
Figure 6-8 Valuation at Commencement of Phase 1 Clinical Trials – Probability Mass 
Function Comparison between Alternative Valuation Methodologies............... 155 
 ix
Figure 6-9 Valuation at Commencement of Phase 2 Clinical Trials – Probability Mass 
Function Comparison between Alternative Valuation Methodologies............... 158 
Figure 6-10 Valuation at Commencement of Phase 3 Clinical Trials – Probability Mass 
Function Comparison between Alternative Valuation Methodologies............... 159 
Figure 6-11 Valuation Prior to Product Registration – Probability Mass Function 
Comparison between Alternative Valuation Methodologies ............................. 161 
Figure 6-12 Valuation Standard Deviations for Unrestricted Models ......................... 163 
Figure 6-13 Valuation Standard Deviations for Restricted Development Time Model165 
Figure 6-14 δV/δX for X = Phase 1 Development Time ............................................ 168 
Figure 6-15 δV/δX for X = Phase 2 Development Time ............................................ 169 
Figure 6-16 δV/δX for X = Phase 3 Development Time ............................................ 170 
Figure 6-17 δV/δX for X = Product Registration Assessment Time........................... 171 
Figure 6-18 Valuation Standard Deviations for Restricted Development Cost Model 172 
Figure 6-19 δV/δX for X = Phase 1 Development Cost ............................................. 174 
Figure 6-20 δV/δX for X = Phase 2 Development Cost ............................................. 175 
Figure 6-21 δV/δX for X = Phase 3 Development Cost ............................................. 176 
Figure 6-22 δV/δX for X = Regulatory Assessment Costs......................................... 177 
Figure 6-23 Valuation Standard Deviations for Restricted Salvage Value Model....... 179 
Figure 6-24 δV/δX for X = Phase 1 Failure Salvage Value........................................ 181 
Figure 6-25 δV/δX for X = Phase 2 Failure Salvage Value........................................ 182 
Figure 6-26 δV/δX for X = Phase 3 Failure Salvage Value........................................ 183 
Figure 6-27 δV/δX for X = Registration Rejection Salvage Value ............................. 184 
Figure 6-28 Valuation Standard Deviations for Restricted Commercialisation Cash 
flows Model..................................................................................................... 186 
Figure 6-29 δV/δX for X = Probability of “Average” Sales ....................................... 189 
Figure 6-30 δV/δX for X = “Average” Revenue Expectation..................................... 190 
Figure 6-31 δV/δX for X = “Non-Average” Revenue Expectation............................. 191 
Figure 6-32 δV/δX for X = Post Registration R&D Time .......................................... 192 
Figure 6-33 δV/δX for X = Post Registration R&D Expenditure ............................... 193 
Figure 6-34 Valuation Standard Deviations for Restricted Discount Rate Model....... 194 
Figure 6-35 δV/δX for X = Development Stage Discount Rate.................................. 196 
Figure 6-36 δV/δX for X = Commercialisation Stage Discount Rate ......................... 197 
Figure 6-37 Valuation Standard Deviations for Restricted Development Risk Model 198 
Figure 6-38 δV/δX for X = Phase 1 Success Probability............................................ 200 
Figure 6-39 δV/δX for X = Phase 2 Success Probability............................................ 201 
 x
Figure 6-40 δV/δX for X = Phase 3 Success Probability............................................ 202 
Figure 6-41 δV/δX for X = Regulatory Registration Success Probability................... 203 
 
LIST OF TABLES 
Table 2-1 Biotechnology Sub-Sector Definitions .......................................................... 9 
Table 2-2 Drug Development Process Description ...................................................... 11 
Table 2-3 Victoria's Biotechnology Precincts .............................................................. 16 
Table 2-4 NSW Biotechnology Precincts .................................................................... 16 
Table 2-5 Queensland Biotechnology Precincts........................................................... 17 
Table 2-6 South Australian Biotechnology Precincts................................................... 18 
Table 3-1 Qualitative Research Themes ...................................................................... 53 
Table 3-2 Valuation Model Inputs............................................................................... 61 
Table 4-1 Benefits of Diversified Development Portfolio - Probability of Market 
Launch............................................................................................................... 78 
Table 5-1 Set of Potential Independent Variables ...................................................... 112 
Table 5-2 Descriptive Statistics................................................................................. 114 
Table 5-3 Regression Results .................................................................................... 116 
Table 5-4 Media Coverage Descriptive Statistics ...................................................... 126 
Table 5-5 Sentiment Augmented Models .................................................................. 129 
Table 6-1 Model Inputs and Population Descriptors .................................................. 146 
Table 6-2 Commercialisation Cash flow Cost Assumptions ...................................... 149 
Table 6-3 Risk Free Rate Source Data....................................................................... 152 
Table 6-4 Inflation Forecast Source Data .................................................................. 152 
Table 6-5 Fixed Input Expected Valuations............................................................... 153 
Table 6-6 Expected Value Accretion between Development Stages .......................... 154 
Table 6-7 Valuation Comparison at Commencement of Phase 1 Clinical Trials......... 157 
Table 6-8 Valuation Comparison at Commencement of Phase 2 Clinical Trials......... 159 
Table 6-9 Valuation Comparison at Commencement of Phase 3 Clinical Trials......... 160 
Table 6-10 Valuation at Commencement of New Drug Application .......................... 161 
Table 6-11 Value Accretion at the 25th Percentile between Development Stages ....... 162 
 
 xi
ACKNOWLEDGEMENTS 
I don’t believe many PhD’s would commence without an aspect of naive optimism. 
Whilst I was certainly naïve, the support I received from my supervisors, wife and 
family went far beyond what I could have optimistically hoped for. 
 
My PhD journey is one that would not have ended in submission without the support 
and guidance of my three supervisors Roslyn Russell, Gina Nicoletti and Robert 
Brooks. To you all I am more grateful than I can express, so often through the process 
your counsel would convert a seemingly unsurmountable mountain into a mere speed 
hump. I was so fortunate to have a supervision team with such an extensive skill base 
and able to work together so seamlessly.  
 
To my wife, thank you for your unending generosity of spirit. Your support every step 
of the way – even when the finished date seemed permanently stuck on “about another 6 
months” – meant I had no choice but to finish. To my family and in-laws, thank you for 
your support and understanding. The consistent support I have received from you all 
over my life means that it longer surprises me however that does not make it any less 
significant, in fact the opposite. 
 
To all the RMIT business staff who make post graduate research study possible – thank 
you for putting up with complexities of large research student group. To my research 
colleagues, thank you for the many experiences in the research lab and beyond. The 
quality of the experience is so often about the people and I thank you making the 
business research laboratory a positive space for study and friendship.  
 
To the management of BioDiem, the industry sponsor of this research, thank you for 
your support, both financial and in kind which made this study possible. Richard 
Wadley and Bob Borland especially, thanks for your feedback and input, particularly in 
the formative period. 
 
 xii
Finally, to the study participants, thank you for making time in your busy lives to give 
the study richness and for illustrating the strength of the Australian biotechnology 
industry. 
 xiii
ABSTRACT 
Biotechnology generated solutions have been hailed as potential cures to many of the 
problems facing the world today. New therapeutics will eradicate disease, new 
agricultural products will solve food shortages, and industrial application will improve 
productivity with reduced environmental impact.  
 
Despite the much anticipated benefits of biotechnology, the industry faces significant 
challenges that must be overcome in the coming decades. Biotechnology is an 
inherently complex field with a high degree of uncertainty and associated risks. In 
addition to the risk associated with project development and delivery, businesses 
looking to extract an economic return from the provision of biotechnology products and 
services face significant financial risk. This is exacerbated by the long lead times in 
biotechnology product development and the expensive nature of research and 
development. 
 
This thesis looks investigates the multi faceted problem of biotechnology valuation in 
Australia using a multi method approach designed to provide greater insight into the 
valuation challenges facing the industry and identify key value drivers. The approach 
incorporates a broad qualitative investigation, complimented by more focused 
quantitative studies into specific valuation issues surrounding IPO and project valuation. 
 
Australian biotechnology firms face a significant challenge to raise sufficient capital in 
order to remain internationally competitive. The current industry structure and funding 
mechanisms encourage creation of small firms with narrow pipelines, exacerbating the 
risk of company failure and acting as an impediment to sustainability and, therefore, 
investment in the sector. Despite the challenges facing the Australian biotechnology 
industry, the nation possesses a competitive advantage in the strength of local science 
which, if fully leveraged, should see the development of an internationally competitive 
industry. Through improved funding mechanisms which encourage the creation of 
sustainable business models, increased investor participation in the industry should see 
 xiv
a greater portion of the value generated through biotechnology retained by local 
participants.  
 
An IPO is likely the largest single capital raising in a company’s history. A quantitative 
investigation into the factors influencing the amount of underpricing and money left on 
the table for Australian biotechnology IPOs found that the amount of money left on the 
table was more critical than the level of underpricing. Additionally the impact of market 
sentiment on biotechnology IPOs was investigated and increased media coverage in the 
lead up to IPO was found to be positively related to the amount of money left on the 
table.  
 
Using project valuation models, the drivers of value over the life of a typical 
biotechnology project were identified. Value in biotechnology firms is driven by the 
commercial viability of the products under development. Managers and investors should 
be continuously focused on the likely commercial outcomes from the products in 
development. Development costs and times are also key drivers of value and the ability 
of management to control these elements is crucial.  
 
Analysis of project valuations using a traditional DCF model found value estimates 
exhibited a greater level of uncertainty than those calculated using the more 
contemporary methods of decision tree analysis (eDCF and binomial real options) and 
binomial lattices. Additionally, incorporation of management flexibility into valuation 
assessment using real options techniques increased the perceived value of 
biotechnology projects. The value of management flexibility was found to be most 
relevant for early stage projects where the option to abandon was found to greatly 
influence values. 
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CHAPTER 1 INTRODUCTION 
1.1 THESIS MOTIVATION 
Broadly speaking, biotechnology is the term used to describe the application of 
technology to biological processes. Whilst this broad definition includes such practices 
as the ancient art of brewing beer, modern application of the term is used more 
specifically to describe the use of modern technology for biological application. This 
thesis focuses on the area of biotechnology within the development of new human 
therapeutics, within which around 50% of all Australian biotechnology firms operate.   
 
Biotechnology generated solutions have been hailed as potential cures to many of the 
problems facing the world today. New therapeutics will eradicate disease, new 
agricultural products will solve food shortages, and industrial application will improve 
productivity with reduced environmental impact. 
 
Despite the much lauded benefits of biotechnology, the industry faces significant 
challenges that must be overcome in the coming decades. Biotechnology is an 
inherently complex field with a high degree of uncertainty and associated risks. In 
addition to the risk associated with project development and delivery, business looking 
to extract an economic return from the provision of biotechnology products and services 
face significant financial risk. This is exacerbated by the long lead times in 
biotechnology product development and the expensive nature of research and 
development (R&D). 
 
Many biotechnology firms have difficulty in raising sufficient capital to adequately fund 
their R&D programs often forced into effective sale of a portion of their intellectual 
property (IP) in order to finance development through to completion. The resulting loss 
of ownership reduces the return to the initial biotechnology firm, acting as a 
disincentive to further investment. If investment risk in biotechnology ventures could be 
reduced, the improved risk profile would encourage additional investment in the 
industry. 
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For Australia, biotechnology will form an increasingly important component of our 
financial, environment and social wellbeing. With limited natural resources and 
uncompetitive unskilled labour costs relative to our Asian neighbours, the ability to 
leverage off our competitive advantages such as the strength of our academic and 
research skill base is axiomatic to continued economic prosperity.  
Australia’s industrial competitiveness, and hence our standard of living, will be strongly 
influenced by whether we can grasp the opportunities presented by biotechnology, and 
underpinned by the knowledge and skills of our researchers (Australian Government 
2000, p. 9)  
The Australian biotechnology industry is faced with particular challenges and 
opportunities. The relative scale of the domestic market in comparison with the larger 
international competitors in what is a global market creates particular difficulties in 
raising sufficient investment capital to be internationally competitive. Greater insight 
into the value drivers for Australian biotechnology investments will help reduce 
investment uncertainty in the industry, facilitating increased capital flows to the sector 
and improving the long term prospects of the sector and hence the Australian economy. 
1.2 RESEARCH AIMS AND QUESTIONS 
The ultimate aim of this research is to investigate the Australian biotechnology sector 
and its ability to compete internationally given the country’s tangible and intellectual 
resources. This thesis fulfils this aim through the investigation of the following primary 
research question: 
• What are the key drivers of value for Australian biotechnology firms? 
 
In addressing the primary question, the following secondary questions are also 
addressed: 
• What are the challenges and opportunities for Australian biotechnology firms? 
• What factors endogenous and exogenous to the firm affect the amount of capital 
raised by Australian biotechnology companies through IPOs? 
• How can Australian biotechnology firms signal their fair value to the investing 
community? 
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• What is the appropriate methodology for valuation of biotechnology 
investments? 
1.3 SIGNIFICANCE AND INNOVATION 
The primary contribution of this thesis is in providing a greater understanding of the 
unique characteristics of the Australian biotechnology industry and the valuation 
challenges therein. The research is a multi-method design which provides insight into 
the multidimensional problem regarding the challenges facing the biotechnology 
industry. In the face of investment uncertainty, Australian companies have particular 
difficulties raising sufficient capital to be competitive in an international market. This 
thesis examines the impact on the Australian industry of the funding scarcity then goes 
on to investigate the key value drivers of Australian biotechnology investments.  
 
The multi-method approach utilises three discreet research methodologies which 
synergistically combine to provide greater insight. The initial phase consisted of 
interviews of senior management1 from eight publicly listed Australian biotechnology 
firms. This component of the research provided context for subsequent stages and 
provided data in support of the literature.  
 
A particularly poignant issue is the industry-wide challenge in raising sufficient capital 
to develop proprietary intellectual property and remain competitive in an international 
market. Additionally, the high degree of uncertainty regarding the valuation of 
biotechnology intellectual property, both from a capital budgeting and investment 
assessment perspective, is a significant barrier to capital raising within the industry. 
 
One of the symptoms of the lack of development funding available to Australian 
biotechnology companies is the relative immaturity at which Australian firms choose to 
raise capital from the public markets via an initial public offering (IPO). As a result the 
sub-sector of publicly listed Australian biotechnology companies are typified by their 
narrow and immature product pipelines with small market capitalisations relative to 
equivalent international markets, particularly the world leading US market. As a result 
of the lack of venture capital investment in the Australian biotechnology market, the 
                                                
1 Participants were spread between chief executive officers, chief financial officers and chief scientific 
officers. 
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public markets have acted as a proxy venture capital provider. An IPO is one of the 
most significant capital raisings in a company’s life and for an Australian biotechnology 
firm this is particularly so as the long lead times and large cost of biotechnology product 
development place firms at risk of failure due to capital constraints.  
 
Underpricing is the term used to describe the consistently observed phenomenon 
whereby the shares of a newly issued firm close at a price higher than the issue price at 
the end of the first day of trading. This premium between market valuation and issue 
price is valuable capital which the issuing firm forgoes and is effectively money “left on 
the table” to the benefit of investors in the offer. The capital constraints of the 
Australian biotechnology industry imply that the issue of underpricing is of critical 
importance to the sector. This thesis provides one of the first examinations of 
underpricing of Australian biotechnology IPOs and the relationship between prospectus 
information, market sentiment, underpricing and money left on the table.  
 
Greater uncertainty surrounding firm valuation has been shown to be associated with 
greater degrees of underpricing. Biotechnology investment is inherently uncertain due 
to the long lead times, large costs and high risks associated with product development. 
Additionally the global nature of competition within the sector, technological risk and 
commercial uncertainties render investments in biotechnology related projects 
particularly uncertain. If greater insight into the valuation of biotechnology projects 
were available, investment uncertainty could be reduced. An improvement in the risk 
profile of the Australian industry would encourage increased investment in the sector 
improving international competitiveness. Furthermore, additional capital would provide 
funds for firms to develop more mature product development portfolios prior to listing. 
A more mature product portfolio combined with reduced valuation uncertainty would 
serve to decrease investor uncertainty surrounding biotechnology IPOs, enabling the 
issuing firm to raise more capital at IPO, with reduced underpricing.  
 
The final research component examines traditional and contemporary valuation models 
and their application to biotechnology assessment. These models provide an 
understanding of the value drivers for biotechnology investment and provide a nexus 
between the first two components of the research design through the examination of 
endogenous project factors on valuation and uncertainty. Managers of biotechnology 
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projects can apply this information to optimise the value increments from project 
investment and, similarly, investors can reduce investment uncertainty through the 
application of the developed models. 
1.4 STRUCTURE OF THIS THESIS 
This thesis consists of seven chapters including this introduction.  
 
Chapter 2 provides a summary of the relevant literature and is comprised of three 
components. The first section provides an overview of the Australian biotechnology 
sector and a comparison with the major international competitors. Australia possesses a 
competitive advantage in the strength of our research however this is not fully exploited 
due to the funding challenge. The second section reviews the literature relating to IPO 
underpricing, commencing with a general discussion of the phenomenon before moving 
to Australian and biotechnology specific observations. The final component explores 
the relative strengths and weaknesses of traditional and contemporary valuation tools. 
  
Chapter 3 details the research methodology outlining the multi-method approach. This 
chapter describes the research design and illustrates the sequential link between the 
initial broad qualitative study into the challenges and opportunities facing the industry 
and subsequent more focused quantitative analysis of IPO underpricing and valuation 
issues. 
 
Chapter 4 is the first of three results and discussion chapters. This chapter presents the 
results and discussion from the qualitative investigation into the challenges and 
opportunities facing the Australian biotechnology industry. This chapter is presented as 
a summary discussion of the semi-structured interviews conducted with senior 
management from eight listed Australian biotechnology companies. The discussion 
highlights key points from the interviews including the common themes which emerged 
as well as contrasting viewpoints. The discussion is linked back to the literature and 
concludes with some recommendations on the way forward for the domestic industry. 
 
Chapter 5 presents the results and discussion from the quantitative analysis examining 
underpricing and money left on the table in Australian biotechnology IPOs. The 
analysis is segmented into two components. Initially a broad model was built based on 
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the existing literature to examine the relationship between factors endogenous and 
exogenous to the firm on underpricing and money left on the table. The cross sectional 
econometric model was analysed in an OLS framework and provided the base for the 
second component. The second component extends the initial model to provide an 
additional econometric analysis examining in greater detail the influence of sentiment 
on underpricing and money left on the table. 
 
Chapter 6 provides the final results and discussion chapter and details four valuation 
models for a typical biotechnology project. This chapter details the construction method 
for each model and describes the application of Monte Carlo scenario testing across all 
models to measure the relative influence of the input variables and the differences in 
valuation uncertainty. The chapter discusses the valuation drivers for biotechnology 
projects and the implications for management and investors in the industry.  
 
Chapter 7 is the final chapter of this thesis and provides concluding remarks. This 
chapter provides a discussion which highlights the nexus between the three discrete 
research components and the implications of this piece of research. To finish, areas for 
future research are proposed. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 INTRODUCTION 
This chapter provides background and context to this study and is divided into three key 
areas pertaining to the Australian biotechnology industry. The first provides information 
regarding the evolution and performance of the industry in a global environment, the 
second examines the issue of capital raising through an IPO and the factors that 
influence the success of the capital raising, and the third reviews the literature relating 
to valuation and capital budgeting with a particular focus on assessment of research and 
development. The chapter finishes with some concluding remarks. 
 
The first component of this chapter provides an overview of the Australian 
biotechnology sector which provides context for the remainder of the study. This 
discussion identifies the opportunities and challenges facing the Australian 
biotechnology industry and provides focus for the remaining components of the chapter.  
 
One of the primary challenges facing the local industry is a lack of private capital for 
early stage commercialisation funds available to the sector. As a result of the lack of 
private funds many Australian biotechnology firms are forced to raise capital via an IPO 
at an early stage in their product and business development cycle. Given the expensive 
nature of biotechnology R&D, a successful IPO is a critical contributor to the success of 
a listed biotechnology company. The second stage of this chapter investigates factors 
contributing to the success of Australian biotechnology IPOs and provides insight into 
the key value drivers for this important capital raising.  
 
The third component of this literature review extends on the IPO valuation 
investigation. Valuation assessments assist in demystifying the uncertainty surrounding 
investment decisions. Through more appropriate valuation tools the uncertainty of 
biotechnology investment can be reduced in turn encouraging greater investment in the 
sector. The literature relating to capital budgeting and valuation is reviewed with 
emphasis on the assessment of (R&D).  
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2.2 THE AUSTRALIAN BIOTECHNOLOGY SECTOR 
The term “biotechnology” is derived through the combination of the words “biology” 
and “technology” thus broadly speaking the term biotechnology can apply to any 
application of technology to biological processes. Many formal definitions for 
biotechnology exist. The United Nations convention on Biological Diversity offers the 
broad definition: 
"Biotechnology means any technological application that uses biological systems, living 
organisms, or derivatives thereof, to make or modify products or processes for specific 
use.” (Convention on Biological Diversity 1992) 
In the report titled “Global Partners: Australian Biotechnology 2004” (Department of 
Industry Tourism and Resources, Advance Consulting & Evaluation and Aoris Nova 
2004) the Australian government adopted the OECD definition: 
“The application of science and technology to living organisms as well as parts, 
products and models thereof, to alter living or non-living materials for the production of 
goods and services.” (OECD 2005) 
More recently the Australian government makes a broader definition, expanding the 
inference on technology to include all industrial processes:  
“Biotechnology … describes the use of biology in industrial processes such as 
agriculture, brewing and drug development.” (Biotechnology Australia 2006) 
These broad biotechnology definitions capture the diversity of the Australian 
biotechnology sector which is made up of entities operating across different fields, all 
presenting unique challenges and opportunities. The complexity and diversity of sub-
sectors in the biotechnology industry has created a number of differing segmentations 
and associated definitions. Table 2-1 shows seven sub-sectors of biotechnology as 
adopted by Hopper and Thorburn (2006). 
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Table 2-1 Biotechnology Sub-Sector Definitions 
Biotechnology Sub-sector Definition 
Human Therapeutics Development of biotech-derived drugs to treat or prevent 
disease, and in vitro fertilisation 
Agriculture Development and delivery of products and services aimed 
at the agricultural sector. This may include promoting plant 
and animal growth, disease identification and prevention, or 
breeding programs 
Diagnostics Development of products and tests aimed at identifying and 
diagnosing human disease. Biotechnology-based 
diagnostics include nucleic acid and monoclonal antibody-
based tests, and may also include hybridisation and 
amplification of the target sequence. Methods in use 
include enzyme-linked immunoassays (ELISA), polymerase 
chain reaction (PCR), Random Amplification of Polymorphic 
DNA (RAPD), microarrays and amplified fragment-length 
polymorphism (AFLP).  These may be supplemented by 
other technologies including fluorescence, 
nanotechnologies, filter techniques, automation and fluid 
flow management 
Suppliers Suppliers of molecular biologicals, such as monoclonal 
antibodies, diagnostic reagents and gene chips 
Chemical, Environmental, Other Use of biotech in mining (bioleaching), chemical 
development (including molecular farming) and 
environment (including pesticide development and 
bioremediation). 
Food and or Beverage development of new foods (including functional foods) and 
food additives 
Bioinformatics Application of sciences and information technologies to the 
organisation, management, mining and use of life-science 
information. 
 
Figure 2-1 shows the proportion of firms within the Australian biotechnology sector 
operating within each of the identified sub-sectors. 
 
Figure 2-1 Australian Biotechnology Companies by Sub-sector (Hopper and Thorburn 2006) 
48%
16%
14%
9%
7%
3% 3%
Human Therapeutics
Agriculture
Diagnostics
Suppliers
Chemical, Environmental, Other
Food and/or Beverages
Bioinformatics
 
Chapter 2 – Literature Review 
 10
 
The biotechnology sector is dominated by firms whose research focuses on human 
health challenges2 comprising just under two thirds of all biotechnology companies in 
Australia (Hopper and Thorburn 2006). The “human therapeutics” sub-sector makes up 
around half of all biotechnology companies in Australia and operates under unique 
regulatory governance. The diversity in challenges and regulatory requirements between 
firms in different biotechnology sub-sectors means that business models and value 
drivers vary greatly from sub-sector to sub-sector. This thesis focuses on valuations 
within the human health sub-sector. This sub-sector was chosen as the majority of 
biotechnology firms fall within this category and these firms have a unique discovery 
process and regulatory environment which allows particular application of 
contemporary valuation methodologies. 
 
A description of each of the stages in the development process for human therapeutics is 
shown in Table 2-2. The manner in which the process is comprised of a series of 
discrete components allows a biotechnology project to be modelled as a series of 
decision gates, facilitating the application of contemporary financial option valuation 
theory to assess project value. 
 
                                                
2 Human health research includes both disease identification through diagnostics and disease treatment 
though human therapeutics. 
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Table 2-2 Drug Development Process Description (Allergan; US Food and Drug Administration) 
Development Stage Description 
Discovery Comprehensive study of all publicly available data 
relating to the chemical entity or target therapeutic area. 
This review includes review of chemical and biological 
data and patent coverage. 
Pre-Clinical Research Initial studies to show that the drug is reasonably safe 
for the purposes of clinical trials. Data in this stage is 
generated through in vitro and in vivo laboratory animal 
testing. 
IND Investigational New Drug application filed with the 
regulator (the FDA in the US). Regulatory approval 
allows the commencement of clinical trials in humans. 
Clinical Trials – Phase 1 Small scale testing on around twenty to eighty (usually) 
healthy humans to determine the toxicity and the 
method of action. 
Clinical Trials – Phase 2 Small scale testing on around two hundred humans 
afflicted with the target disease to gain preliminary data 
regarding efficacy and further data regarding toxicity 
and side effects.  
Clinical Trials – Phase 3 Larger scale trials on humans to gather more data on 
efficacy and side effects to build a risk benefit profile for 
the drug. 
NDA & Regulatory Review New Drug Application (NDA) to the regulator for 
assessment. All relevant data gathered during clinical 
and pre-clinical trials are submitted to the regulator for 
approval. 
Product Launch & Phase 4 Trials Once approved the drug can be launched on the 
market. For some medicines the FDA may require 
additional data to monitor the long term effects of the 
drug. 
 
2.2.1 Evolution of a Sector 
Evolution of the modern international biotechnology market is lead by the US which is 
home to the most mature and successful biotechnology market in the world. The US 
industry has benefited as a result of its early adoption of biotechnology and the amount 
of capital available to the industry3. 
2.2.1.1 International Biotechnology 
The international biotechnology market is dominated by the USA when measured by 
any number of metrics. In their annual biotechnology report, Ernst and Young (2006) 
claim that over three quarters of all biotechnology investment occurs in the US along 
with the contribution of a similar portion of global revenues from biotechnology 
                                                
3 Whilst the availability of funds to US based biotechnology companies is high by global standards, the 
causal relationship with industry success is not immediately apparent. The success of the industry may be 
a result of the funding availability or conversely the funding availability may be a response by the 
providers of funds to industry success. 
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products. Over one third of the world’s biotechnology companies are based in the US 
and around one half of all publicly listed biotechnology companies are similarly located. 
 
Figure 2-2 International Biotechnology Industry Comparison (Burrill 2006; Ernst & Young 2006) 
 
 
Figure 2-2 provides a graphical representation showing the extent to which the US 
biotechnology market dominates the global market. The US generates over 80% of 
global biotechnology revenues despite only 35% of the worlds companies being based 
in the US. The majority of biotechnology employees work in the US and three quarters 
of global research and development expenditure occurs in the US. Cross comparison of 
the pie charts reveals that the US has more employees per company than the rest of the 
world and spends more on research and development per employee. By contrast, the 
Asia-Pacific region has fewer employees per company and spends much less on 
research and development, a symptom of funding scarcity and the lower cost bases 
within which they operate.  
 
The pie charts indicate that the Asia-Pacific region is well represented according to the 
portion of the metric measuring the total number of biotechnology companies 
worldwide however companies within this region are relatively small with significantly 
small research and development expenditures. Canadian based biotechnology 
companies display similar characteristics to those in the Asia Pacific region with a good 
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representation of companies with relatively few employees, however research and 
development expenditure per company is not as low. 
 
Figure 2-3 International Comparison of Biotechnology Market Capitalisations (Ernst & Young 
2006) 
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Figure 2-3 provides a comparison of the average market capitalisation of biotechnology 
companies located around the world. Firms listed in the US have easily the largest 
market value. In the US, biotechnology companies have access to greater levels of 
private funding allowing them to develop their product portfolios to a more mature state 
compared with competing firms around the world. As a result, firms listing in the US 
have more mature product pipelines enabling them to raise more capital at IPO. 
 
Australian biotechnology firms are often forced to raise capital through a public listing 
due to a lack of alternative funding sources (Herpin, Karuso and Foley 2005; Vitale and 
Sparling 2003). As a result, many Australian biotechnology firms raising capital via an 
IPO have narrower pipelines with products further from market launch compared to 
their international competitors. A company with a narrow pipeline and early stage 
products is a more risky investment proposition, which reduces the amount of capital 
that can be raised. 
2.2.1.2 Australian Biotechnology 
Australia has a proven history of quality research from academic and research 
institutions focused on health and medical research (Australian Government 2004). 
With many biotechnology companies spawned from academic research discoveries, it is 
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clear that our education system has helped fuel the local biotechnology industry. Whilst 
Australia is a small player in the global market, it produces 3.0% of OECD life science 
publications from only 0.3% of the world’s population (Economist Intelligence Unit 
2005). Even though Australia is a small player in the international market Figure 2-4 
shows that Australia is the dominant player in the Asian region biotechnology sector. 
The majority of Asian biotechnology research and development investment expenditure, 
revenues, employees and public companies come out of Australia. 
 
Figure 2-4 Asia Pacific Biotechnology Industry Comparison (Burrill 2006; Ernst & Young 2006) 
 
 
Within Australia, biotechnology head offices are concentrated in locations within the 
capital cities of the eastern states, particularly Victoria and NSW as shown in Figure 
2-5. Around 15% of Australian biotechnology firms were located in Queensland in 2004 
and since then the state has experienced growth in biotechnology start ups at a rate 
greater than the national average (Innovation Dynamics 2006).    
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Figure 2-5 Number of Publicly Listed and Unlisted Biotechnology Firms by State (Department of 
Industry Tourism and Resources, Advance Consulting & Evaluation and Aoris Nova 2004, p. 14) 
 
i Victoria 
Victorian biotechnology is geographically concentrated around biotechnology precincts. 
Victoria is home to the largest number of biotechnology firms, hosting around one third 
of the nations firms within six high profile biotechnology precincts and around half of 
all Australian biotechnology employees (Department of Industry Tourism and 
Resources, Advance Consulting & Evaluation and Aoris Nova 2004). The six Victorian 
biotechnology precincts are located in Melbourne and are described in Table 2-3. 
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Table 2-3 Victoria's Biotechnology Precincts (Department of Industry Tourism and Resources, 
Advance Consulting & Evaluation and Aoris Nova 2004). 
Precinct Summary 
Bio21 Research transfer unit and business incubator to facilitate 
business development and technology commercialisation 
for 15 Melbourne academic institutions.  
Monash Science Technology 
Research and Innovation Precinct 
Linked to Monash University and CSIRO and home to the 
National Stem Centre. This precinct is also located near 
the Australian Synchrotron Project. 
Alfred Medical Research and 
Education Precinct 
Based on the Alfred hospital campus, this is a biomedical 
and educational precinct. 
Werribee Technology Precinct Collaborative research and industry hub focusing on 
veterinary biotechnology 
Grains Innovation Park Collaborative research and industry hub focusing on 
agricultural biotechnology 
LaTrobe R&D Park Technology park located adjacent the Bundoora campus 
of LaTrobe University 
 
ii NSW 
Biotechnology firms in NSW are less geographically clustered than those in Victoria. 
Research activity tends to be clustered around the campuses of teaching hospitals which 
also house many of the university clinical schools (NSW Government 2004). Sydney is 
home to forty international pharmaceutical companies (Department of Industry Tourism 
and Resources, Advance Consulting & Evaluation and Aoris Nova 2004) which can be 
a valuable source of funding for Australian biotechnology companies. 
 
Table 2-4 NSW Biotechnology Precincts (Department of Industry Tourism and Resources, Advance 
Consulting & Evaluation and Aoris Nova 2004). 
Precinct Summary 
Australian Technology Park Research centre focusing on human health and medical 
sciences. 
St Vincent Biotechnology Precinct Draws together University NSW, St Vincent’s Hospital, the 
Garvan Institute and the Victor Chang Cardiac Research 
Unit 
Macquarie University  Home to the Australian Proteome Analysis Facility and 
located amongst five biotechnology firms who have 
evolved as spin-offs from the university and the local 
CSIRO laboratories. 
 
iii Queensland 
The Queensland state government has dedicated substantial investment to development 
of the local biotechnology industry through the Queensland Biotechnology Strategic 
Plan 2005-2015 (Queensland Government 2005). The Queensland biotechnology 
industry is growing faster than the national average with 31% of all new Australian 
biotechnology companies established between 2001 and 2005 based in Queensland 
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(Innovation Dynamics 2006). The Queensland biotechnology industry has a lower 
proportionate representation of human therapeutic companies and higher representation 
of agricultural biotechnology firms (42% and 25% respectively), compared to the 
national averages of 16% and 48% (Innovation Dynamics 2006).  
 
In addition to the precincts detailed below, the government has identified investment in 
necessary infrastructure as a major focus of their 2005-2015 strategic plan for the 
industry (Queensland Government 2005). Part of this investment will facilitate 
development of two new precincts in Brisbane, one dedicated to health and food 
sciences and the other a national ecosciences precinct.  
 
Table 2-5 Queensland Biotechnology Precincts (Department of Industry Tourism and Resources, 
Advance Consulting & Evaluation and Aoris Nova 2004). 
Precinct Summary 
Biosciences Precinct Based at the University of Queensland this precinct 
connects over 1200 scientists from the Institute for 
Molecular Bioscience, the Australian Institute for 
Bioengineering & Nanotechnology, the Queensland Brain 
Institute, the Australian Genome Research Facility, the 
CSIRO and the Queensland Department of Primary 
Industries and Fisheries. 
Kelvin Grove Facilitates linkages around the Royal Brisbane and 
Women’s Hospital and includes the Queensland Institute 
for Medical Research and the Queensland University of 
Technology Institute of Health and Bioscience Innovation. 
Griffith University  A bioscience cluster at the university forms the basis for 
natural products discovery program bringing together the 
university, Astra Zeneca, the Eskitis Institute for Cellular 
and Molecular Therapies. 
Brisbane Technology Park Home to over 45 technology firms including multinational 
pharmaceutical companies. Combined revenue for park 
residents is in excess of A$160 million with more than A$5 
million annually invested in research and development. 
 
iv Western Australia 
Western Australia’s biotechnology sector is based in Perth and focuses on biomedicine, 
agriculture and the environment. Technology Park, located near Curtain University in 
Perth has been established for more than twenty years and is the state’s largest 
technology precinct. The precinct is home to a number of listed biotechnology 
companies, publicly funded research agencies and international pharmaceutical 
company bases.  
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v South Australia 
The South Australian government’s contribution to the local biotechnology industry is 
managed through BioInnovation SA, which was established in 2001 to implement the 
state’s bioscience strategy and assist with policy development. The state has five major 
biotechnology precincts which are described in Table 2-6. 
 
Table 2-6 South Australian Biotechnology Precincts (BioInnovation SA 2006; Department of 
Industry Tourism and Resources, Advance Consulting & Evaluation and Aoris Nova 2004). 
Precinct Summary 
Thebarton Bioscience Precinct Adjacent to University of Adelaide’s Research Park, this 
precinct is one of the largest biomedical clusters in 
Australia. 
Waite Precinct The Waite campus of the University of Adelaide hosts 
many research and development organisations with a 
focus on agricultural research including plant, veterinary 
and environmental science 
Florey Precinct Cluster focused on life and medical science research with 
collaboration between CSIRO, research institutes, the 
state’s universities and the Women’s and Children’s 
Hospital.  
Mawson Precinct Research and teaching hub focused on defence, 
biomaterials and information communications technology. 
Flinders Precinct Biotechnology and marine related research with 
collaboration between Flinders University, Flinders 
Medical Centre and Flinders Science Park. 
 
vi Australian Capital Territory 
The ACT is home to the third largest research and development cluster in Australia 
(Department of Industry Tourism and Resources, Advance Consulting & Evaluation and 
Aoris Nova 2004). A number of biotechnology firms have emerged clustered around 
The Australian National University’s Innovation Centre. Whilst the ACT has more 
biotechnology companies per capita than the national average, none of the companies 
are currently publicly listed on the ASX. 
vii Tasmania 
Tasmanian biotechnology is focused on research and lacks the mechanisms and skills 
base required to effectively commercialise its research output (Tasmanian Government 
and AusBiotech 2005). Research strengths in agriculture and marine biotechnology are 
not supported by commercialisation funding (Tasmanian Government and AusBiotech 
2005). With poor commercialisation opportunities, Tasmania has only four 
biotechnology companies, which is less than 1% of the national total (Hopper and 
Thorburn 2006).  
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2.2.2 Funding 
The Australian biotechnology industry is dominated by small companies with products 
in the early stages of development. A few mature firms do exist in the sector with 
diverse product portfolios and positive cash flows, however, these are a minority. The 
skewness in the distribution of biotechnology companies towards those with few 
products in development is in part a result of the funding mechanisms available to 
biotechnology research and development (Herpin, Karuso and Foley 2005).  
 
The majority of biotechnology intellectual property (IP) is generated within a public 
research institution (Vitale 2004a). Unfortunately, whilst Government programs provide 
assistance for commercialisation of biotechnology discoveries, funding is not of the 
same magnitude or lengthy timeframe as other countries with biotechnology industries 
(Sparling 2003). Once validated, new ideas are usually spun-out into a private company, 
a strategy which is now encouraged by the performance assessment criteria for research 
institutions and an abundance of early stage funding (Herpin, Karuso and Foley 2005).  
 
Once a validated idea has been spun-out, the private company faces fierce competition 
for scarce development funding from the multitude of small biotechnology companies. 
Unlike the US, venture capitalists are not major investors in Australian biotechnology 
companies and those that do invest in the sector do not do so with the required scale or 
patience to develop a drug to any meaningful distance through the clinical trial process 
(Vitale 2004a). 
 
The amount of capital available to Australian biotechnology firms is significantly less 
than that available to US firms. Figure 2-6 compares typical capital raisings for US and 
Australian biotechnology companies and highlights the differences in funding 
availability across all stages of a biotechnology firm’s life cycle. The disparity in capital 
availability increases as firms move through the cycle, particularly once a research 
project is spun-off into a private company and begins to look for VC and angel funding. 
As a result, Australian companies that raise capital through an IPO typically raise less 
than A$20 million compared to more than $A50 million for US based companies.  
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Figure 2-6 Australia vs. US Biotechnology Life Cycle Funding Comparison in $AUD (Australian 
Government 2004, p. 111) 
 
 
Interestingly, Sparling and Vitale (2004) report that although the amount of venture 
capital funding available to Australian biotechnology firms is significantly less than that 
available to firms in the US, the average age of Australian biotechnology companies 
going to IPO was 6.5 years compared to 4.7 years for non-biotechnology IPOs and 5.9 
years for US biotechnology IPOs. US companies typically have more mature product 
pipelines when they opt for an IPO indicating that the rate of product development in 
Australian companies is slower than their US competitors at least partly due to reduced 
access to capital.  
 
The lack of venture capital participation in the Australian market is often blamed on 
Australian VCs having a relatively high level of risk aversion, however, an alternative 
postulation is that Australian VCs face a lack of attractive investment opportunities 
(Vitale 2004a). During the 2004-2005 financial year, Australian venture capital firms 
reviewed more than 10,000 firms for potential investment. Of these, just over 1,000 
underwent more detailed evaluation with investment made in 176 companies 
(Australian Bureau of Statistics 2005). Industry representatives are commonly heard 
lamenting the lack of venture capital funding available to Australian biotechnology 
companies whilst the venture capital industry bemoans the lack of attractive investment 
opportunities available (Vitale 2004c). Despite these protestations, the reality is likely a 
combination of both. Even so, Australian venture capital firms do seem to be more risk 
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averse than their US counterparts which may be an impediment to the development of 
the local industry.  
 
The amount of Australian venture capital available for investment has grown steadily 
over the past five years at an average compound annual growth rate of 17.7% 
(Australian Bureau of Statistics 2005). Whilst the total amount of available venture 
capital has grown, the amount of unallocated funding has grown at a greater rate and at 
June 2005 there was over A$5 billion in unallocated venture capital funding. 
 
Figure 2-7 Allocated and Unallocated Australian Venture Capital (Australian Bureau of Statistics 
2005) 
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Figure 2-8 shows the activities of firms receiving venture capital backing in the years 
from 2000-2005. Whilst there has been increased investment in biotechnology, 
pharmaceutical and health firms (BPH), the increase has not been significantly greater 
than the total amount of venture capital investment nationwide. During 2004 and 2005 
the share captured by BPH firms was constant at 13% of the total. During the year 
ended June 2005 A$463 million was invested in 192 BPH firms, an increase from 
A$246 million in 63 firms during the year ended June 2000 (Australian Bureau of 
Statistics 2005). 
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Figure 2-8 Allocation of Australian VC funding by Investee Activity (Australian Bureau of 
Statistics 2005) 
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The Australian health and medical research industry attracts a low share of the global 
pharmaceutical research and development investment (Australian Government 2004). 
Figure 2-9 shows that investment by the pharmaceutical industry in 2003 was around 
A$300 million, or 0.042% of gross domestic product (GDP). Australia’s contribution to 
global pharmaceutical sales, OECD GDP and research output indicates that Australia 
should aim to capture increased investment from international pharmaceutical 
companies commensurate with our contribution to the industry. If Australia were to 
capture a portion equivalent to the amount of research output we would see international 
pharmaceutical investment increase to around A$1.8 billion. Based on the benchmarks 
shown in Figure 2-9, the Australian Government proposed that a ‘whole of government’ 
approach should aim to attract a total of A$1 billion (2003 dollars) investment from 
international pharmaceutical companies (Australian Government 2004).  
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Figure 2-9 Benchmarking Australia's International Pharmaceutical Investment (Australian 
Government 2004, p. 100) 
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2.2.3 Government Support 
The Australian Federal Government’s National Biotechnology Strategy, which is part of 
the “Backing Australia’s Ability” program. sets out the principles upon which public 
funds are invested in the sector (Australian Government 2000). Through the strategy, 
the Federal Government aims to encourage effective commercialisation of intellectual 
property developed in Australia to generate a commensurate return from its investment 
and ensure Australia remains competitive in the global biotechnology market. The 
vision for Australian biotechnology, upon which the strategy is based, states: 
Consistent with safeguarding human health and ensuring environmental protection, that 
Australia capture the benefits of biotechnology for the Australian community, industry 
and the environment (Australian Government 2000, p. 7). 
The Australian government believes the nation as offers a competitive advantage to 
locally based biotechnology companies (Department of Industry Tourism and 
Resources, Advance Consulting & Evaluation and Aoris Nova 2004) citing the 
possession of: 
 strong economic credentials,  
 a highly skilled workforce,  
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 an innovative culture with excellent research and development infrastructure, 
 internationally competitive business costs, 
 an open and efficient regulatory environment,  
 a dynamic financial services sector. 
 
The Commonwealth government supports biotechnology research and development 
through a number of programs. The National Health and Medical Research Council 
(NH&MRC) provides substantial research funding to the sector, with biotechnology 
related grants totalling around $210m in 2006, the state by state distribution of which is 
shown in Figure 2-10. Of the biotechnology project grants, 76% were directed to 
universities, research institutes received 23% with hospitals receiving the balance 
(Hopper and Thorburn 2006). 
 
Figure 2-10 State by State Distribution of Biotechnology Related NH&MRC Grants for 2006 
(Hopper and Thorburn 2006) 
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2.2.4 Listed Companies 
Around seventy biotechnology firms are currently listed on the Australian stock 
exchange (Australian Government 2006). Biotechnology firms are perceived as being of 
relatively high risk, owing to the wide range and extent of risks, to which firms in the 
sector are exposed. Figure 2-11 shows the performance of the Australian Health index 
relative to the All Ordinaries index over the past 10 years. The Health index (as defined 
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by the ASX) includes companies who are involved in the research, production and 
marketing of pharmaceutical products as well as those who manufacture and provide 
healthcare products and services. The historical performance of the health index 
displays greater volatility than the All Ordinaries index. The index experienced an 
industry-wide boom during the end of last century and the beginning of this century 
which corresponded with the rise of the technology sector and the sequencing of the 
human genome. The sector suffered from reduced investor interest correlating with the 
much publicised technology sector bust and the protracted recovery was spread over 
many years with the index bottoming out late in 2002.  
Figure 2-11 Weekly ASX All Ordinaries and Health Index levels (ASX 2006) 
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The Australian biotechnology sector is commonly believed to be an underperforming 
and immature sector that does not attract the same level of investor interest as the 
world-leading US biotechnology industry. Interestingly, in their study of Australian 
biotechnology firms that listed between 1998 and 2002, Sparling and Vitale (2004) find 
that the Australian biotechnology firms outperformed shares of US biotechnology IPOs, 
Australian non-biotechnology IPOs and shares of the ASX top 200 listed companies.  
 
Despite the strong reported performance of the Australian listed biotechnology sector 
the industry continues to have difficulty in attracting institutional investment. The 
reliance on “unsophisticated” investors for funding combined with a lack of quality 
news flow exposes the industry to greater fluctuations in value (Aegis 2006b).  
Unfortunately, during 2005, one of the major institutional investors in the sector, 
Queensland Investment Corporation, chose to reduce its holdings in a number of life 
science companies which had a negative impact on the performance of the health and 
biotechnology index (Hopper and Thorburn 2006). 
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Sparling and Vitale (2004) cite market conditions and a lack of alternative funding as 
being the primary motivators for biotechnology listings. Venture capital funding, which 
is a major provider of funds to American biotechnology firms prior to IPO, is noticeably 
lacking for the Australian sector. The lack of venture capital funding has forced 
Australian biotechnology firms to use the public markets as a source of public funding, 
and indeed, in his 1998-2003 study, Vitale (2004b, p. 2) finds that the returns on these 
firms “resemble typical venture capital returns – a very few big winners, a few 
reasonable earners, and a large number of washouts”.  
2.2.5 Australia as a Global Competitor 
The Australian pharmaceutical industry is a net importer with annual imports in 
pharmaceuticals in 2003 of $4.4 billion versus exports of just under $2 billion 
(Economist Intelligence Unit 2005). The same report goes on to rank Australia’s 
attraction to pharmaceutical investors relative to the UK, USA, Singapore, India, 
Germany and Japan and finds that overall Australia ranks second behind Singapore. The 
study assessed each nation based on a range of factors across the pharmaceutical value 
chain including costs, business environment, industry skills pool and regulatory 
processes. Whilst Australia scores less well than Singapore and India on costs, it is 
significantly cheaper than the US and European nations and offers a good business 
environment, with a strong local talent base operating under a sound regulatory regime. 
In order to capitalise on the nation’s advantages, the report calls for stronger 
development of the local biotechnology industry to support the pharmaceutical sector. 
The Asian region has many nations capable of producing pharmaceutical product at 
lower cost than Australia however this is currently easily outweighed by non-cost 
benefits (Economist Intelligence Unit 2005).  
 
One of the major challenges facing the Australian biotechnology sector is a lack of post-
seed investment capital available to companies (Australian Government 2004). This 
problem is targeted by the Australian Government in the National Biotechnology 
Strategy (2000) which flags foreign investment and development partners as a key 
objective of the strategy.  
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In its 2003 review of the National Biotechnology Strategy, the Australian Government 
cites commercialisation difficulties as being the primary weakness in the Australian 
biotechnology sector. Despite commercialisation difficulties, Australian companies are 
capturing an increasing portion of global intellectual property, evidenced by the 
Australian share of US biotechnology patents of 0.64% in 2002 compared with 0.45% 
in 1979 (Australian Government 2003). In order to overcome the commercialisation 
challenges, the report suggests that consolidation amongst existing firms will create an 
industry that is more sustainable and internationally competitive. Despite consolidation 
reducing the number of firms in the industry, larger, more diversified companies offer a 
more attractive investment proposition and as a result the amount of commercialisation 
funding available to the sector from domestic and international sources should increase.  
2.3 IPOS 
Due to the lack of private funding available to Australian biotechnology companies, 
many cite a lack of alternative funding sources as one of the primary motivators for 
their IPO capital raising (Herpin, Karuso and Foley 2005).  Given the amount of capital 
required to develop a biotechnology product, it is important that an IPO should raise the 
maximum amount of available capital. That is to say that the amount of money left on 
the table should be minimised, such that the amount of underpricing is kept to a 
minimum. 
 
This research builds on numerous international studies that have investigated the 
phenomenon of IPO underpricing. An early study by Ibbotson (1975) reports average 
first day returns of 11.4% to investors in United States companies’ common stock new 
issues during the 1960s.  Subsequent studies support the notion of IPO underpricing in 
both the United States and other parts of the world. Loughran, Ritter and Rydqvist 
(1994) provide a summary of publications investigating this issue in 25 countries 
around the world from the 1960s through to the early 1990s with all countries exhibiting 
an average initial return to IPO subscribers of between 4.2% and 80.3%.  
 
The existing literature describes many theories explaining the existence of the 
underpricing phenomenon. The following discussion deals with key publications 
covering the major explanatory hypotheses, viz, information asymmetry, uncertainty, 
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pricing, wealth retention, and sentiment, as they apply to biotechnology firms in the 
Australian context 
2.3.1 Information Asymmetry 
Rock (1986) hypothesises that underpricing is a result of information asymmetries 
between informed investors, uninformed investors and the issuing company. Issues that 
are more underpriced would face greater demand by informed investors, creating a 
situation where uninformed investors receive a lower share of stocks issued for highly 
underpriced issues as compared to lower underpriced issues. This is termed the 
“winners’ curse” as investors are more likely to receive a higher allocation in offerings 
with lower levels of underpricing. As a result of the “winners curse” uninformed 
investors will only invest in new offerings if on average new offerings are underpriced. 
The mechanism whereby the IPO market manages to avoid the “lemons” problem4 is a 
result of the investment bank’s role as an intermediary between the issuer and investors. 
The investment bank will need to underprice in order to ensure demand for new 
offerings by informed and uninformed investors but will also need to ensure that the 
amount of money left on the table is not so great that future issuing companies will 
cease to use their services. 
2.3.2 Uncertainty 
Ritter (1984) extends Rock’s hypothesis and, in an analysis of 1028 firms that went 
public in the US during the period from 1977 to 1982, finds evidence to suggest that the 
level of risk surrounding investment in an issuing firm is indeed positively related to the 
level of underpricing of that firm’s issued capital. Defining risk as the uncertainty that 
uninformed investors have regarding the aftermarket price of the offer, Ritter (1984) 
finds that risky firms are more underpriced and that in hot issue periods a greater 
portion of risky firms come to market. 
 
Beatty and Ritter (1986) further investigated the relationship between investor 
uncertainty surrounding the value of the issuing company and find that the greater this 
                                                
4 Akerlof (1970) proposed the lemons problem in his discussion on information asymmetries and the 
impact on market based transactions. In his discussion he uses the stylised example of a bad car, or 
“lemon”, will sell for the same price as a good car as the buyer cannot know the difference between a 
lemon and a good car due to information asymmetries between buyer and seller. 
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uncertainty, the greater the level of underpricing. They studied the same data set as 
Ritter (1984) and find that whilst on average underpricing is a persistent phenomenon, 
there are some issues for which shares decline in price once they start trading. This 
implies that it is in the investors’ interest to devote resources to researching the fair 
value of the issuing company and thus reduce the ex-ante uncertainty surrounding the 
issue price. Additionally, they find that whilst underwriters display characteristics 
indicative of uncertainty regarding the after-market price, those that (on average) under 
or over price for issue uncertainty suffer from lost market share. 
 
Use of a reputable independent accountant has been shown in previous studies to reduce 
the level of uncertainty surrounding an IPO. An independent accountant is used to 
verify the accounts presented in the prospectus for accuracy. It is supposed that a more 
reputable accounting firm offers greater certainty as to the accuracy of the company 
accounts presented in the prospectus as a representation of historical earnings 
performance and thus reduces the uncertainty surrounding the IPO. Titman and 
Trueman (1986) provide a theoretical model describing the process whereby the choice 
of auditor is a relevant piece of information for investors assessing an issuing firm’s 
value. Those companies engaging more reputable independent accountants offer 
shareholders greater certainty and as such shareholders require less underpricing return 
as incentive for investment.  
 
The price of shares offered has been shown in previous studies to be negatively related 
to the underpricing of a company’s IPO. Chalk and Peavy (1987) analyse a sample of 
649 firms that went public in the US during the period from 1975 to 1982 to examine 
the relationship between issue price and underpricing. They find that low-priced firms 
are more heavily underpriced and postulate that the returns to shareholders may be 
compensation for transaction costs, risk, liquidity or a size effect5. The argument used to 
explain this phenomenon is that smaller offerings tend to have a smaller price (Tinic 
1988). Informed investors are only able to concentrate their research efforts on a 
restricted number of companies (due to time constraints) and as such, smaller offerings 
will attract less scrutiny. Thus IPOs with lower price per share are expected to be 
                                                
5 Smaller firms have been shown to have higher risk adjusted returns than larger firms (Banz 1981). 
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correlated with smaller capital raisings but with greater returns to shareholders in the 
first day of listing to compensate potential investors for increased uncertainty.  
2.3.3 Signalling Hypothesis 
An investment bank facilitating a flotation has a challenging task. It is required to set 
the issue price at a level which provides a maximum return to the issuing company 
while still allowing sufficient underpricing to uninformed investors (Beatty and Ritter 
1986). From the perspective of biotechnology companies (which are by nature highly 
capital intensive), the more funding they are able to generate, the more likely they will 
be to successfully develop their product pipeline.  
 
The signalling hypothesis suggests that underpricing exists as a signal of a firm’s 
quality in order to ensure demand for subsequent offerings. Allen and Faulhaber (1989) 
derive a theoretical model based on the assumption that the issuing firm holds the best 
information about its prospects, and as such, firm valuation. Based on this premise, they 
derive a model to suggest that in the presence of asymmetric information, firms signal 
the quality of their offering by underpricing. Further, they provide analysis of previous 
empirical studies to support this notion.  
 
The signalling hypothesis has not been generally supported and Michaely and Shaw 
(1994), in their study of United States IPOs from 1984-1988, find that those firms with 
greater underpricing at IPO tended to return to the market less frequently and for lower 
amounts than those firms with lower levels of underpricing. In the absence of the 
signalling hypothesis, an issuing biotechnology company would prefer less underpricing 
so that more wealth is retained by the company to fund their capital intensive research.  
2.3.4 Entrepreneurial Wealth 
Much of the research effort into the underpricing phenomenon has focused on the 
relationship between uncertainty and underpricing. Using a theoretical model for IPO 
pricing equilibrium, Habib and Ljungqvist (1998) propose that, for an issuing 
entrepreneur, it is not the level of underpricing that is of concern but instead the impact 
that underpricing has on the issuing entrepreneur’s wealth, i.e. the amount of money left 
on the table. In their later work, Habib and Ljungqvist (2001) analyse a sample of 1376 
firms that went public in the US between 1991 and 1995 and find empirical support for 
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the proposition that owners will care about underpricing to the extent that they stand to 
lose wealth from it.  
 
This notion is supported by Loughran and Ritter (2002) who provide an explanation for 
underpricing as a means of underwriter compensation. Their contention is that whilst 
underpricing represents a loss of company wealth, the extent to which the pre-issue 
shareholders personally benefit from subsequent increases in share price, offsets 
concern they may have regarding company wealth. 
2.3.5 Sentiment 
The majority of explanations for the observed underpricing relate to information 
asymmetry and uncertainty around the offering as described in sections 2.3.1 and 2.3.2. 
The work of Ibbotson and Jaffe (1975) and Ritter (1984) additionally suggests there are 
well known sentiment effects that produce hot issue periods in IPO markets.  
 
Hot issue periods are characterised by greater levels of IPO underpricing, with an 
increased volume of IPO capital raisings, and larger capital raisings (Helwege and 
Liang 2004; Ibbotson, Sindelar and Ritter 1994). A pioneering paper by Ibbotson and 
Jaffe (1975) first tested the econometric relationship between underpricing and hot issue 
periods. Theirs was a time series analysis of IPOs in the US from January 1960 to 
October 1970 and they find evidence that periods of greater underpricing corresponded 
with more firms coming to market. 
 
In their more recent work, Brailsford, Heaney and Shi (2004) use a wider data set which 
included data from all new listings in the US from January 1960 to July 2000. This 
work supports earlier studies and finds that during periods of greater underpricing more 
firms came to market as issuers respond to market conditions. Additionally, significant 
autocorrelation was found between underpricing of IPOs from one period to the next 
supporting the notion that the new issue market gathers momentum during hot issue 
periods.  
 
The existence of hot issue markets has been linked to the state of the equity market as a 
whole, with hot issue periods tending to correspond with times of rising equity markets.  
In accordance with this, Dimovski and Brooks (2004a) find that times of rising equity 
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markets correspond with greater underpricing of Australian industrial IPOs. The key 
challenge is to find variables that capture the movements in market sentiment. 
Brailsford, Heaney and Shi (2001; 2004) conduct an analysis at the overall market level 
and find a role for the number of new issues, the level of underpricing and general 
market conditions. Dimovski and Brooks (2004b; 2004a) find a significant role for 
variations in the market index as a sentiment variable for Australian IPOs in general. 
However to date there has been no research published that focuses on biotechnology 
IPO underpricing and the role of sentiment.  
 
There are alternative variables that can be used to measure sentiment type effects. One 
possible alternative sentiment variable is media coverage during the issue period. 
Demers and Lewellen (2003) find that more underpriced offerings receive a greater 
number of media cites in the months post IPO. Due to data constraints they used a 
filtered sample of 593 IPOs that went public in the US during the period from January 
1990 to February 2000 and find a relationship between media coverage in the month 
prior to listing and underpricing. With investor sentiment providing a significant 
contribution to underpricing, media coverage during the issue period and for high first 
day returns will encourage investment in subsequent listings.  
 
Conversely Pollock and Rindova (2003) put forward a theory of media legitimisation. 
They analyse a sample of 225 IPOs in the US during 1992 and find that greater levels of 
media coverage in the period one year prior to IPO is negatively related to the level of 
underpricing. They put forward this relationship in support of their media legitimisation 
theory which states that increased media coverage provides a form of validation of a 
new firm’s legitimacy, hence reducing perceived investor risks associated with that 
firm. 
2.3.6 Australian Observations 
The international phenomenon of IPO underpricing is also found in the Australian 
capital market. Research focusing on the new issue market in Australia supports the 
findings of international studies and shows that the underpricing phenomenon exists for 
new issues on the Australian Stock Exchange. 
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Using a filtered sample of 93 new issues on the Australian Stock Exchange from July 
1966 to June 1978, Finn and Higham (1988) conduct an early investigation into 
underpricing in Australia with comparison to the more heavily researched international 
markets. They propose that barriers to entry for Australian brokers prior to 1987 could 
facilitate non-competitive pricing of new issues however this does not justify the 
consistency in their results with the international literature. 
 
To investigate the uncertainty argument for the underpricing of new offerings, How, 
Izan and Monroe (1995) analyse a sample of 340 industrial IPOs in Australia between 
1980 and 1990. They proxy uncertainty using the quantity of available information 
about the listing firm and find that, consistent with Ritter (1984), greater uncertainty 
regarding the firm is significantly correlated with greater underpricing. Additionally, 
they find support for Rock’s (1986) winner’s curse hypothesis and find that firms can 
reduce the level of underpricing by engaging a reputable underwriter for the issue. 
 
The relationship between uncertainty and underpricing of Australian IPOs is supported 
by Dimovski and Brooks (2004a) in their study of 358 industrial and resource new 
issues between 1994 and 1998. They model market sentiment using the All Ordinaries 
share price movement as a proxy and find that IPOs are more underpriced during 
periods of rising market sentiment. 
 
Brailsford, Heaney and Shi (2001) analyse IPOs on the ASX between 1976 and 1997 
using a time series regression model to investigate the presence of hot and cold issue 
markets. They find that hot issue periods are related to market conditions and conclude 
that managers time their listings to capitalise on favourable market conditions. They 
find that during hot issue periods, issues are more underpriced with a greater number of 
firms coming to market, however underpricing observations lead observed volume 
changes by up to six months. The impact of resource stocks was also investigated and 
these firms were found to be smaller in size with lower issue prices and tended to have 
greater levels of underpricing.  
 
Consistent with Brailsford, Heaney and Shi (2001), How (2000) finds that Australian 
mining IPOs are more underpriced than Australian industrial firm issues. How (2000) 
uses a sample of 130 mining listings on the ASX between 1979 and 1990 and also finds 
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that the degree of underpricing is dependent on the year of listing consistent with the 
presence of hot issue periods. 
 
The entrepreneurial wealth hypothesis was supported in an Australian context by da 
Silva Rosa, Velayuthen and Walter (2003) who find that underpricing does not 
represent the true wealth impact on the issuing entrepreneurs. In their sample of 333 
industrial firm IPOs on the ASX between 1991 and 1999, venture capital backed IPOs 
exhibited greater levels of underpricing (but not significantly different) than those 
without venture capital. Conversely, the issuers of venture capitalist backed IPOs 
experienced less wealth loss (but not significantly different) than those without backing.  
2.3.7 IPO Underpricing in the Biotechnology Context  
For managers of firms such as biotechnology companies who rely heavily on raising 
external funds to finance their R&D, the IPO process poses a significant challenge. 
Cash flows generated by intangible assets, particularly internally generated intangibles 
such as R&D will be less certain (Barron, Byard, Kile and Riedl 2002). The investing 
public requires details of the nature and success of R&D in order to attempt to put a 
value on the firm, while managers are often reluctant to disclose this information for 
fear of expropriation of proprietary knowledge (Deeds, Decarolis and Coombs 1997). 
Investors in young biotechnology companies will assess the firm in order to establish 
the likelihood of that firm producing a product(s) that will generate revenues and profits 
to justify their investment. Deeds, Decarolis and Coombs (1997) focus on US listed 
biotechnology companies to examine the impact of firm specific data on the amount of 
equity raised in an IPO. The data set comprised a final sample of 89 biotechnology 
firms that went public in the US between 1982 and 1993. Using a regression framework 
they find that factors including the number of products in development, the number of 
times employees’ work had been cited, and the geographic location of a firm had a 
significant impact on the amount of capital raised in their IPO. The argument they pose 
is that these factors are signals to the market as to the likelihood of the firm producing 
revenue (and profit) generating product(s) at some stage in the future and, as such, are 
indicators of value and correlated with the amount of cash generated by the IPO capital 
raising.  
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There are a number of variables that might impact on capital raisings and IPO success 
for a biotechnology company. Citation indices have been previously used as a proxy 
measure for the quality of the research team (Deeds, Decarolis and Coombs 1997). A 
higher quality research team would be expected to better capitalise on existing 
proprietary intellectual property, develop new intellectual property and indeed see the 
successful development of the intellectual property into a product capable of delivering 
returns to shareholders. In the context of a biotechnology IPO it would then be expected 
that those firms with greater citations of employees’ publications offer investment in a 
superior research team, by definition giving a greater expectation of positive research 
and development outcomes. If the reduced uncertainty increases the likelihood of 
research and development success then, ceteris paribus, those companies would be 
expected to raise more capital at IPO with less money left on the table. 
 
In contrast, recent research by Corolleur, Carrere and Mangematin (2004) found 
evidence that more qualified and senior research staff tend to become involved with 
projects offering greater potential rewards, albeit at a higher risk of failure. Whilst these 
projects may offer a more difficult path to valorisation of intellectual property, the 
potential monetary and reputation gains outweigh the additional risk. The increased 
uncertainty surrounding the success of a riskier company’s product development will 
see investors in that company’s IPO demanding greater return as compensation. 
 
The ability of a biotechnology company to produce high margin products is largely 
dependent on its ability to protect its intellectual property through the patent process 
(Carbone 2003). A company that has no patent protection faces increased competitor 
risk, jeopardising its first to market advantages and profit margins, leading to a reduced 
share of the target market. This being the case, the increased risk resulting from 
inadequate intellectual property protection will create additional uncertainty 
surrounding future cash flows, requiring greater underpricing as compensation to 
investors in the issue. 
 
Underwriters for companies from new industries have little guidance to value beyond 
traditional valuation methods in use at the time (Pukthuanthong 2006). Using a sample 
of 447 biotechnology and 447 non-biotechnology (a total of 894) firms that went public 
in the US between 1980 and 2004,  Pukthuanthong (2006) conducts an analysis looking 
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for evidence of learning in underwriter valuation of new industry (biotechnology) 
listings. Underwriters of biotechnology IPOs early in the sample underestimated the 
value of R&D investment, quality of human capital and large market drugs with these 
items correlated with smaller IPO values and larger underpricing. Later in the sample 
these factors correlated with higher value IPOs but were not with underpricing and 
Pukthuanthong (2006) put forward this as evidence of underwriter learning. 
 
Lack of familiarity with a new industry creates uncertainty surrounding the values of 
firms operating within that industry. How (2000) finds that resource firms are more 
likely to come to market in times of positive market sentiment. Pukthuanthong (2006) 
finds similar results for the biotechnology industry indicating that firms with greater 
pricing uncertainty exhibit selectivity in IPO timing and choose to come to market when 
capital markets are buoyant. Similarly, Finkle (1998) and Deeds, Decarolis and Coombs 
(1997) both find that US biotechnology firms coming to market during hot issue periods 
had larger IPOs which supports the broader market research into the presence of hot 
issue periods and the impact on IPOs. 
2.4 VALUATION 
Underpricing has been shown in numerous studies to be related to the degree of 
uncertainty surrounding the issue. That is to say that those companies with business 
models that are well understood by the investment community (such as a manufacturing 
company) tend to have less underpricing at IPO. Conversely, those companies with 
greater uncertainty (e.g. biotechnology) surrounding valuations tend to be more 
underpriced and leave more money on the table. 
 
Valuation models provide the analyst with insight into the inherent value associated 
with a particular project or entity and as such reduce the uncertainty associated with 
investment in the project or entity under investigation. If the investment community had 
access to models that provide greater insight into the value of biotechnology 
investments, some of the uncertainty inherent in these investments would be reduced. 
This in turn should result in an increase in investment in the industry, enabling firms to 
maintain ownership of valuable intellectual property for longer through the 
development process to capture a greater portion of drug development value. 
Additionally, reduced uncertainty surrounding biotechnology valuation should result in 
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less underpricing and money left on the table by Australian biotechnology firms, thus 
increasing the amount of money available for R&D investment. 
 
This section focuses on two primary valuation methods. The initial discussion examines 
discounted cash flow valuation (DCF) and provides a brief summary of the concept 
combined with discussion on the limitations and criticisms of this methodology. A 
number of extensions on traditional DCF models have been proposed in response to 
common criticisms, the most significant of which are also discussed. 
 
The most telling criticism of DCF valuation is the inability of the method to incorporate 
the value of management flexibility. Real option analysis is a contemporary capital 
budgeting tool which incorporates the value of management flexibility. This section 
provides a summary of the evolution of the underpinning theory together with its 
advantages and limitations. 
2.4.1 Discounted Cash Flow 
DCF valuation is the term used to describe the valuation method where all cash flows 
directly attributable to the assets being valued are forecast and then discounted back to a 
present value using an appropriate discount rate. This valuation method has been in use 
since the first half of the twentieth century when early publications by Fisher (1930) and 
Williams (1938) describe valuation methods to account for risk and the time value of 
money.  
 
DCF and the closely related internal rate of return6 (IRR) valuation methods have been 
the most commonly adopted capital budgeting tools in the second half of the twentieth 
century (Ryan and Ryan 2002). In his 1970 survey of 180 firms Klammer (1972) finds 
that DCF and IRR methods are the primary capital budgeting tool for 55% of firms, 
having increased from 14% in 1959 when accounting rate of return and payback period 
were the most commonly used tools. Ryan and Ryan (2002) surveyed Chief Financial 
                                                
6The internal rate of return (IRR) method involves forecasting all cash flows for a project then using an 
iterative process to solve for the discount rate that corresponds to a zero net present value. The derived 
IRR is then compared to a hurdle rate of return to provide an “invest” or “abandon” recommendation. The 
process for forecasting cash flows is the same as that for a DCF model and the hurdle rate is typically that 
which would be used as the discount rate in a DCF model. 
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Officers from 205 Fortune 1000 companies and find that IRR and DCF are the most 
commonly used capital budgeting methods and that the majority of firms included 
sensitivity analysis of these models in their assessments. 
2.4.1.1 Methodological Summary  
On the surface, typical DCF analysis is a relatively simple process however selection of 
an appropriate discount rate with which to discount cash flows can pose a significant 
challenge. The discount rate should be reflective of the risks associated with forecast 
cash flows however  quantification of those risks poses some difficulty and as a result, 
the weighted average cost of capital (WACC) for the firm is often used as a proxy. This 
approach assumes that markets are efficient and, as a result, the cost of capital is 
reflective of the relevant risk exposure of the firm. Where a project differs from those 
typically undertaken, the use of the WACC may not be appropriate as this is 
representative of risks of the firm as a whole which is a reflection of the projects 
historically undertaken by the firm. 
2.4.1.2 Limitations 
DCF valuation methods are fundamentally flawed as they do not correctly assess 
growth options and will understate the value of an investment with a significant portion 
of value associated with growth options (Myers 1984). This notion is supported by 
Kester (1984) who argues that the opportunity to invest in a project can be worth more 
than the net present value of the project itself. 
  
Hodder and Riggs (1985) state that as DCF models consider only the most probable 
estimate of cash flows, asymmetry in payoffs are ignored and thus project value is 
underestimated in situations where managers are able to flexibly respond to their 
environment to minimise losses and maximise profits. Additionally, application of DCF 
methods provides an invest/discard signal to management at the commencement of the 
project which does not communicate the inherent uncertainty in the underlying inputs 
(Junkui Yao and Jaafari 2003). Furthermore, the adoption of a constant discount rate for 
the term of the project ignores changes in uncertainty and risk as the project moves 
through to completion and information is revealed (Junkui Yao and Jaafari 2003). 
 
In their widely cited article, Hayes and Abernathy (1980) criticise underinvestment in 
long-term strategic assets (such as research and development) by corporate America in 
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the period from 1960 through to 1978 as contributing to a reduction in international 
competitiveness. In a subsequent paper Hayes and Garvin (1982), argue that widespread 
adoption of DCF capital budgeting tools compounds research and development 
underinvestment due to the inherent flaws in DCF methodology. 
 
Gold (1976) postulates that DCF evaluation has a bias towards short term revenue 
generating projects as the application of large discount rates to cash flows not expected 
to occur in excess of 3 to 4 years in the future will often render them inferior to 
alternative short term money market investments. To reject such projects is to risk 
erosion of competitive strength over time as new technology investments are rejected, 
creating a long term strategic disadvantage.  
 
Haley and Goldberg (1995) analyse the theoretical shortcomings of DCF capital 
budgeting tools in a quantitative framework. Their model tests the relationship between 
management reliance on financial capital budgeting tools and the success of that firm’s 
research and development program. Three measures of research and development 
success are used, those being: annual patent submissions divided by annual sales 
relative to the industry median, the annual patent submissions divided by annual 
expenditure on research and development relative to the industry median, and research 
and development expenditure as a percentage of sales relative to the industry median. 
Based on data for the 45 largest firms from each of three industries7 Haley and 
Goldberg (1995) find empirical support for the notion that firms who place greater 
importance on the application of DCF models for R&D assessment have poorer 
performing R&D divisions. They support the theoretical concerns surrounding 
application of DCF models to assess research and development projects and conclude 
that firms who rely heavily on DCF models are exposed to risk of competitive strength 
erosion over time. 
2.4.1.3 Discounted Cash Flow Methodological Extensions 
The merit of DCF project evaluation has been subject to much debate in industry and 
academia (on both sides of the fence) resulting in a number of extensions to traditional 
DCF models emerging in response to criticism. 
                                                
7 The three industries included in this study were the chemicals, computer and steels/metals. 
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i  Non-constant discount rate 
Traditional DCF methods apply a discount rate reflective of the non-systematic risks 
associated with the cash flows under analysis. This poses particular problems with 
respect to assessment of biotechnology research and development due to the long lead 
times in product development and the non-constant nature of project risks over this time 
frame (Myers and How 1997).  
 
As a result of the inconsistent nature of project risk over time, Hodder and Riggs (1985)  
propose the use of differing discount rates over the forecast life of the project stating 
that, once a project and cash flows become more consistent, the use of a lower discount 
rate is appropriate. Myers and How (1997) similarly argue that risks are time varying 
and for a biotechnology project, uncertainty surrounding likely development costs is 
less than that for commercialisation cash flows and hence a reduced discount rate 
should be adopted.  
ii Probability weighted decision tree 
Incorporation of probability weighted decision trees is a response to the criticism that 
DCF models consider only the “average” forecast outcome and therefore assume 
symmetric distribution of possible alternatives around this average (Trigeorgis 1996). 
The decision tree facilitates the inclusion of asymmetric cash flow expectations through 
specific settings of a discrete number of alternative outcomes. Decision tree analysis 
involves forecasting the cash flows associated with a range of possible outcomes and 
then discounting cash flows at an appropriate discount rate, which is usually the 
weighted average cost of capital, and adjusting for the expected probability of 
occurrence for each outcome (Copeland and Keenan 1998).  
 
A problem with the application of decision tree analysis in this manner is that the 
assumption of a constant discount rate assumes that risks are equal across all branches 
of the decision tree and uncertainty is resolved at a constant rate over time (Trigeorgis 
1996). Decision tree analysis usually incorporates the abandonment outcome at various 
points through the model’s time horizon and the addition of the option to abandon 
should have the effect of reducing perceived project risk (Junkui Yao and Jaafari 2003).  
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The use of decision tree analysis is particularly suited to drug development projects due 
to the staged nature of the R&D and regulatory approval process (Kellogg and Charnes 
2000). A number of industry databases are available which provide industry-wide 
statistics regarding the likelihood of success at each stage in the process. Unfortunately, 
direct use of this data in a DCF model with a decision tree framework provides 
misleading results as the data includes all project failures, many of which occur for 
financial reasons. An accurate DCF decision tree model should only use the proportion 
of projects that have been abandoned for safety or efficacy reasons (Villiger and 
Bogdan 2005).  
iii Monte Carlo scenario testing 
Despite the incorporation of numerous outcome possibilities, DCF decision tree analysis 
suffers from one of the pitfalls of the DCF model upon which it is based as it only 
provides a point estimate of value which is deceptive in its precision because it is based 
on imprecise assumptions (Gold 1976). Haley and Goldberg (1995) find that 
incorporating scenario testing within DCF models facilitates outputs beyond traditional 
point estimates of net present value improves the information available to those 
responsible for investment decision making, providing some insight into model 
uncertainties versus project risk. 
 
Hertz (1964) provides an early insight into the advantages of incorporating large scale 
scenario testing into DCF models for project assessment and valuation modelling. Using 
a sufficiently large number of iterations based on assumed distributions of possible 
model input values, an estimate of the model output (e.g. NPV) distribution can be 
generated.  
 
The term Monte Carlo was coined after the gambling casinos of Monte Carlo in 
Monaco (Ulam 1991) and is used to describe the process of statistical sampling outlined 
by Hertz (1964). Improved access to increased computational power in modern times 
has seen an increase in both the functionality and application of this tool (Boyle and 
Broadie 1997). 
2.4.2 Real Options Valuation 
In response to mounting criticism of the applicability of DCF models in assessing 
research and development projects, Myers (1984) first postulates the notion that value in 
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research and development is effectively option value and coined the expression “real 
option”. Since Myers’ publication, a large amount of academic literature has been 
devoted to espousing the applications of financial option theory to the valuation of real 
options such as occur in biotechnology research and development. 
 
Research and development is considered to comprise real options as investment in a 
single stage of R&D gives the owner the right, but not the obligation, to continue to the 
next stage in development (Copeland and Antikarov 2001). Analysis of R&D using 
simple DCF models may generate a “do not invest” signal when the project is 
considered in isolation however when the value of the options created by the R&D 
investment are included8 this may well alter the investment signal (Dixit and Pindyck 
1995).  
 
The option to continue a R&D program is only one alternative that should be considered 
when applying real option analysis to project evaluation. In addition, options to defer 
investment, expand, contract, put on hold, abandon for salvage value and the option to 
default can also be quantified in a real options model (Trigeorgis 1996). 
 
Despite academic support for quantitative application of real options analysis, there has 
not been widespread uptake of the theory by industry. In their survey of 28 
biotechnology and pharmaceutical companies and 27 financial services companies 
Hartmann and Hassan (2006) found that the application of DCF related models was at 
least four times more likely than the use of real option models. Despite the domination 
of DCF techniques, there was an increase in adoption compared to that observed by 
Ryan and Ryan (2002) who surveyed over 200 Fortune 1000 firms and found that less 
than 1% of these always used, and 88% never used, real option methods.  
 
Despite the current lack of support by industry, Copeland and Antikarov (2001) forecast 
that by 2010 real options analysis will be the dominant tool for investment analysis. 
Although uptake by industry has not been as strong as forecast, the survey results may 
provide misleading information as many managers are in fact applying real options 
                                                
8 For example, a company may commit to a project with a negative NPV on the basis that this project will 
lead to other positive NPV opportunities. 
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analysis in practice without necessarily applying the associated quantitative model 
(McDonald 2006).  
2.4.2.1 Methodological Summary  
The underlying logic supporting application of existing financial option theory to 
valuation of real options is widely supported by academia, however, the manner in 
which this is best applied is varied, with three main techniques receiving the majority of 
support in the literature. 
i Binomial Decision Tree 
Based on a decision tree similar to that used in combination with extended DCF models, 
the binomial decision tree seeks to overcome some of the inherent problems with a DCF 
tree. This method is described by Jagle (1999) and applies the notion of the risk neutral 
replicating portfolio9 developed by Cox, Ross and Rubinstein (1979). This method 
allows all values within the tree to be discounted at the risk-free rate using risk adjusted 
success probabilities for each stage of the tree.  
 
DCF valuation forms an important component of this method in that it is used to value 
the underlying assets, that being a fully developed product. This is justified based on the 
“marketed asset disclaimer” which states that the present value of expected cash flows 
is the best unbiased estimate of value (Copeland and Antikarov 2001). As the value of 
the underlying asset is forecast for all outcome states, the value of the volatility in the 
underlying asset is implicit in the DCF calculations for each of those states of being. 
ii Binomial Lattice 
The binomial lattice method is described by Kellogg and Charnes (2000). As with the 
binomial decision tree, this method also uses the notion of the risk neutral replicating 
portfolio, however the underlying tree is of a different format. Rather than a decision 
tree, a binomial lattice is used to model movement in option value through the evolution 
of the project with the volatility in the underlying asset explicitly calculated based upon 
forecasts for the optimal project outcome.   
 
                                                
9 Refer to Chapter 6 of this thesis for a discussion of the risk neutral portfolio and an example of the 
binomial decision tree and binomial lattice methods. 
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iii Black Scholes 
The pre-eminent theory for the pricing of financial options is that provided by Black 
and Scholes (1973) which built on earlier research by Merton (1973) and for which 
Merton and Scholes received the 1997 Nobel prize in economics10. Benaroch and 
Kauffman (1999) apply this theory to produce a continuous time model for valuation of 
real options. 
 
One of the underlying assumptions of the standard Black Scholes option pricing model 
is that the option is only exercisable at maturity (i.e. a European option) and the 
underlying asset does not pay dividends (Black and Scholes 1973). In the case of a 
biotechnology project, cash flows resulting from such activities as milestone payments 
defined in licensing agreements represent a failure to meet the dividend assumption 
reducing the practicality of the model for real options analysis.  
 
Extensions to the Black Scholes model have been developed in order to remove the 
European option and dividend restrictions, however these add computational 
complexity without necessarily providing greater insight into the valuation problem 
(Villiger and Bogdan 2006). The complexity of the Black Scholes valuation model 
inhibits effective understanding for many practitioners which acts as a barrier to 
application (Copeland and Antikarov 2001). 
2.4.2.2 Limitations 
The main barriers to the uptake of real options analysis are perceptions of computational 
complexity and onerous assumptions necessary to conduct quantitative analysis. Whilst 
there is some merit in these arguments, modern literature has sought to overcome these 
issues through the development of methods that can be graphically displayed in a 
relatively simple manner to easily communicate the benefit of real options (Fichman, 
Keil and Tiwana 2005).  
 
Unlike traditional DCF analysis, real options valuation requires an estimation of the 
volatility in the underlying asset value. Due to the nature of “real” options the 
underlying asset is usually not tradeable and thus there is no historical data to be used as 
a guide for price volatility estimation (Godinho 2006). Monto Carlo modelling of the 
                                                
10 Black was ineligible for the prize having passed away in 1995. 
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underlying asset characteristics is proposed as a method for estimation of the volatility 
(Copeland and Antikarov 2001). 
 
Whilst options analysis quantifies the value of management flexibility, the exercise of 
that flexibility may not be practically convenient. Stop loss options (or “puts”) such as 
the option of abandonment may be difficult to exercise in practise and as such the value 
of these may not be as great as predicted by the financial analysis. Fichman, Keil and 
Tiwana (2005) surveyed managers from 123 firms and found that greater value was 
placed on positive “call” real options than negative11 “put” options. 
2.5 CONCLUSION 
Biotechnology has been targeted by Australia’s Federal and State Governments as 
strategically important. The development of a successful biotechnology industry is seen 
as important for the nation’s future economic, environmental and social well-being. One 
of the key barriers to success in the industry that has been identified by numerous 
strategic reports is the inability of Australian firms to raise commercialisation capital, 
particularly when compared to our international competitors.  
 
As a result of the funding shortfall, Australian biotechnology firms have historically 
turned to the public markets for capital at an earlier stage than in other countries, 
particularly the US, whose biotechnology industry is the most successful in the world. 
For any company, an IPO is one of the most important capital raisings in that 
company’s life, however, for a biotechnology company, this is exacerbated by the 
capital intensive nature of biotechnology R&D and the difficulty in raising additional 
funds after IPO. 
 
Underpricing is the term used to describe the phenomenon whereby the price of a firm’s 
shares consistently appreciate on the first day of listing. This can also be expressed as 
money left on the table and new issues with greater uncertainty have been shown to be 
more underpriced and leave more money on the table. Investment in biotechnology 
firms is inherently uncertain due to the long lead times in product development, the 
                                                
11 A call option is one that enables management to flexibly respond to increase positive cash flows (such 
as a growth option) where as a put option is one where management is able to decrease negative cash 
flows (such as an abandonment option). 
Chapter 2 – Literature Review 
 46
costs of development and the uncertain nature of R&D. As a result, biotechnology 
firms, for whom access to capital is a critical issue, tend to leave more money on the 
table than the market average. 
 
Traditional valuation methodologies such as DCF models provide analysts with insight 
into project and firm value, reducing the uncertainty of investment. Unfortunately DCF 
based models fail to capture the value in management flexibility and thus tend to 
systematically undervalue investments with a significant degree of uncertainty to which 
management can respond over the life of the project. The widespread adoption of DCF 
techniques by industry has been blamed for an underinvestment in long term research 
and development, inhibiting longer-term economic prospects. 
 
Real option analysis is a contemporary capital budgeting tool which captures and 
quantifies the value associated with management flexibility. At the present time real 
option methods are not widely applied and it is supposed that this is a result of a lack of 
understanding of the fundamentals underpinning the models. If the models were more 
widely understood, increased adoption could serve to decrease the uncertainty in R&D 
intensive industries, increasing the amount of investment capital available and helping 
address a critical barrier to the development of Australia’s biotechnology industry. 
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CHAPTER 3 METHODOLOGY 
3.1 INTRODUCTION 
The research in this project was funded by Australian Research Council Linkage Grant 
LP0347417.  The funding approval was based on the premise that the investigation 
would focus on the “valuation and business models of Australian biotechnology 
companies”. This research methodology was prepared with consideration of the ARC 
application which set out the research proposal and methodology outline. 
 
Excluding medical device companies, the Australian biotechnology industry is 
comprised of around 300 companies (Department of Industry Tourism and Resources, 
Advance Consulting & Evaluation and Aoris Nova 2004) which operate across a 
diverse range of business sectors with a marked difference in product under 
development. Each business sector and product type has fundamental differences in the 
regulatory framework and requirements and the nature of commercial opportunities. 
These differences require each biotechnology sub-sector to be analysed specifically to 
determine the specific valuation and business model idiosyncrasies that exist. This 
thesis focuses on the largest biotechnology sub-sector in Australia, that being human 
therapeutic development companies, which comprise in excess of 40% of the total 
biotechnology industry (Department of Industry Tourism and Resources, Advance 
Consulting & Evaluation and Aoris Nova 2004). 
 
The research methodological framework which forms the basis for this research is 
presented in this chapter. Discussion is subdivided into five main areas: research aims 
and questions, research design, qualitative investigation, quantitative review of 
Australian biotechnology IPOs and a quantitative review of valuation methodologies. 
3.2 RESEARCH AIMS AND QUESTIONS 
The ultimate aim of this research is to investigate the Australian biotechnology sector 
and identify the key drivers of value. Through the identification and quantification of 
the drivers of value for the sector it is hoped that greater investment capital will flow 
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into the industry, better enabling it to compete internationally given the countries 
tangible and intellectual resources. This thesis fulfils this aim through the investigation 
of the following primary research question: 
• What are the key drivers of value for models for Australian biotechnology 
firms? 
 
In addressing the primary question, the following secondary questions are also 
addressed: 
• What are the challenges and opportunities for Australian biotechnology firms? 
• What factors endogenous and exogenous to the firm affect the amount of capital 
raised by Australian biotechnology companies through IPOs? 
• How can Australian biotechnology firms signal their fair value to the investing 
community? 
• What is the appropriate methodology for valuation of biotechnology 
investments? 
3.3 RESEARCH DESIGN 
Epistemology relates to how truth and knowledge are defined in the research context 
(Lincoln and Guba 2000). How the researcher views epistemology depends on the 
paradigm operating in that research context, i.e., the “basic belief system or world view 
that guides the investigation” (Guba and Lincoln 1994, p. 105). This research consists 
of multiple methods grounded in alternative epistemologies.  
3.3.1 Multi-Method Research 
Practical “real world” problems are usually multi-faceted, thus an investigation into the 
circumstances surrounding those problems and possible solutions also requires a multi-
faceted approach. The aim of research utilising a mix of quantitative and qualitative 
methodologies is to draw from the strengths and minimise the weaknesses of each 
research paradigm (Johnson and Onwuegbuzie 2004). Denzin and Lincoln (1998) argue 
against any hierarchy of merit in research techniques, with both qualitative and 
quantitative researchers providing useful data but with different emphases. Qualitative 
studies emphasise richness and depth that quantitative studies cannot obtain whilst 
quantitative studies provide an objective analysis of measurables and causal 
relationships between variables.  
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This research consists of multiple methods applied across multiple stages. Schmied 
(1993) notes that a stage of qualitative research is often a precursor for quantitative 
analysis as the categories to be included in the analysis need first to be identified. The 
initial stage was explorative and qualitative in nature and provided the foundations for 
the subsequent quantitative stages whilst also providing a strong link to the existing 
literature surrounding the state of the Australian biotechnology sector.  
 
The initial analysis of the qualitative research data supported the literature in identifying 
particular challenges to Australian biotechnology firms in raising sufficient 
development capital in the face of valuation uncertainties. Due to the exploratory nature 
of this phase of the research, and the depth and richness of information being sought, a 
qualitative research method was adopted.   
 
The second stage of research was grounded in positivism to allow an objective 
assessment of, and a quantitative reference to, issues highlighted in the qualitative 
investigation. The quantitative components of this research provide a focused 
investigation which addresses the secondary research questions and supports the 
qualitative findings in addressing the primary research questions. Figure 3-1 provides a 
diagrammatical representation of the research methods starting with the breadth of the 
qualitative research, leading to the more focused quantitative analysis. 
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Figure 3-1 Research Staging & Focus 
 
 
3.3.2 Research Structure 
The multiple research methods formed components of the research design as illustrated 
in Figure 3-2. The research question was formed based on an initial survey of the 
existing literature and discussions with BioDiem Ltd, an Australian biotechnology 
company and the industry sponsor of this research. From this initial foray, the research 
questions were formed which were then used to guide a more detailed review of the 
literature. 
 
Stage 1
(Qualitative)  
Industry Challenges & Opportunities 
Stage 2a
(Quantitative)  
IPO Value 
Stage 2b
(Quantitative)  
Project Value 
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Figure 3-2 Research Structure 
 
 
There were two major themes that were identified in the literature that were crucial to 
this study. Firstly, high levels of uncertainty surrounding valuation of biotechnology 
assets, namely intellectual property. Secondly, the early stage at which Australian 
biotechnology companies were likely to raise capital through an IPO when compared 
with participants in the USA, home of the largest and most successful biotechnology 
industry in the world. This guided the research towards an investigation of the 
Australian biotechnology industry and the factors influencing the behaviour of firms 
contained therein. 
 
The challenge Australian biotechnology companies face when raising development 
capital was highlighted through the qualitative data gathering process, providing direct 
support for the relevance of the stage two investigation into Australian IPOs and the 
factors that influence “underpricing” and the amount of money left on the table during 
the floatation process.  
Research 
Questions 
Literature Review 
Stage 1 
Elite Interviews 
Stage 2a 
 IPO Valuation 
Stage 2b 
 Contemporary 
Valuation 
Techniques 
Results &  
Discussion 
Conclusions 
 
Preliminary Literature Review 
& Industry Consultation 
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The two quantitative components of this research were conducted concurrently. The 
investigation of Australian biotechnology IPOs supports the notion that investors show 
behavioural patterns consistent with valuation uncertainties, providing supporting 
motivation for the second quantitative component of this research. Contemporary 
valuation techniques attempt to provide realistic assessment of firm value thus reducing 
the uncertainty surrounding biotechnology valuations. Thus the second quantitative 
analysis used a number of contemporary valuation models to assess the value of a 
typical biotechnology product to allow a comparison between the different techniques 
applied. 
3.4 QUALITATIVE SECTOR INVESTIGATION 
The data collection method for this component of the study was designed to collect rich 
data under the broad topic “what are the challenges and opportunities facing Australian 
biotechnology companies”. Qualitative data collection provides “richness” that 
quantitative data is unable to provide (Denzin and Lincoln 2005) and provides a depth 
to the context and picture of the Australian biotechnology scene. Semi-structured 
interviews were chosen as the data collection method to allow greater breadth than more 
focused “structured” interviews are able to do (Denzin and Lincoln 2005).  
3.4.1 Interview schedule 
From the literature review, key themes were identified which warranted further 
investigation. These themes formed the basis of the interview schedule and questions 
were developed accordingly. An initial generic schedule was developed and then 
provided to BioDiem for expert comment. Feedback from BioDiem was incorporated 
into the proposed schedule to produce a generic schedule as the basis for the interview 
process. The diversity of products developed under the “biotechnology” definition and 
the differing challenges and opportunities associated with each warranted some unique 
investigation for each participant. The generic interview schedule was adapted for each 
participant to allow investigation of the unique circumstance facing each company. 
However themes and issues presented in Table 3-1 were common to all interview 
schedules. 
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Table 3-1 Qualitative Research Themes 
Theme Issues 
Funding • Availability & the impact on the Australian biotechnology 
industry 
Initial Public Offerings • Influence of alternative funding sources on the motivation to 
float 
• Determinants of success 
• Impact of public listing on business success 
Business model • Description, risks, strengths and opportunities 
• Sustainability, product development and business model 
evolution 
• Relationship between management and business model. 
Impact of evolution. 
• Role of alliances 
• Role for pharmaceutical companies and academia. 
Valuation • Valuation methodologies 
• Drivers of value 
 
The interview schedule was designed to allow all topics to be covered within a 1 hour 
discussion. The interviews were recorded on a digital voice recorder and the recorded 
data was then transcribed verbatim into Microsoft Word format to allow the detailed 
exploration of data described in section 3.4.4.  
3.4.2 Ethical Considerations 
A plain language summary of the project together with the proposed interview 
schedules and participant disclaimer were submitted to the RMIT Human Ethics 
Committee (HEC) for approval. The project was deemed to be of medium level ethical 
risk due to the participants being recorded and Australian Stock Exchange (ASX) listing 
requirements that all price sensitive information be made available via dissemination 
through the ASX.  
 
During the recruitment process participants were advised that the interviews would be 
recorded with the recordings and subsequent transcripts to be stored in a secure area. 
Both the participant and the researcher signed a consent form to acknowledge that they 
understood this process. 
 
To protect participants’ privacy, a pledge of anonymity was given with only the 
researcher having access to the raw data. There was some concern from one participant 
that even as anonymous contributors they may be inadvertently identified as a result of 
data descriptions included in resulting publications. The small number of listed 
Australian biotechnology firms does expose participants to risk of identity revelation, 
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however this was mitigated through careful presentation of the data in all resulting 
publications.  
 
As an additional security precaution, participants were advised that they would be 
provided with a copy of all research findings prior to publication. In the event that they 
were unhappy with the presentation of their input the researcher would have the 
opportunity to revise the submission. In the event that the researcher was unable to 
appease the participants’ concerns, they had the right to withdraw from the project at 
any time without prejudice.  
3.4.3 Invitation process & participant information 
“Elite” interviewing is a technique borrowed from the political sciences when 
conducting semi-structured interviews with “elite” decision makers or persons, who are 
able to inform on a particular area under enquiry (Burnham, Layton-Henry, Grant and 
Gilland 2004). Elite interviewing is an appropriate term whenever the respondent is an 
expert in the topic under investigation (Kezar 2003). 
 
Senior executives from listed Australian biotechnology firms were targeted for 
participation in this study because of their experience in the topic areas. The subset of 
listed biotechnology firms captures the more mature firms in the industry, likely to have 
been through numerous rounds of capital raisings prior to IPO. Executives from listed 
biotechnology companies were targeted as “elite” respondents to comment on the 
problems facing the industry as a whole.  
 
Senior executives come from a variety of backgrounds which can influence the relative 
importance which they place on the various challenges and opportunities facing the 
industry. To capture this diversity, the invitation process targeted Chief Executive 
Officers (CEOs), Chief Financial Officers (CFOs) and Chief Scientific Officers (CSOs). 
Victoria is home to the largest population of listed and unlisted biotechnology 
companies in Australia with the capital, Melbourne, housing six biotechnology 
precincts which are home to over a third of the nations biotechnology companies and 
around half of all employees in the industry (Department of Industry Tourism and 
Resources, Advance Consulting & Evaluation and Aoris Nova 2004). The diversity of 
Melbourne’s biotechnology industry was deemed to protect the project from sampling 
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bias and thus, to contain data collection costs, the project targeted Melbourne based 
firms.  
 
Initially firms were sent a hard copy invitation via Australia Post outlining the project 
aims and methods and the potential benefits to participants and the industry. Invitations 
were addressed directly to senior executives and a follow up phone call was made one 
week after posting. On the basis of the phone call, those invitees who were interested in 
learning more of the project were sent a soft copy of the plain language statement, 
disclaimer, and a proposed interview schedule. All three of these documents were 
previously approved by the RMIT HEC. 
 
No limit was placed on the number of respondents required for the study and 
recruitment continued until the information generated through the interview process 
approached saturation. In the initial rounds of interviewing a wide and varied 
commentary was collected however as the number of respondents increased 
commonalities in the data emerged. In total 24 invitations were issued with eight 
acceptances. The eight acceptances comprised of three CEOs, three CFOs and two 
CSOs with a diverse range of experience both in Australia and abroad.  
 
The interviews took place between September 2004 and August 2005 and were 
conducted at the participants’ workplaces for their convenience. 
3.4.4 Data Analysis  
The interview transcripts were entered into NVivo qualitative software to manage and 
analyse the data. This software package assisted in the coding, sorting and storage of 
data according to recurrent themes, as defined in the interview schedule, and others that 
emerged during data collection and analysis. The data analysis process consisted of four 
separate components: 
• Transcription and Nvivo import 
• Review and coding 
• Report printing for themes identified 
• Data reduction and discussion 
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The review and coding was an important part of this research as it allowed a detailed 
examination of the data from which common themes and contrasts emerged. The 
documents were coded according to the themes that were identified in the interview 
schedules as well as other themes that emerged during the course of the discussion. The 
themes were sorted according to five broad headings and the information contained 
within each subheading was separated into narrower subheadings. This process was 
continued until the data under each subheading was of a common context. The final 
coding theme “tree” that resulted from this process is shown in Figure 3-3. 
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Figure 3-3 NVivo Coding Theme Tree 
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Each of the nodes in the coding theme tree contained verbatim transcription of the 
discussion relating to that topic which was printed to produce a coagulation of all 
discussion pertaining to that particular theme. These reports were then used to inform a 
discussion highlighting the similarities and differences of opinion that were presented, 
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as well as linking the discussion to recent literature. This process required several drafts 
as the data was incrementally condensed with each draft. This process was deemed to be 
complete once the data could no longer be condensed without reducing the value of the 
data. The final version was then distributed to interview participants for their comment 
prior to final review and inclusion in this thesis. 
3.5 QUANTITATIVE REVIEW OF INITIAL PUBLIC OFFERINGS  
The motivations for a company to raise capital via an IPO can be many and varied. 
However a key concern is usually to gain a successful injection of a significant amount 
of capital into the business (Arkebauer and Schultz 1991). For biotechnology 
companies, which are inherently capital intensive businesses with long product lead 
times, the amount of capital raised that they can dedicate towards development of their 
product pipeline is a critical measure of the success of their IPO (Deeds, Decarolis and 
Coombs 1997). Stuart, Hoang and Hybels (1999) support this notion in their study of 
venture capital backed biotechnology IPOs which used the total capital raised by 
venture capital backed biotechnology IPOs as a measure of listing success. Success of 
IPO capital raisings can be measured by the size of the capital raising, level of 
underpricing, and the performance of the issuing company in the years post-listing 
(Brau, Brown and Osteryoung 2004). A listing that raises less capital, is more 
underpriced and leaves more money on the table, will have been less successful in 
meeting the primary requirement to inject significant capital into the business.  
 
This thesis analyses biotechnology IPOs in Australia from 1994 to 2004 in three key 
dimensions related to their capital raising – underpricing returns, money left on the table 
and total proceeds raised. The analysis tests the relationship between the information 
provided to potential investors within the IPO prospectus and these key measures of 
listing success and performance. Three models have been used: first using the amount 
of money left on the table (measured as the number of shares issued multiplied by the 
first day share price movement) as the dependent variable; second using underpricing 
(the first day shareholder returns) as the dependent variable; and third using total 
proceeds raised (measured as number of new shares issued multiplied by the issue price) 
as the dependent variable. While all companies that list on the stock exchange are 
interested in these three measures, they are of particular concern for biotechnology 
companies given the high cost and long lead time in product development, and the 
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uncertainties regarding the valuation of their intellectual property assets (Schwartz 
2004). 
 
The models developed in this stage of the research test the relationships between data 
contained within Australian biotechnology company prospectuses and the success of 
their IPO, as measured by the amount of money left on the table, the amount of 
underpricing, and the total proceeds raised. Significant relationships identified in 
previous literature were used as the foundation from which the models were built and 
tested using an ordinary least squares regression framework. The data set used in this 
paper was constructed by extracting information from the prospectus documents of 34 
biotechnology companies which listed on the Australian Stock Exchange between June 
1994 and May 2004. Where possible, a copy of the prospectus was used in its original 
format (either electronic or hardcopy). In cases where this was not available, prospectus 
information was sourced from the Connect4 Company Prospectus database. Market 
pricing data was sourced from Datastream. Only those biotechnology firms coming to 
the market for the first time were considered. Of the 34 biotechnology companies, 
twenty-nine focused their research efforts on human therapeutics, four on medical 
devices and one on animal health.  
3.6 QUANTITATIVE REVIEW OF VALUATION METHODOLOGIES  
In the past, organisations were able to hold their competitive advantage by possessing 
certain tangible assets, such as manufacturing equipment, that enabled the production of 
goods in the most efficient and effective way possible.  However, the most valuable 
assets of knowledge-based organisations (such as biotechnology companies) are 
intellectual assets with a high degree of uncertainty in value and application.  Measuring 
and valuing intellectual capital, such as patents or individual and organizational 
knowledge, is a difficult task in any industry sector but the degree of difficulty is 
multiplied exponentially in biotechnology due to the unique and complex and costly 
nature of its resources, dependence on continuing research and development (R&D), 
volatility of outcomes and increasing global competitive pressures (Nicol and Nielsen 
2001). 
 
Beatty and Ritter (1986) found that the greater the uncertainty surrounding the value of 
a firm, the greater the level of underpricing for that firm’s IPO. The cash flows 
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generated by intangible assets, particularly internally generated intangibles such as 
R&D, are less certain than those generated by traditional tangible assets (Barron, Byard, 
Kile and Riedl 2002). This phase of the research seeks to investigate the application of 
alternative valuation techniques for biotechnology investment valuation in an effort to 
expose the key value drivers in a biotechnology project and reduce the level of 
uncertainty surrounding investment in biotechnology assets.  
 
Following from the discussion in Chapter 2, two common real option valuation methods 
were chosen for a detailed analysis and comparison with traditional DCF and eDCF 
models. The simple binomial option proposed by Jagle (1999) was chosen for its 
simplicity and the additional valuation accuracy with regards to life science project 
valuation claimed by the author. The decision tree which forms the basis for this 
binomial option valuation method is the same as that for more common eDCF 
valuation, making for an interesting comparison between the two methods. 
 
Kellogg and Charnes (2000) compare the use of binomial lattice option valuation with 
eDCF valuation for a biotechnology firm in the US between 1994 and 1996. They found 
the binomial lattice valuation works well in the early stages of development when 
valuation uncertainty is highest. The binomial lattice valuation method was included in 
this research to allow comparison between the alternative option and DCF methods and 
to test all models using current data on biotechnology drug development. 
 
Monte Carlo simulation is a method of statistical sampling to examine the behaviour of 
physical or mathematical systems and was named after the gambling casinos of Monte 
Carlo in Monaco (Ulam 1991). This method is particularly useful when examining 
functions with large numbers of degrees of freedom as it allows an examination of the 
relationships between dependent and independent variables that may not be possible 
with complex integral calculus. The application of Monte Carlo simulation in finance is 
particularly useful given the complex nature of valuation equations resulting from the 
large number of degrees of freedom. This analysis enables the practitioner to gain 
insight into expected values and the probability of these values occurring (Razgaitis 
2003). The use of Monte Carlo simulation provides insight into the complex scenarios 
in order to gain a clearer understanding of the relative merit of differing valuation 
techniques (Lohmann and Baksh 1993). 
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A theoretical biotechnology project was created using publicly available industry data. 
Industry averages were adopted wherever possible in order to simulate a typical 
biotechnology project. The project was assumed to have completed preclinical research 
and development and was about to commence phase 1 clinical trials. The data required 
to build the two DCF and real option valuation models is described in Table 3-2. Data 
for each of these inputs was collected from publicly available sources, details of which 
are provided in Chapter 6.  
 
Table 3-2 Valuation Model Inputs 
Development Time Time expected for each of the three clinical trials required for 
regulatory approval plus the time required by the regulator to 
assess the product. 
 
Development Cost Costs associated with clinical trials and regulatory approval.  
 
Commercialisation Cash Flows All cash flows generated in the event of successful product 
registration with the regulator. 
 
Project Risk The probabilities of successfully completing each clinical trial 
as well as the probability of receiving regulatory approval. 
 
Discount Rate The appropriate discount rate for development and 
commercialisation cash flows to reflect the inherent risk in 
each.  
 
Inflation Expected inflation rate over the life of the project. 
 
Risk Free Rate The expected risk free rate of return over the life of the 
project. 
 
 
A valuation model was built for the theoretical biotechnology project described above 
using each of the real option methods described by Jagle (1999) and Kellogg and 
Charnes (2000) as well as traditional DCF and eDCF methods. These models predicted 
value estimates for the project at critical points in the project development cycle. Monte 
Carlo simulation was then used for each valuation model to determine the expected 
distribution of each value estimates and to test the sensitivities of each model to the 
underlying input assumptions.  
3.7 CONCLUSION 
This research methodology outlines a multi-method approach to investigate the multi-
faceted aspects of the valuation challenges facing Australian biotechnology companies. 
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The first stage of this proposal consists of a detailed literature review upon which 
subsequent research is based.  
 
A qualitative investigation of the issues facing Australian biotechnology companies 
forms a broad foundation, providing context for the two focused quantitative research 
components. A greater understanding of the challenges facing biotechnology firms 
provides direction for the subsequent valuation focus.  
 
Two quantitative components of this research delve into the issue of biotechnology 
valuation at the firm and project level. An analysis of biotechnology initial public 
offerings provides insights into the key value drivers for firms during this critical capital 
raising period. Additionally, Monte Carlo simulation of contemporary valuation models 
provides insight into the key value drivers for a biotechnology project with implications 
for both managers and investors. 
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CHAPTER 4 THE AUSTRALIAN EXPERIENCE IN 
PRACTICE 
4.1 INTRODUCTION 
The Australian biotechnology sector faces significant challenges that must be overcome 
if industry participants are to establish themselves as sustainable businesses with 
attractive long term prospects. Current practices encourage the spinning off of 
promising ideas into new entities with one or few products which are forced to compete 
for scarce development capital. As a result of a lack of capital from venture capitalists 
and other sources, firms are often forced into an IPO whilst their products are still in the 
early stages of development, and as a result the amount of capital they are able to raise 
is limited. Once listed, companies are faced with the additional costs associated with 
being a listed company and, due to the risky nature of early stage biotechnology 
projects, have difficulty in attracting long term educated investors such as institutional 
investors.  
 
Biotechnology shareholder registers are typically highly fragmented with a significant 
portion of “mum-and-dad” investors. Unfortunately a lack of understanding by 
shareholders of the underlying science and the long term nature of the industry means 
that trading decisions are often based on sentiment, driving significant share price 
movements unrelated to changes in the value drivers. As a result, building lasting value 
is a challenge to firms which then face difficulties raising additional capital to finance 
their development programs.  
 
This chapter looks in detail at the challenges facing the Australian biotechnology sector 
elicited from discussion with senior executives from eight ASX listed biotechnology 
firms. The challenges facing the industry can be overcome through greater collaboration 
between all sector participants including academics, private industry, and government. 
A greater emphasis needs to be placed on building firms with sustainable business 
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models which will help improve the risk profile of the sector and attract additional 
investment. 
 
The key findings from the interview data were subdivided into five main discussion 
points: capital raising and the availability of funds, the Australian business model, 
biotechnology valuation, and Australia’s challenges and opportunities as a global 
competitor. 
4.2 CAPITAL RAISING AND AVAILABILITY 
“Development capital is the biggest issue for the Australian biotech industry or any of 
the Australian technology industries.” – Executive E  
By far the most common issue that emerged from the interview process was that 
Australian Biotechnology companies face a significant challenge with respect to the 
ability to raise sufficient capital to develop their product to a level which would enable 
optimum profits to be retained by the business. The industry is immensely capital-
intensive, with the estimated “out of pocket” cost to fully develop a drug from discovery 
through to market launch estimated at USD $100 million  (DiMasi, Hansen and 
Grabowski 2003). When allowance is made for capital costs over the development 
period, combined with the low  probability of success, this estimate increases to greater 
than $800 million12 for each drug successfully developed (DiMasi, Hansen and 
Grabowski 2003). The amount of available Australian investment capital is much less 
than that required to bring a product to market, and less than that available to 
international competitors, particularly in the US.  
 
The sources of funds available to Australian biotechnology companies are diverse and 
include pre-seed funding, early development funding from government, private 
investment (from venture capitalists, high net worth individuals, business angels, and 
pharmaceutical partners) and the public markets via an initial public offering (IPO). The 
                                                
12 The capitalised cost of drug development is the subject of much debate however DiMasi, Hansen and 
Grabowski (2003) support the findings of Landers (2003) using an alternative data set. However 
significant variance exists around this number with Bain & Co. estimating that the capitalised cost to 
produce a blockbuster drug is as much as $1.7b USD including some marketing costs (Ernst & Young 
2006). 
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availability of each of these avenues to funding will depend on the individual business 
characteristics. However, even in the most optimistic case, it is highly unlikely that an 
Australian business will be able to raise $100m USD in order to fully develop a single 
product (Executive G). 
 
Biotechnology companies will require multiple rounds of capital raising throughout 
their lifetime. It is important that capital raisings are carefully planned to avoid 
disappointing investors who have contributed in earlier rounds and who often 
participate in subsequent rounds (Executives A, B) . The magnitude of the costs 
associated with drug development are commonly known, however investors will require 
evidence of tangible progress between fund raisings to satisfy themselves that invested 
capital is being efficiently managed to accrue value in the business (Executive B). 
4.2.1 Pre IPO 
4.2.1.1 Start-up phase 
“There is almost an overabundance of funds now available to start up new entities.” – 
Executive E  
In the early phase of product development, Australia has a relatively large amount of 
capital available (Executives C, D, E, F, H). A potentially commercially relevant piece 
of scientific research can quite easily be used to attract initial rounds of funding to 
enable the company to pursue development of its science. The risky nature of the drug 
development industry means that the majority of projects will never make it through the 
rigorous regulatory approval process to become a marketable product (refer section 
4.3.1). The abundance of early stage funding has encouraged the development of a large 
number of businesses with one or few products which therefore have a high chance of 
failure13 (Executives C, F, E, H). Investors seem to be generally wary of the industry 
because of the high risk profile of biotechnology firms, encouraged by the ease in 
raising start-up capital. 
                                                
13 This notion is supported by Vitale (2004a) who recommends a shift away from the current focus on 
company formation from IP generated within research institutions. 
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“Probably three-quarters of the [biotechnology] companies out there are not viable.” – 
Executive E  
As a result of having a fragmented industry with a large number of small companies 
consisting of one or few research products a long way from reaching the market, the 
competition for subsequent rounds of development funding is fierce. Added to this 
competition is the lack of funds available to more mature businesses which has far-
reaching effects through the restrictions it places on business models.  
 
The risk profile of the industry could be improved if there were fewer businesses with 
each having a larger number of research and development projects (Executives A, C, E). 
This would improve the probability of those businesses successfully bringing a product 
to market and would decrease the competition for scarce development funds. A 
reduction in the number of businesses can be achieved through merger and acquisition 
amongst existing businesses, exits of underperforming businesses and a reduction in the 
number of new entities created. Many of the interviewees believe this would allow the 
development capital currently available to be more efficiently allocated towards the 
most viable companies.  
 
Many biotechnology research projects are spawned in academia and the current funding 
mechanisms encourage the spinning out of new business entities. These new entities are 
then forced to compete with existing biotechnology companies for subsequent rounds of 
scarce development capital. If the amount of early stage government funding was 
reduced as a disincentive to spin off new entities, these new ideas could instead be fed 
into existing biotechnology companies that have the expertise in early stage 
development projects. This would allow greater collaboration between university and 
industry whilst creating biotechnology firms with more sustainable product pipelines 
and reducing the number competing for development funding (Executive C, E). 
“Government money is probably best spent on keeping Australian science competitive, 
so you hire and retain the best [academic scientists] and it is up to the companies to be 
creative, to translate that into something, rather than subsidizing more companies to be 
fed with capital.” – Executive H  
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4.2.1.2 Subsequent funding – Venture Capital 
Following initial rounds of pre-seed and seed funding to start up biotechnology 
businesses there is a lack of funding available to sustain the core business activity of 
research and development. In the United States (US), participants in the most successful 
biotechnology industry in the world14 have traditionally been able to source substantial 
development funding from venture capitalists (VCs). The impact of this has been that 
biotechnology companies seeking a public listing in the US are generally more mature 
than those in Australia, with significantly more scale and more advanced research and 
development programs (Ernst & Young 2006) which have already passed a number of 
regulatory hurdles prior to IPO.  
 
The nature of the biotechnology industry, with its high risk profile and long lead times 
in product development, means that likely returns to local venture capitalists will often 
not meet their expectations. An Australian venture capitalist will often invest with a 
goal of achieving an annualised return of around 40% over a three to four year period 
(Executive A). Given that the average time to develop a pharmaceutical product is 12 
years15 (DiMasi, Hansen and Grabowski 2003), there is significant contrast between the 
industry value chain and VC return preferences (Executive A). 
 
In order to overcome this disparity between product development times in excess of 10 
years and a three to four year investment horizon, an IPO is often used as a vehicle to 
provide a return to the venture capitalist (Executive C, E). This requires VC funded 
biotechnology companies to move to IPO whilst their products are still at a stage where 
significant investment of time and capital is required prior to market release. The 
immaturity of the development pipeline means that the issuing company has a limited 
size at IPO and as a result can only raise limited funds and often an order of magnitude 
less than that required to successfully develop a product. If the VCs had a longer 
investment horizon they could work with the businesses to bring in secondary investors 
and grow the business to a more sustainable size prior to IPO (Executive C). 
                                                
14 In 2005 the US was home to 49% of the worlds public biotechnology companies who contributed 76% 
of the revenues produced globally by the sector (Ernst & Young 2006). 
15 Debate exists as to the impact of increased regulation on the time required for clinical trials however 
Keyhani, Diener-West and Powe (2006) find that the time spent in development has not increased 
between 1992 and 2002 which supports DiMasi, Hansen and Grabowski (2003). 
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The short term investment horizon of local venture capitalists is not a phenomenon that 
is experienced in the US. Successful biotechnology companies in the US often go 
through numerous rounds of venture capital fund raisings prior to listing which enables 
them to raise significantly more funds at IPO which, in turn, improves the likelihood of 
success through more diversified development programs (Executive C). 
 
As an alternative source of venture capital funding, successful biotechnology companies 
can look to international markets to secure development capital prior to listing. The US 
venture capitalists are a potential source of funds for the local biotechnology industry. 
However, competition for funding at an international level will ensure that only those 
businesses able to compete internationally will be successful (Executive F). 
 
The risky nature of the drug development industry implies that firms able to diversify 
their research effort should be able to improve their risk profile. Conversely, venture 
capitalists will often invest in a biotechnology company with the proviso that funds will 
be channelled into one lead product (Executive H). In a cash starved industry this may 
be a necessity, however, it serves to exacerbate the risky nature of the industry and 
further promotes the creation of businesses with narrow product pipelines.  
 
Whilst the lack of venture capital funding in the biotech industry is often cited as having 
a negative impact, at the firm level there is also a downside to VC involvement. As the 
biotechnology industry is a comparatively risky business, VCs wanting to minimise 
their investment risk will negotiate extremely tough terms. To protect their investment, 
VCs will often demand preferred shares to ensure that in case of business failure they 
would receive some return prior to any remaining assets being divided amongst the 
remaining shareholders.    
 “VC involvement is not always good. If you were a founder, it is bad. … VCs take 
preferred shares, and if you are a founder you only get common shares.  So everything is 
fine if everything is fine, but once you start having to liquidate a company a VC extracts 
a 200% or 300% return before the pie gets divided.” – Executive H  
Given the difficulties with raising development capital from VCs, biotechnology 
companies will often go to the public markets as an alternate source of capital. Whilst 
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there are additional costs and issues associated with being a listed entity, relative to the 
onerous demands of a VC term sheet, the public markets can be a more accessible and 
less restrictive source of funding for many Australian businesses (Executive E). 
4.2.2 IPO 
As a result of the lack of development funding available through venture capitalists and 
other sources, Australian biotechnology companies tend to go to the public markets for 
funding through an IPO at a much earlier stage compared with those in other developed 
countries. 
 “In effect the public listing market in Australia has acted like a venture capital market, 
because we have not had a venture capital market.” – Executive E  
Raising capital via an IPO is likely to be the largest capital raising in a young 
biotechnology company’s life, however, the amount of capital raised will be well short 
of that required to successfully develop a new pharmaceutical product. In the analysis 
presented in Chapter 5, involving 34 Australian biotechnology IPOs between 1994 and 
2004, the average amount of capital raised was $23.4 million or $11.2 million excluding 
CSL and Cochlear. A capital raising of $11.2 million is an order of magnitude below 
what is required to successfully bring a product to market and, if the probability of 
success is included in the calculation, it is two orders of magnitude below what is 
required. If additional capital were available, biotechnology companies would have a 
more mature product pipeline when they eventually go through the IPO process. This 
would enable them to raise larger amounts of capital from the public markets, thus 
creating a more sustainable group of publicly listed biotechnology firms (Executive B). 
Having a more mature product pipeline and more capital for product development 
would change the risk profile of the listed biotechnology sector and, in turn, encourage 
greater investor interest in the secondary markets.  
 
A listed company faces increased administration and corporate governance costs on top 
of the huge investment required to successfully bring a pharmaceutical product to 
market. Whilst an IPO may be a source of funds accessible to Australian biotechnology 
businesses in the event that there are no alternative options of sufficient scale, they 
should be wary of pursuing this avenue without due consideration of the associated 
costs of being a listed company.  
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“The whole system here really pushes companies out [into the public market] 
prematurely and sets them up for failure.” – Executive C 
4.2.3 Life after IPO 
The aim of going through an IPO is to source a significant amount of funds. However, 
for a small biotechnology company, the costs related to being ASX listed can represent 
a significant proportion of total costs, taking away money that could otherwise be 
invested in the core business of research and development. On top of the direct costs of 
meeting listing obligations, the increased administrative workload means that staff is 
distracted from operational roles within the business, restricting the resources that are 
available for value-generating research and development. This is a heavy burden on 
cash starved businesses in the sector which could be avoided if companies were able to 
find sources of funds other than the public markets (Executive A, E). 
 
Whilst the industry could benefit from consolidation (refer section 4.2.1.1), owners of 
the businesses will often be reluctant to hand over control of their research and 
development project. This can be especially relevant where the owner is a founding 
scientist.  
 “There is talk about M and A’s coming in, aggregating the industry and in theory that is 
fine … [However] you have still got owner interaction at the research and development 
level and they are not prepared to give up their babies at this stage.” – Executive A  
4.2.3.1 News Flow 
Continuous disclosure obligations of the ASX require that listed businesses must 
disclose all price sensitive information to the public as and when the company becomes 
aware of it. This news flow is assessed by the investing public which estimates the 
impact on the business and hence on the value of its shares. For biotechnology 
companies, the volume of news flow produced is often relatively low compared with the 
market as a whole and this is magnified when a biotechnology company has only one or 
few products in development (Executive C, G). A lack of news flow potentially creates 
investor uncertainty regarding the state of the business and, as uncertainty increases, 
ceteris paribus, the company value potentially decreases. 
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 “Australian Biotechs are forced into the public domain early, and the consequence of 
that is your share price is being re-rated daily, usually on information that is unrelated 
to your actual progress.” – Executive G  
4.2.3.2 Secondary Market 
Demand for biotechnology shares in secondary markets is generally low as typified by 
low trading volumes and limited involvement from institutional investors and 
investment funds. Poor demand for shares makes it difficult for listed biotechnology 
companies to raise additional funds in the domestic market (Executive E). Whilst an 
IPO is a funding mechanism which generates a substantial inflow of capital, firms need 
to be wary of their longer term capital requirements prior to committing to a public 
listing. Additionally, given the small market capitalisation of firms, sale of additional 
shares will result in dilution of control of the existing shareholders (Executive H).  
 
Performance of biotechnology shares in the secondary market will be dependent on 
mainstream investor confidence in the biotechnology value proposition. As business 
models mature and products are launched, improved company risk profiles will see 
increased investor interest, which will drive greater attention from financial analysts. As 
investors become more familiar with the industry, confidence in the value proposition 
should improve. This should see increased investment in the sector enabling firms to 
capture more value from their IP as they are able to finance products further down the 
value chain.  
“Private funding tends to be fairly small amounts of money. It need not be if super funds 
or investment funds gain more confidence over time.” – Executive G  
4.2.3.3 The Investment Community 
The high risk profile of businesses in the sector is exacerbated by the infancy of the 
industry, which in turn does not inspire investor confidence in the value proposition. 
The immaturity of businesses is exemplified by the high proportion of businesses with 
products in the early stages of product development and the lack of diversity in product 
pipelines.  
“Apart from two or three, no one has a product even close to the real market stage, 
where they will have a large distribution income coming in …  While that is the case, the 
investment market, is going to be, naturally, a bit wary.” – Executive B 
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As businesses mature and we begin to see models for success, interest in the sector from 
the investment community should begin to rise. Increased investor attention will 
demand greater analyst coverage of the sector which, as the analyst base gains 
experience, will help to direct cash flows into the sector. Currently there is a lack of 
experienced analysts with the ability to adequately evaluate investment opportunities 
and offset some of the investment risks associated with the industry (Executives C, E, 
G). 
 
Without an experienced analyst base, an important moderator of investment opinion is 
missing from the sector. This is compounded by the low levels of news flow generated 
by industry participants, the result of which is stock market valuations which are subject 
to large variations and largely sentiment driven (Aegis 2006a).   
“In the biotech research and development area the market is not particularly 
sophisticated and can be very speculative because people jump to conclusions” – 
Executive A  
Whilst the risks associated with investment in biotechnology may deter potential 
investors there is investment money available for risky ventures such as the mining 
industry (Executives A, G). Similar to biotechnology, the mining industry evolved from 
a base of speculation-driven investment to become an industry with an informed analyst 
base, able to assess opportunities and provide the investment community with a 
comparative indication of quality (Executive A, E, G).  
 
The diversity of the biotechnology industry makes evaluation of opportunities difficult 
because, unlike the mining industry, there is no homogenous information base (such as 
mineral purity levels) which can be used as a measuring stick (Executive G). Despite 
this challenge, development of an educated and experienced analyst base would provide 
the industry with a mechanism for directing funds into the sector. 
“[Australian investment] fund, are quite happy to have a go at speculative things such 
as mining ventures … however there isn’t a good analyst base in the Australian biotech 
markets.  There are not people who are the gatekeepers of what is good and who is not 
good.” – Executive E  
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As a result of a lack of an informed investor base, money is not efficiently channelled 
out of underperforming businesses into those with product portfolios of higher potential 
and more sustainable business models. As a result we have not seen a significant 
number of failures in the industry and the businesses that require and deserve additional 
funding have greater difficulty in sourcing it due to the increased competition.  
“There is no culling process in the Australian market. … time will sort that out to some 
extent, but the more non-informed money is available, the less of that culling process 
occurs.” – Executive E  
i Superannuation Investment 
The superannuation sector is a potentially significant source of funds for the 
biotechnology industry, through direct investment in IPOs and secondary markets as 
well as indirect investment through VC funds (Executives E, G). Given the risky nature 
of the industry, any investment by superannuation funds would have to be carefully 
managed to protect the retirement nest eggs of fund members. 
“I would be ropable if I thought that my super fund was investing in these companies 
which are no place for widows and orphans.” – Executive A   
In the US, superannuation funds invest in VC funds, which in turn invest a proportion 
into the biotechnology sector (Executive E). In this way, the experienced VC industry 
acts as a mechanism to direct capital towards the most attractive opportunities, helping 
to mitigate some of the risk associated with the sector.  
ii Institutional Investors 
Investors in biotechnology companies listed on the ASX are primarily retail, consisting 
of mostly ‘mum and dad’ investors with minimal representation from institutional 
investors. For a listed business, this means their shareholder base is very diverse, with 
few large holdings, and often held by investors without a strong knowledge of the 
sector. Problems also arise in that shareholders do not fully appreciate the challenges 
faced by the business and as a result are unsatisfied with their short-term returns 
(Executive C). 
 
The diverse and segmented nature of a typical listed biotechnology company 
shareholder base creates an additional administration workload for management in 
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having to communicate with a large number of shareholders, many of whom do not 
fully understand the biotechnology business model and its associated challenges 
(Executives C, D, E). Time spent by staff managing their shareholder base is 
considerable and distracts staff from the core business. This is particularly a problem for 
companies which have no investor relations team between senior executives and the 
shareholders.  
 
If there were greater involvement in the sector from institutional investors, the breadth 
of the shareholder base could be reduced as the institutional investors have the scale to 
hold large parcels of shares (Executive C). To facilitate greater institutional investment 
in biotechnology, a more experienced and educated analyst base is required to direct 
capital to the most deserving firms (Executive E). This would benefit the industry, 
enabling those businesses with large institutional investors to more efficiently 
communicate with their more consolidated shareholder base. Additionally, an increase 
in ‘educated money’ in the sector would reduce the dramatic impact that sentiment 
currently has on share prices (Shiller 2005).  
4.2.4 An International Comparison 
The therapeutic drug market is globally competitive, thus it is important that the 
environment in Australia be structured to allow locally-based companies to compete on 
a global scale. As a result of the relatively meagre availability of funds to the domestic 
market, Australian biotechnology firms are much smaller than those in the US with less 
diverse product pipelines and the subset of companies listed on the stock exchange 
typically have products at a much earlier stage in development. 
 
The biotechnology industry in the US leads the world, with the average revenue per US 
listed biotechnology company being more than three times that of the rest of the world 
(Ernst & Young 2006). Unlike Australia, VCs in the US are actively involved in the 
sector and a typical firm could expect multiple rounds of VC funding prior to IPO. As a 
result, the average size of biotechnology IPOs in the US is significantly larger than 
those in Australia. During 2005 there were 13 IPOs in the US at an average of over 
USD $48 million compared with 10 in Australia at an average of around USD $5 
million (Ernst & Young 2006). 
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One interviewee with extensive first-hand US experience describes the contrast with the 
Australian situation:  
“The model in Australia seems to be to get some early stage funding drip feeding into 
the company and with no idea of building value before being subjected to the vagaries of 
the public market. In the US a company would start off funded by a university or 
whatever and it would go maybe 4 rounds of private equity and build itself to the point 
where, at IPO it could come out with a market capitalisation of $100m. It would not 
want to come out until it had some products in the clinic and … a reasonable news 
flow.” – Executive C  
4.2.4.1 Foreign Listings 
For Australian companies to access the US financial markets requires a scale not 
currently seen in the domestic sector, apart from the most mature players who do not 
have the same capital requirements as the early stage businesses. Typical US investment 
banks require firms to have a market capitalisation of greater than $150m before being 
able to access public markets in the US (Executive E).  
 
Australian firms face a significant challenge to achieve the scale required to source 
capital through a public listing in the US. If they can overcome this challenge, the 
rewards are potentially significant as a cross-listing in the US has been shown to 
improve valuation multiples (such as price-to-book and price-to-earnings) for foreign 
based firms (Sundaram and Logue 1996). Thus if Australian-based firms can list on the 
US markets then they should realise a higher valuation as well as greater access to 
capital (Executives B, C, E).  
 
US investors prefer a local presence as this enables efficient management of 
communications (Executives C, E). Unfortunately, the cost of setting up and 
maintaining a foreign base challenges the viability of maintaining that base (Executive 
D). Whilst this is a significant consideration, the potential rewards in the form of 
improved valuations and access to capital to drive growth in the company make the 
additional expense a worthwhile investment if the expansion is strategically managed.  
 
The Sarbanes-Oxley reporting requirements currently being implemented in the US 
create an almost insurmountable financial burden for a firm the size of a typical 
Australian biotechnology company. Conversely, educated investors will realise that it is 
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not in their interests to have small research and development firms spending their 
limited capital resources on reporting when those funds could otherwise be spent on 
productive research (Executive B). It remains to be seen what reporting requirements 
will be placed on the smaller firms, however, whilst this is being decided, the 
availability of the US public markets to smaller biotechnology firms remains uncertain.  
“If the US regulators are going to try and put the same standards for larger companies 
on to the smaller ones, costs will be horrific.” – Executive B  
4.3 BUSINESS MODEL 
The immaturity of the Australian biotechnology sector means that very few products 
have been successfully developed. As a result there is no proven road map for success in 
the local sector which adds to the uncertainty in the industry (Executive C). Until 
successful business models emerge we will continue to see diversity in the manner in 
which firms extract value from the field. 
 
Typically an Australian biotechnology business looks to develop its products as far 
through the development cycle as possible, given the firms funding constraints. Once 
the business approaches a point where it is unable to fund further development, 
management will look to licence the product to a partner, usually a pharmaceutical 
company, which has the ability to fund the remaining development process and 
facilitate commercialisation. Generally, the partner will provide the biotechnology firm 
with cash flows in the form of a sign-on fee, milestone payments attached to key 
development hurdles and a royalty based on the sales volume of the final product 
(Executive D). 
 
Traditionally, a firm would look to reinvest a portion of profits into the business to fund 
research and development in order to maintain a competitive advantage and protect 
future income streams. Unfortunately, very few Australian biotechnology companies 
have evolved to the stage where they have a reliable income stream from which they 
can finance research and development efforts. As a result of the shortfall in capital 
available to the local industry, firms are wholly dependent on their ability to out licence 
their products in order to further their research and development programs. 
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“I see the business model in Australia as completely flawed.  Discover something, sell it 
early and wait for somebody else to do something.” – Executive F  
4.3.1 The Biotechnology Value Chain 
A simple depiction of the drug development value chain is shown below in Figure 4-1. 
Based on data from the US, only 1% of the total number of new therapeutic research 
projects that are commenced can expect to make it into clinical trials, and of those that 
do make it into clinical trials, only around 25% will successfully make it through to 
registration with the Food and Drug Administration (FDA) (Abrantes-Metz, Adams and 
Metz 2005). 
Figure 4-1 Biotechnology Value Chain & Development Success Rates (Abrantes-Metz, Adams and 
Metz 2005) 
Discovery
Development Manufacturing, 
Sales & 
Marketing
Pre Clinical Stg 1 Stg 2 Stg 3
Success Probabilities  
 
The set of Australian biotechnology firms listed on the ASX represents a subset of the 
biotechnology industry as a whole and comprises the most mature firms in the industry. 
Among those, generally the most advanced product in the pipeline will be in the early 
stages of development, with only a minority having a product at phase two clinical trials 
or later. For a product entering phase two clinical trials, the probability of successfully 
bringing that product to market is only 33% (0.58 * 0.57) thus a company with only one 
or two products in their pipeline has considerable exposure to the risk that none of its 
products make it to market.  
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Table 4-1 Benefits of Diversified Development Portfolio - Probability of Market Launch 
This table shows the probability of at least one product in a portfolio of X products being successfully 
launched on the market (where X is a number from 1 to 5). For the sake of simplicity, this table assumes 
all X products are at the same stage of development. The probabilities shown in this table have been 
calculated based on the probabilities of successfully passing each round of clinical trials published by 
Abrantes-Metz, Adams and Metz (2005) and assume that the probability of successful completion of each 
round of clinical trials is independent of the result in the previous round or the results of other products in 
the pipeline. 
 Number of Products 
Development Phase 1 2 3 4 5 
1 26% 46% 60% 71% 78% 
2 33% 55% 70% 80% 86% 
3 57% 81% 92% 96% 98% 
 
In order to minimise the exposure to the risk of failing to successfully bring a product 
through clinical trials, a biotechnology company must have more than one product in its 
pipeline. Table 4-1 above has been computed based on the data from Figure 4-1 and 
shows the diversification benefit of each additional project in the pipeline. The table 
shows the probability of a firm successfully bringing a product to market depending on 
the number of projects in the pipeline and the development phase of those projects. 
Interestingly a company with three products in phase 1 clinical trials has a 60% chance 
of successfully bringing at least one of those to market whilst a company with two 
products in phase 2 clinical trials has only a 55% chance of successfully bringing at 
least one to market. 
“If you want to build something of substance, something that has any chance of viability, 
it has to have a portfolio.” – Executive C 
A company that has a project closer to completion of clinical trials has a greater 
likelihood of converting that expense-generating project into a consistent revenue-
generating product and thus producing profits. Without a fully developed product, 
biotechnology firms are reliant on milestone payments for revenue which are uncertain 
and lumpy by nature and, if they are the only form of revenue that a firm has, the 
business will be challenged to manage the regular expenses of a development program. 
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“Take science out of it and have a look at the fundamentals of the businesses that we are 
building here. They are flawed. … You cannot actually build a business on lumpy 
milestones.  You might get a milestone but if the project falls over then you are back to 
square one.  So should we not actually be going the other way and saying, right, let’s get 
products first, let’s get revenue and from that, build up the intellectual property. … We 
have in-licensed a later stage product, because it has a very high probability of success. 
… Ideally we would go after something that was on the market, so that we could actually 
sell and make profit. It is all about making profit; businesses only grow because of 
profit.” – Executive F  
4.3.1.1 Evolution 
“One never really realises the full benefit of pharmaceuticals until one is actually the 
owner of the marketed product and shares very substantially in the final market 
product” – Executive D  
Currently Australian biotechnology companies are at the early stages of product 
development and dependent on licensing deals with pharmaceutical companies to 
generate revenues. As products are developed and move through the value chain to 
eventual market launch, the revenue stream for biotechnology companies will lose the 
inconsistency of milestone payments and begin to correlate with product sales. This will 
provide biotechnology companies with a source of capital to fund further research and 
development enabling them to maintain ownership to a point closer to market launch 
prior to seeking a licensing partnership with a larger pharmaceutical company. 
Biotechnology companies would thus be able to capture more of the value created 
through product development which will in turn generate greater returns to 
shareholders.  
 
As a product in development moves through the value chain, the likelihood of 
successfully making it to market increases with each step in the process. Thus, ceteris 
paribus, a biotechnology company with product(s) closer to market launch has a 
reduced risk profile. Biotechnology companies will naturally evolve with their products 
and move down the value chain. However, to expedite the process and improve the 
business risk profile, acquisition of products further down the development pathway can 
improve the value proposition for potential investors and increase the amount of 
development capital flowing into the business. Unfortunately, due to the capital 
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constraints of the sector, acquisition of late stage research is an option only available to 
a subset of the industry. 
“We had too many things at the start end of the pipeline. We needed to get hold of 
something that was closer to fruition so that we had a better story to tell.” – Executive B  
Movement down the value chain brings a new set of challenges and biotechnology firms 
will need to expand their existing skill sets to meet those challenges. Once a product has 
regulatory approval there is considerable investment required to successfully 
manufacture, market and distribute the product. Existing pharmaceutical companies 
have proven competencies in manufacturing therapeutics to meet global demand, 
combined with distribution networks with global reach and established sales and 
marketing teams. A small biotechnology company cannot hope to compete with these 
established players, however, opportunity exists for biotechnology companies to move 
into this space with niche products.  
 
i Expansion through Specialisation 
Product sales ultimately depend on those responsible for treating a particular disease or 
condition prescribing that drug for treatment. A product that is typically sold through a 
pharmacist via referral from a general practitioner will require an extremely large 
marketing effort and sales team to reach the general practitioners. Products that are 
administered directly through a specialist clinician will require significantly less 
marketing and sales investment as the number of specialist clinicians will be far less 
than the number of general practitioners. The reduced cost to distribute and market a 
product to specialist clinicians provides biotechnology companies with the opportunity 
to expand beyond pure product development and into sales and distribution, enabling 
them to capture more value from the therapeutic development chain (Executives C, F). 
 
An example which highlights the differing marketing resource requirements of drug are 
a cancer chemotherapy treatment versus an asthma treatment. The asthma drug is 
administered by the patient and distributed through a retail chemist via prescription 
from a general practitioner, whereas, the cancer chemotherapy treatment will be 
distributed and administered directly through the treating clinician. The number of 
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treating clinicians will be significantly less than the number of general practitioners 
allowing a much smaller sales force to service the former market. 
 
The concept of distribution to specialist clinicians using a small sales team was coined a 
“specialty pharmaceutical business” by Executive F. A small sales team is able to work 
closely with the research team responsible for developing the drug which should see the 
evolution of a highly educated sales team able to more effectively interact with the 
administering clinicians. Development of close relations with the clinicians allows 
information to flow from the research team to those administering the product and back 
from the clinician and patient to the research team (Executive F). This assists the 
biotechnology company in effectively managing and responding to challenges and 
opportunities as they occur. 
 
The small size of the Australian relative to the global market creates an opportunity for 
local biotechnology companies to move down the value chain locally whilst partnering 
with a larger pharmaceutical company to supply to the larger global markets. This 
strategy will allow the biotechnology company to expand their business model and gain 
expertise in sales and distribution in Australia. As additional products move through the 
development pipeline, opportunity exists for the biotechnology firm to leverage off this 
experience and expand into nearby emerging markets. This process of regional 
expansion into product commercialisation was described as a company goal for the 
majority of executives in the study. 
“Once you build something in Australia you can build it out regionally.  Obviously there 
are emerging markets that are closer to us than to our potential partners overseas.” – 
Executive C 
ii Business Evolution and Value Capture 
Evolution of the biotechnology business model down the drug development value chain 
is seen as the mechanism for capturing a greater portion of the total value generated in 
the process. The notion of capturing additional value as products move through the 
value chain is based on historical deal terms for out-licensing products at different 
stages in the development cycle. Traditionally there has been a disproportionate increase 
in the value of terms negotiated (compared with the additional cost incurred) for each 
successful step in the chain (Kalamas, Pinkus and Sachs 2002).  
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Recently there has been a change in the competitive landscape for biotechnology 
products, with existing pharmaceutical companies challenged by ageing pipelines and 
increasingly looking to in-license biotechnology products to fill the shortfall in 
development stage products. Figure 4-2 below shows how pharmaceutical firms have 
been investing greater amounts of capital for decreased return in contrast to the 
biotechnology sector.  
Figure 4-2 Decreasing Pharmaceutical R&D Productivity (Ernst and Young, page 29, 2006) 
 
 
With reduced internal research and development productivity, pharmaceutical 
companies have increasingly come to rely on biotechnology firms as a source of new 
products. This has seen an increase in the demand for biotechnology products at all 
stages in development (Belsey and Pavlou 2005).  
 
The stage at which a biotechnology company is willing to out-licence a product will be 
largely determined by the terms of trade they can negotiate at that stage in development. 
If biotechnology firms were offered/able to negotiate more favourable deal terms for 
earlier stage products, we could see an increase in the number of deals done earlier in 
the value chain and a shift in value capture, away from the later stages back through the 
pipeline.  
 
The amount a pharmaceutical company should pay for early stage products will be 
influenced by the likelihood of a product successfully reaching the market, thus an early 
stage product should have a lower value than a later stage product. Kalamas, Pinkus and 
Sachs (2002) state that the terms offered by pharmaceutical companies to in-license 
products from biotechnology firms are disproportionately higher for later stage products 
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given the probability of successfully developing an early stage product. Their Monte 
Carlo analysis of drug licensing deals shows that pharmaceutical companies would be 
better off increasing the number of products in their portfolio to diversify product 
development risk by offering more attractive terms for earlier stage products. Recent 
financing trends indicate that large pharmaceutical companies are indeed looking to 
partner with biotechnology firms to develop products from earlier stages in the product 
development chain (Anderegg, Thayer and Williams 2006).  
 
If pharmaceutical companies offered more attractive terms for early stage products, 
early stage biotechnology firms would be able to capture a greater portion of the value 
generated through the drug development value chain. Dwindling efficiency of in-house 
pharmaceutical research and development has resulted in an increased focus by big 
pharma on early stage biotechnology research (Jones and Clifford 2005). Should this 
trend continue, the potential exists for a paradigm shift in the traditional biotechnology 
model, away from evolution down the value chain, towards biotechnology 
specialization in discovery and early stages of drug development. This shift towards a 
more segmented industry, with participants focused on one or few components of the 
value chain, is comparable to the personal computer industry where different 
components, such as the processing chip and memory, are manufactured by different 
suppliers. Greater focus on a narrower segment of the value chain would allow firms to 
focus their expertise and could lead to increased efficiencies industry-wide (Executive 
H). 
4.3.1.2 Sustainability 
The current Australian biotechnology business model, which has one or few products in 
early stage clinical trials and aims to out-licence to a big pharmaceutical company in 
exchange for milestone payments and royalties, is not seen to be sustainable given the 
low probability of successful development and current deal terms. In order to develop 
into sustainable businesses, Australian biotechnology companies need to increase their 
expected return on investment, which could be accomplished by carrying their products 
further through the value chain and/or negotiation of better deal terms with 
pharmaceutical companies. 
 
The ageing pipelines of pharmaceutical companies (see Figure 4-2 above) provide 
evidence of the difficulty in sustaining the biotechnology business model. With the 
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majority of value generation skewed towards later stages in the development cycle, 
pharmaceutical companies have increasingly evolved to focus on late stage 
development, manufacturing, distribution and sales with discovery and early 
development done by small biotechnology firms (Executive D). 
 
The majority of participants in the study saw the successful biotechnology firm of the 
future occupying a greater space in the drug development value chain. In order to 
sustainably occupy the development space, firms would need to continue to bring new 
products into their pipeline to replace older products as they mature and move towards 
patent expiry. New products could come from internal discovery programs and would 
also require firms to license in early stage products. (Executives A, B, C, D, F). 
 
To mitigate the risk of project failure and improve the sustainability of the 
biotechnology business model, firms should look to increase the number of research 
projects in their pipeline (refer section 4.3.1). The capacity for increasing the number of 
projects in their pipeline is limited by access to capital, however, through merger and 
acquisition, economies of scale can help to realise cost saving synergies at the same 
time as reducing the business risk profile. Recent activity in the industry, such as the 
acquisition of Meditech by Alchemia, improves the survival prospects of the industry, 
by improving administrative efficiencies and diversifying product development risk.  
4.3.2 A Response to the Funding Environment 
“The lack of funding is definitely going to have an impact on the model because models 
are usually a consequence of environments.” – Executive F  
Australian biotechnology firms are constrained by a lack of capital from broadening 
their business model to occupy a greater portion of the drug development value chain. 
To achieve this will require additional funding, both from sources external to the 
business coupled with internally generated cash flows as current products in the pipeline 
begin to reach the market and generate royalty revenue streams (Executive F). 
Therefore, without access to substantial capital in the near term, expansion of scope 
across a broader section of the value chain will be achieved in incremental steps.  
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The typical business model of a biotechnology firm is to undertake research and 
development to identify new chemical entities and develop them to a point where they 
are able to get a return commensurate with the investment, and exposure of the business 
(Executive D). Unfortunately for Australian biotechnology firms, the point at which 
they are forced to out-license their product is often determined by their ability to 
continue to fund development as opposed to development reaching a point where a sale 
would generate optimal returns for the business.  
 
For the local industry, the lack of development funding means that firms are forced into 
a sale of their intellectual property (IP) at too early a stage, with the purchaser usually 
being a foreign company (Executive F). As the major part of value capture is skewed 
towards the later stages in product development this means that significant potential 
wealth gain is lost from Australia to the benefit of competing international industries. 
 
The nature of the Australian biotechnology industry means that the majority of firms in 
the sector have their business models influenced by their access (or lack thereof) to 
capital. However, firms need to be careful in their communication with investors and 
potential investors during fund raising activities as the message they portray regarding 
the urgency of their capital requirements can affect their ability to raise capital. If 
investors are aware that fund raising is driving the business then the company will be 
penalised in the form of reduced valuations combined with greater difficulty sourcing 
capital (Executive B).  
 
The largest risk to a biotechnology firm is the risk of failure in product development 
(Executives B, E).  Following product development risk is the risk that a firm will be 
unable to source the level of funding required to run their development program to a 
point where they are able to capture a commensurate portion of the value generated 
(Executive E). Whilst the business model should not be entirely dictated by access to 
capital, the formation of the company should be determined with consideration of 
potential investors (Executive A). For a company with multiple research opportunities, a 
focus on one which has greater potential for external investment will allow the company 
to source more capital to drive development of proprietary technology which can later 
be applied to subsequent products in the pipeline (Executive E). 
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The inability of Australian companies to raise the level of capital necessary to develop 
their pipelines to a point where a sale is motivated by fulfilment of firm objectives as 
opposed to a need for funding has had some positive impacts on Australian businesses. 
Firms are forced to look at international funding opportunities, which is appropriate 
given the global nature of the market for therapeutic drugs (Executive B). Additionally, 
Australian biotechnology companies have evolved into more streamlined businesses 
compared with their US competitors (Executives A, B, C, D, E, F). 
 
The reduced scale of Australian firms has allowed them to control costs, however, it can 
also affect their ability to be internationally competitive. By keeping staff numbers low, 
the ability of a firm to recruit the range of skills necessary to be internationally 
competitive is compromised and this is evidenced in the lack of products that have been 
successfully developed by the local sector (Executive E). The reduced level of funding 
also encourages the model of a one-product company which will more than likely fail 
given the historical probabilities of successful development of pharmaceutical drugs 
(Executive C). 
4.3.2.1 Product Focused Companies 
A product focused company is one which is based on development of new therapeutic 
drugs – the product. These biotechnology companies rely on the successful 
development of their pipeline for revenues. However, given the funding environment in 
Australia, they will typically have one product that is the focus of their research effort 
and expenditure, with others at earlier stages in the development chain. Obviously the 
survival of a company is dependent on the successful development of products, 
however, given the historical probabilities of successful drug development, they are 
likely to fail if they have only one or few products in development. Unfortunately 
investors will often demand that efforts be focused on the most advanced product in the 
pipeline, which is setting the company up for failure (Executives C, G, H).  
 
Those companies that are able to successfully bring a product to market have a revenue 
stream to fund their alternative research projects. Conversely, those companies unable 
to bring their initial product to market are in the unenviable position of having limited 
funding for their alternative projects in the early stages of development as a result of 
previous investment in one (failed) project. Once a company has invested a significant 
portion of their capital in their lead product, the survival of the business becomes 
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increasingly tied to the success of that product. As more capital is invested into that 
project it is progressively more difficult for the company to justify investment in 
alternative projects (Executive G).  
 
Whilst investors may wish to increase the likelihood of the most promising product 
being successfully developed by focusing research effort and expenditure, the 
repercussions are potentially damaging for the business and sector as a whole 
(Executives A, C, E, G). Historical probabilities suggest that companies focused on one 
lead product are more likely to fail. Given the current level of investor uncertainty 
towards biotechnology, combined with the large impact of investor sentiment on 
company values, failure of one or few biotechnology companies is likely to see an 
exodus of capital out of the industry which will further jeopardize the prospects of the 
remaining firms (Executive A).   
 
The benefits of diversification need to be carefully considered given the complexity 
associated with each research project. Whilst there are obvious benefits to 
diversification in terms of risk management, firms should try to match their pipeline 
with their proprietary knowledge.  The level of technical complexity involved with the 
development in one therapeutic area means that it is very difficult for a small firm to 
possess the knowledge required to run a second development project in a second 
therapeutic research area.  
“In this business you want to be very focused on what you do.  You build expertise in a 
particular area and you stick to it until such time as an expansion beyond that area 
makes sense.” – Executive D 
Consolidation in the industry would see the formation of teams with greater diversity in 
research experience, enabling companies to sustain more diverse research interests. 
Despite the benefits of diversity in research specialisation, care must be taken to ensure 
that the complexities of all the research interests are understood at senior management 
level to enable intelligent strategic decisions.  
4.3.2.2 Technology Platform Companies  
Many biotechnology companies have ownership of a novel piece of technology with 
potential application to a variety of areas. Owners of a technology platform are usually 
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focused on developing one or few products using the technology, and through 
successful product development, generate significant revenues for the business and 
provide a form of validation for the technology.  
 
The diversity of research alternatives generated by a technology platform creates 
opportunities for the owning biotechnology company to bring revenues into the business 
at an early stage by out-licensing the platform to firms with expertise relevant to a 
particular research application. In this way, the research is being conducted by those 
with expertise in its application, at the same time generating revenues for the owning 
business which can help fund its own product development pipeline  (Executives C, H).  
 “I like to call it the ‘pay as you go’ model. You don’t have anything yet, but you let 
other people use your platform, so that you can get something in return while you are 
building your own pipeline. It allows you to establish a business with cash flows as soon 
as possible.” – Executive H  
The variety of potential applications for a technology platform provides the owning 
company with numerous research alternatives, providing a potentially diverse product 
pipeline for the business. This diversity poses similar challenges as those faced by a 
product focused company, in that there is often difficulty in assembling research teams 
with the ability to develop products from differing research areas (Executives C, E).  
4.3.2.3 Virtual Companies 
The “virtual” biotechnology company is one that conducts its drug discovery and 
development work external to the firm through a contractor(s) (Broderson 2005). This 
model has evolved in response to the scarcity of funding and allows more effective 
management of the operational costs of the business. This model allows managers to be 
flexible in choosing the best supplier of development talent whilst maintaining the 
ability to change the scope or scale of research activities quickly at minimal cost.  
 
By outsourcing research and development work, virtual companies can potentially 
manage a more diverse product pipeline by ensuring that each project is in the hands of 
those with the necessary skills. This allows the firm to enjoy the risk mitigation benefits 
of diversification whilst still having projects optimally developed.  
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Despite the benefits of having a diverse pipeline being developed in the hands of 
experts in each of the relevant fields, management is still exposed to operational risks as 
a result of actual and perceived difficulties in understanding the complexities for each 
project. Whilst external consultants can provide expert opinion on the research 
programs, it is important that management have a high level of understanding in all of 
the firm’s research areas in order to assess opportunities as they arise, and ensure firm 
resources are efficiently allocated.  Investors will also be wary of an overly diverse 
product portfolio owing to concerns around management’s lack of adequate expertise in 
all project areas (Executive A). 
“Having somebody else outside developing [a product] means that you never properly 
develop the expertise within.” – Executive A   
The virtual model relies on people external to the business working on product 
development, the key value driver for the business. The business is exposed to 
additional risks resulting from the loss of control through having people who are not 
employees of the business spending 100% of their time on the most important value 
driver for the firm. If the people working on the development projects are employed 
directly by the firm then the employees can feel truly a part of the company and in 
effect take some ownership of the program (Executive C). Additionally this means that 
the expertise that is developed throughout the process is kept in-house, enhancing the 
firm’s level of proprietary knowledge. 
4.3.3 Management 
The quality of the management team is vitally important in ensuring that a company is 
able to successfully capitalise on its IP.  
“I  would rather have a first-class management team and a good product as opposed to 
a first-class product and a rotten management team.” – Executive G 
Despite the magnitude of the capital requirements to produce a drug, participants in the 
Australian industry are mostly small businesses who are forced to actively manage their 
costs, including keeping staffing levels to a minimum. In the US the average number of 
employees per biotechnology company is around 100 which is in stark contrast to the 
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Asia-Pacific region which has an average of around 20 employees per biotechnology 
company (Burrill 2006). 
 
The process of raising capital in a small company with limited human resources often 
requires personnel from different parts of the business to assist in the process. Staff are 
thus drawn away from core competencies. For a biotechnology company this will often 
mean taking scientists out of the laboratory, away from the primary value driver of the 
business and adding further delays to the long lead times associated with product 
development (Executive B).  
 
In keeping staffing levels at a minimum to control costs, often staff will be required to 
manage a number of different components of the business, which can have employees 
working outside their primary skill set. The drug development industry is internationally 
competitive, thus, in order to successfully compete, Australian biotechnology 
companies must employ teams of internationally competitive experts. At current 
funding levels this is extremely difficult to manage and as a result the ability of the local 
industry to compete on a global scale is compromised (Executive E).  
 
As products are successfully launched, the more consistent revenues generated through 
product royalties will allow biotechnology firms to expand the expertise of their 
management teams. This will enable them to conduct in-house a greater range of the 
tasks required to develop a product and facilitate evolution of the firm down the value 
chain (Executives C, E).  
 
A particularly sensitive issue for the industry is the role of scientists in management of 
the business. A person with limited scientific background will have great difficulty in 
understanding the science driving the research and development programs and, as a 
result, find it very difficult to manage a biotechnology company with products at the 
early stages in development (Executive C). Managers of early stage companies should 
have the ability to understand the science and at the same time possess the skills 
required to be able to manage the research programs.  
“You don’t have to be a brilliant scientist to be a good scientific manager.” – Executive 
D  
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A biotechnology company that moves down the value chain and evolves from being a 
loss-making research and development company to a commercial operation will require 
a different set of management skills (Executive C). Management change can be a 
particularly sensitive issue for biotechnology firms where the founding scientists are 
involved in the management of the firm and are reluctant to give up control of their 
research and development programs (Executives A, E). Despite the challenges of 
management change, Sparling and Vitale (2004) found that firms at IPO were 
dominated by CEOs with a science background but in the years to follow a greater 
portion of CEOs with a business background moved into the industry. 
4.3.4 External Relationships 
The ability of biotechnology companies to maintain open communication lines with 
their suppliers, customers and competitors is vitally important. The sustainability of the 
biotechnology business model is dependent on the firm’s ability to bring research 
projects into the company, add some value then move the project out to another 
company with the scale to complete clinical trials and provide manufacturing, sales and 
marketing expertise. Some discoveries will require development expertise that the 
biotechnology firm does not possess, requiring the project to be placed in the hands of a 
firm with the expertise to successfully add value to the project (Executive C). Without 
industry-wide links, the biotechnology business model becomes unsustainable and 
growth opportunities are limited. 
 
Formation of partnerships to facilitate product development is a mechanism for 
biotechnology firms to develop expertise outside their core competency (Executive C). 
This can be particularly relevant for a company whose platform technology has 
application to a diverse range of research projects, some of which will likely require 
technical expertise that the firm does not possess. Through partnerships, biotechnology 
firms can expand their level of expertise which allows them to diversify their research 
pipeline, in turn improving the risk profile of the business.  
 
Partnerships provide a form of validation of a firm’s technology (Nicholson, Danzon 
and McCullough 2005) which can flow on to positively improve the ability of a 
biotechnology firm to attract additional partners as well as improve investor 
assessments of value (Executives C, H). Prior to the formation of a partnership, the 
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potential partner will assess the IP. Partnership formation is thus an indicator of the 
quality of that IP.  
“As a small company it is important for us to get the credibility of working with 
companies that have names, size, and experience, much greater than us” – Executive C 
4.3.4.1 Academia 
Academic institutions allow discovery research to be conducted with less commercial 
focus than industry-based research.  All of the study participants agreed that the 
research done in the academic environment is vitally important for ensuring the 
continued development of IP to supply the Australian biotechnology industry. 
“Academics are very good at the cornerstone research. It’s not cost effective for an 
organisation to go and start to discover stuff, so all of our projects are collaborative 
with academia, perhaps with one or two exceptions.” – Executive F  
As the biotechnology sector matures, existing businesses will need to replenish their 
product pipeline, and academic spawned research will form an important source of new 
research and development projects (Executives B, C, D, E, F, H). The reduced 
commercial focus of research done in academic institutions allows for greater 
flexibility, providing an environment conducive to innovative research and discovery. A 
potential pitfall in the biotechnology sector relying on academia to supply early stage 
discovery research is that the flexibility and lack of commercial focus that is allowed 
also means that the outcomes from investment in academic research are uncertain 
(Executive H).  
 
In order to ensure the sustainability of the biotechnology business model, a number of 
the study participants cited greater interaction with academic researchers as important. 
Executive F saw greater collaboration through focused funding from industry to 
academics as allowing them to focus on research thus reducing the time spent raising 
money through government grants. The biotechnology company would work closely 
with the academic and in return for providing funding would have some influence in the 
direction of research. 
 
The current availability of seed funding encourages promising new discoveries in the 
academic system be spun off into new business entities (Herpin, Karuso and Foley 
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2005) with two thirds of all start-ups in the year from July 2002 to July 2003 coming 
from research institutes (Department of Industry Tourism and Resources, Advance 
Consulting & Evaluation and Aoris Nova 2004). Figure 4-3 shows the diversity in 
funding initiatives available to public sector research. The large number of small start-
up companies serves to increase competition amongst existing biotechnology 
companies.  
Figure 4-3 Public Sector Funding Initiatives to the Australian Biotechnology Industry (Department 
of Industry Tourism and Resources, Advance Consulting & Evaluation and Aoris Nova 2004, p. 44) 
  
 
Once existing biotechnology firms begin to move products out of the laboratory and 
into the market, proven pathways of successful product development will emerge 
(Executive C). Rather than being spun off into new business entities, new ideas from 
academia should be commercialised through the leading biotechnology firms with a 
proven history of development and success in taking research discoveries through to 
products on the market (Executives C, E). To facilitate this process, greater 
communication between industry and academia is necessary, combined with creation of 
a culture within universities of assisting industry as an integral part of the 
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commercialisation process as opposed to acting as a competitor to industry (Executive 
E). Governments can encourage this process through an adjustment to the current 
funding regime, with more considered funding of start-up ventures and greater funding 
for successful development programs (refer section 4.2.1.1). The current research and 
development tax concessions are designed as an incentive for innovation, however for 
loss-making biotechnology companies, the value of the future tax offsets are reduced as 
short term capital requirements could cause firm failure prior to profitability and 
realisation of the tax concession16. 
4.3.4.2 Big Pharma 
The later stages of drug development are dominated by the pharmaceutical industry. 
Large multinational pharmaceutical companies have developed the infrastructure to 
successfully manufacture, distribute and sell therapeutic drugs on a global scale 
(Executives B, C). The relative size of Australian biotechnology companies compared 
to the existing infrastructure owned by pharmaceutical firms means that they are unable 
to compete in the late stages of the value chain in the large world markets (Executives 
A, B, C, D). Pharmaceutical patent expiries and difficulties in replenishing their product 
lines from in-house research creates opportunities for biotechnology companies to work 
with pharmaceutical firms in the earlier stages of the development cycle and gain 
exposure in the large international markets (Executives A, B, C, D, E).  
 
With Australian biotechnology companies unable to raise the capital required to fully 
finance development of their products, they are dependent on external relationships to 
bring products to market. The partner provides the capital, scale and expertise to bring 
the product through the final stages of development, registration with the relevant 
regulator, manufacturing, distribution, sales and marketing. In the majority of cases this 
partner will be a large international pharmaceutical or biotechnology company and 
biotechnology companies must manage their development programs with consideration 
of potential partnership opportunities.   
                                                
16 Companies having revenues less than AUD $5 million and research and development expenditures of 
less than $1 million are entitled to a tax rebate payable in cash in the year the expenditures are incurred. 
Clinical trials costs will greatly exceed $1m per annum thus many biotechnology firms are ineligible to 
receive the rebate and instead receive a tax concession which can be claimed against other tax liabilities 
or future tax debt. 
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When a biotechnology company out-licences a product to a pharmaceutical company to 
complete the final stages of development, the pharmaceutical company is effectively 
purchasing the IP surrounding the product. So whilst the product in development will be 
a therapeutic drug, for the biotechnology company, the product to be sold to the 
pharmaceutical company is the information and data package associated with the 
therapeutic drug in development (Executive G).  
 
As in any industry, firms need to be aware of their customers needs and design their 
products to meet those needs. A biotechnology firm needs to have potential 
pharmaceutical partnerships in mind early in the development cycle and they need to 
design their research programs with consideration of those partnerships (Executive D). 
Design of the development programs with a partner in mind requires the biotechnology 
company to carefully consider the commercial aspects of the ultimate product, including 
the route to market, the market size and the competitive landscape (Executive C). 
Furthermore, in the process of negotiation with potential partners, firms should 
continuously be assessing the marketplace for biotechnology products and this 
information should be fed back to guide development at the early stages in the pipeline  
(Executive D). 
 
The market for therapeutic drugs is global, thus the scale required to manufacture, 
distribute and run the sales and marketing campaign is well beyond the capabilities of 
the current Australian biotechnology sector. The global pharmaceutical industry 
consists of numerous large scale firms with the proven capacity to produce drugs to 
meet global demand and run effective sales and marketing campaigns. The 
infrastructure necessary to run these campaigns means that biotechnology firms will 
continue to be dependent on pharmaceutical partnerships (Executives C, D, F).  
 
Traditionally pharmaceutical companies “owned” the drug development space, 
however, as they have grown in scale, the efficiency of their development programs has 
fallen. Smaller biotechnology firms are now recognised as more efficient innovators and 
the pharmaceutical industry is increasingly dependent on biotechnology research 
programs to sustain their product pipelines (Executives E, F). The market for 
therapeutic drugs is protected by patents which only have a finite lifespan. As current 
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pharmaceutical patents expire pharmaceutical companies become further dependent on 
the biotechnology industry to replenish their product lines and cover their fixed 
overhead costs (Executive A). 
 
The relationship between biotechnology and pharmaceutical firms is one of co-
dependency, which introduces risks to both businesses. When a biotechnology firm out-
licenses a product to a pharmaceutical company they relinquish control over the 
remainder of the development program as well as the sales and marketing strategy. As a 
result, the biotechnology company is exposed to the risk that the pharmaceutical partner 
may make a decision surrounding the product that could affect the development and/or 
sales of the product. The size of pharmaceutical businesses means that one product in 
development will not receive the same level of focus, nor be as critical to the business, 
as it is for a smaller biotechnology firm.  
“Australian biotechnology companies are very exposed to ‘big pharma’.  [The latter] 
can make a decision or change a policy which can challenge a small biotechnology 
firm’s existence” – Executive A  
Biotechnology companies need to actively manage their relationships with 
pharmaceutical partners to control their exposure to the risks generated through the 
relationship. Management of this relationship through contractual means should be a 
tool of last resort to be used when all other options have been exhausted (Executive D). 
Australian firms have not been particularly good at managing this relationship in the 
past (Executive A), however, there is an increasing awareness of the importance of 
continuous liaison management as a preventative measure to manage this exposure 
(Executive D).  
4.4 VALUATION 
“The valuations and business models for biotechnology businesses are so completely 
different from everywhere else. From a traditional point of view, there is no business. 
There are no cash flows. There is no product, there are none of the tangibles that basic 
business premises rely on.” – Executive B  
The uncertainty surrounding biotechnology research and development makes valuation 
of biotechnology projects, and the businesses involved in sector, a daunting task. This 
Chapter 4 – The Australian Experience in Practice 
 97
task is made more difficult by the complexity of the underlying science which adds to 
the uncertainty surrounding firm prospects.  
 
If more accurate valuation methods were applied by experienced investment analysts 
who possess an in-depth knowledge of the unique nature of the industry, then we should 
see a more efficient allocation of investment funds in the biotechnology sector towards 
those companies with the most attractive risk/return profiles (Executive E). This process 
would see the best companies in the sector attracting greater levels of funding at the 
expense of firms less attractive to investors. With time, this would allow the successful 
biotechnology firms to forge pathways of success, and sift out the underperforming 
businesses, encouraging consolidation in the industry. The underlying premise of this is 
a more accurate valuation of biotechnology investment opportunities which is facilitated 
by improved valuation methodologies.  
 
The level of uncertainty surrounding biotechnology valuation is related to the difficulty 
in forecasting the business cash flows. For a company with products in the early stages 
of development, regular predictable revenues are not likely until a product, which can 
be more than 10 years in development, is on the market. Whilst it is in the company’s 
interest to generate revenues in the near-term in order to minimise the burn rate of cash 
reserves this does not always have a positive impact on company valuations. With the 
uncertainty of biotechnology investments, much of the value is related to the “blue sky” 
potential of products in development. Once cash flows start coming into the business, 
the investment community will look at those cash flows as a more tangible premise 
upon which to value the business at the expense of the “blue sky” potential of the 
development programs (Executive E). This focus on current cash flows at the expense 
of future potential will often reduce company values. 
4.4.1 Current Application 
“In biotechnology there is really no proven model for valuation.” – Executive H  
The level of uncertainty involved in the assessment of a biotechnology opportunity 
implies that any valuation tool will be based on assumptions regarding those 
uncertainties, thus reducing the value of any insights provided by the model (Executive 
C). Whilst the outcome of the model may only be of limited benefit, the process of 
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estimation of the cash flows resulting from a project help to give the company a 
commercial focus for their research programs (Executive A, C).  
 
Traditional discounted cash flow (DCF) methodology is the most common valuation 
method employed by participants in the biotechnology industry (Executives A, B, C, 
D). Despite its widespread use, the significance of a DCF valuation is not highly 
regarded as the models are easily manipulated to give the user a desired estimate of 
value (Executives A, B, C). The application of DCF valuation to biotechnology projects 
suffers from an inability to capture management flexibility, which is particularly 
relevant given the long lead times associated with biotechnology product development 
(Executives D, F).   
 
DCF valuation requires the analyst to estimate the cash flows resulting from a project. 
For a biotechnology project this requires the analyst to forecast revenues well into the 
future as a result of the long lead times in product development. Cash flow forecasts 
assume that the development program is successful, which is unlikely, given the 
historical success rates of biotechnology product development (Executive D). Where 
revenues are not likely to be generated within three years, the validity of DCF valuation 
is compromised (Executive F).  
 
To incorporate the possibility of a failure in product development, DCF theory is 
combined with a biotechnology development decision tree. This allows the analyst to 
incorporate the likely probabilities of a research project successfully moving through 
the development chain in incremental steps. This decision tree analysis provides useful 
insight to management of biotechnology firms allowing them to see the incremental 
change in value as each phase of development are successfully negotiated (Executives 
A, B, C, D).  
 
Estimation of the likelihood of successful product development is usually based on an 
assessment of the likelihood of successfully passing each incremental stage of the 
clinical development process. This information is then fed back into the model to form 
the probabilities of occurrence of each of the cash flows associated with the decision 
tree. The range of products that fall under the umbrella of biotechnological drug 
development is very broad and the risk factors facing these products are equally diverse. 
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Thus the use of broad industry averages to inform the valuation can quickly render a 
model irrelevant (Executive E). 
 
The high levels of uncertainty of biotechnology projects, particularly those in pre-
clinical or early clinical development, mean that the majority of biotechnology 
opportunities will not be economically viable under a DCF assessment (Executive C). 
The application of option pricing theory to biotechnology investment allows 
management flexibility to be incorporated into the investment analysis. Despite 
potentially offering superior assessments of investment opportunities, the majority of 
the study participants saw the complexity of real option theory as a barrier against its 
application.  
“If you take the time and effort to build a very thorough real options model with Monte 
Carlo analysis of the various combinations and permutations, I think you can build a 
very, very good model. The problem is I have not got two months to go and actually 
build one.” – Executive F  
The number of assumptions required to assess a biotechnology opportunity introduces a 
high level of sensitivity to user inputs in the model outcomes. Through manipulation of 
the underlying assumptions, the analyst is easily able to alter the results to point towards 
a predetermined belief (Executives A, C). The sensitivity of biotechnology valuation 
models to the underlying assumptions dilutes the significance of the valuations 
(Executives A, B, C, D, E). The valuation estimated by the model may be of only minor 
significance, however, useful insight can be gained through a more detailed 
examination. Sensitivity analysis of the model output by varying the underlying 
assumptions provides useful information about the critical drivers of value (Executive 
C). This insight allows managers to focus their efforts towards issues that the firm is 
most dependent on for value generation.  
 
In addition to providing management with insight regarding the drivers of firm value, 
the process of valuing a firm’s projects provides a tool that can be used to signal the 
commercial orientation of the firm to potential investors. A firm that is able to produce 
a model valuing the business sends a signal to potential investors that the company has 
commercial understanding (Executive B). Despite the benefits to the business from 
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conducting a thorough evaluation of company value, ultimately firm value is 
determined by market forces (Executives A, E, H).  
“It doesn’t matter what your model says if you just can’t do the deal.” – Executive A  
4.4.1.1 Drivers of Value 
Biotechnology valuations in Australia have a history of being widely speculative. The 
high degree of uncertainty surrounding the likelihood of successful development 
combined with the lack of a sophisticated investor community able to discern the 
critical value drivers contributes to the variation in firm valuations (Executive E). As a 
result of valuation uncertainty, the industry is subject to sentiment driven fluctuations in 
value. In effect this has created a situation where the ability to create ‘hype’ and 
excitement surrounding a firm’s product pipeline can be a value driver for the business 
(Executives A, E). Whilst value can be created through ‘hype’ in the short term, this is 
not a method for sustainably growing value and can be detrimental to the long term 
prospects of the firm (Executive A). 
 
Sensitivity analysis of a valuation model can provide insight into the issues that drive 
the valuation output. The time value of money means that biotechnology projects are 
particularly sensitive to time as a result of the long lead times in product development. 
The importance of time can outweigh the costs of development. A company that is able 
to decrease development times, even at additional cost, can improve the value of the 
firm (Executive C).  
 
The quality of a firm’s IP underlies its ability to develop a valuable product. Along with 
a high quality patent portfolio, the firm needs to possess the right people with the 
necessary skills to realise the portfolio value. Coupled with this, is the necessary ability 
to access sufficient levels of capital in order to fund IP development to a point where a 
return is generated commensurate with the associated risks (Executive D).  
 
In assessing the quality of a firm’s IP, a detailed analysis of the firm’s ability to protect 
its patent portfolio is a critical component in maintaining a competitive advantage. It is 
not the quantity of patents a firm holds but instead the quality of its patent protection 
that is important (Executive E). This is an issue that is often not examined to the level of 
detail that it requires. 
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“You need to do an analysis of whether the patent is likely to stick or not and what the 
true patent position is. Have you got a patent grant in the United States? Has it been 
challenged? What are the closest related patents? What is the opportunity for people to 
develop patents around it? Are there alternate technology strategies around your 
product? All those issues are really critical.” – Executive E  
4.4.1.2 Assessment of Opportunities 
When examining a potential project, the valuation of the opportunity is not critical in 
forming an investment decision due to the inherent uncertainties in biotechnology 
valuations (Executive B). The valuation process can provide insight, helping 
management focus on the key value drivers for the project. However, this is not 
information critical to forming the investment decision (Executive C). Of primary 
importance are the strategic fit of the opportunity with the existing development 
programs and the ability of the firm to manage the project (Executives A, B, C, D, E, F).  
 
A new opportunity that does not match well with existing projects has the potential to 
negatively affect the overall business. Resources will be required to develop the 
necessary expertise in the new area, which for resource constrained biotechnology 
firms, can reduce their ability to maintain support for their existing programs (Executive 
B). Additionally, if the firm does not possess the necessary skills to understand and 
appreciate the science, management will be restricted in its ability to add value to the 
research, thus those opportunities may be better off being placed in the hands of those 
with the expertise to do justice to the research (Executives C, D). 
4.5 AUSTRALIA AS A GLOBAL COMPETITOR: CHALLENGES AND 
OPPORTUNITIES  
The drug development industry is a global industry with a broad range of competing 
businesses ranging from small niche operators to the large multinational pharmaceutical 
companies. To successfully compete, Australian firms must overcome the local 
challenges and capitalise on their strengths and opportunities to evolve into 
internationally competitive businesses (Executives D, E, F).  
“The reality is that if you are going to be internationally competitive in the 
biotechnology industry, there is no prize for second. You have to be either first or don’t 
do it.” – Executive E 
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The fundamental mechanism which allows participants in the drug development 
industry to generate a return from their research and development efforts is the ability to 
protect their IP through legal and other means (Executive E). The Australian legal 
system provides a framework that the industry can rely on to protect IP and this 
encourages investment in research and development (Executive A).  
 
Australia has a reputation for good quality early stage discovery research (Executives B, 
C, D, E, H). The challenge is for the industry to successfully leverage this opportunity. 
The current environment encourages new ideas spawned in academia to be spun-out 
into a new business entity17, with the number of new businesses created seen as a 
measure of the success of academic research programs (Executives C, E, F). Given the 
likelihood of successful development of a new therapeutic, it seems that the majority of 
these projects will fail, and with them the supporting company. A more accurate 
measure of the success of university research programs should be the number of 
sustainable businesses created as a result of academic research discoveries (Executives 
C, E).  
 
The effect of an excess of early stage funding, and shortfall of subsequent development 
capital, ripples through the industry to pose a significant challenge to the sustainability 
of Australian biotechnology firms, as shown below in Figure 4-4. Due to the 
unattractive nature of their risk profile, many small biotechnology firms have difficulty 
raising sufficient development capital and are forced into an early sale of their IP. The 
revenue stream resulting from this sale is insufficient to fund a diverse research and 
development pipeline and as a result the success of the company hinges on the success 
of one or few products.  
 
                                                
17 For example see the Strategic Development Plan for Victoria (The Victorian Government 2004) which 
quotes the number of new biotech start-ups as a measure of the government success in servicing the 
industry. 
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Figure 4-4 The capital raising challenge to industry sustainability 
• Excess funds to spin off ideas into 
new entities.
• Highly fragmented industry with 
small, unsustainable businesses.
• Poor risk profile of existing firms.
• Lack of investor interest in the 
sector.
• Lack of ‘smart’ money in the sector.
• Firms competing for scarce 
development capital.
• Lack of capital forces sale of IP for 
reduced value capture.
• Insufficient returns into the sector to 
sustain discovery and development.
 
 
An opportunity exists to create stronger links between academia and industry and to 
encourage the formation of larger, more sustainable biotechnology firms with more 
diverse product pipelines and improved risk profiles. A reduced focus on the importance 
of spinning out new ideas into start-ups allows government to shift funding away from 
early stage initiatives towards support of capital intensive development programs. 
Industry can become more directly involved in funding academic research, facilitating 
greater communications between the two, and providing a mechanism for synergetic 
improvements in the drug development process. 
 
The lack of funding available to Australian drug development companies is limiting the 
sector’s potential (Executives A, C, D, E, F). To overcome this challenge and be 
internationally competitive, the industry needs to experience some success to give 
investors an improved sense of confidence and provide a pathway to success for other 
firms. With greater investor interest, the sector should attract more scrutiny from 
investment analysts who act as the gatekeepers between industry and investment funds 
(Executive E). Improved investor education will assist in a more efficient allocation of 
capital in the sector, away from the unsustainable business models, towards the 
sustainable firms with good prospects. Success in the industry will generate greater 
investment in the sector and feed continuous success in a virtuous circle as illustrated 
below in Figure 4-5.  
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Figure 4-5 The Virtuous Circle 
• Successful product development.
• Creation of road maps for success.
• Sustainable businesses 
with diversified portfolios
• Improved investor 
confidence & interest 
in the sector.
• Greater analyst coverage.
• Flow of funds into the sector.
• More “smart” money.
• Greater capacity to 
internally fund development
• Encourage academic research  
collaboration with industry
• Consolidation of existing firms
 
 
The cost of research and development in Australia is relatively low compared with other 
leading biotechnology nations (Executives A, B, C, D, E, H). The relatively low cost of 
research provides an opportunity for local based firms competing in a global market. 
Unfortunately, price alone is not a competitive advantage for Australia because 
scientific research costs in many developing countries are lower than here (Executives 
C, F). Australia, however, does have opportunity as a provider of relatively low cost and 
high quality scientific research. One of the most important drivers of value in the drug 
development industry is the ability to move a product through the development cycle as 
quickly as possible. Australia can further leverage the low cost and high quality of its 
research if it is able to consistently move products through the development pipeline at 
a rate faster than international competitors (Executive C). 
 
Melbourne is home to a large portion of the Australian biotechnology sector and is also 
a centre of excellence in the field of oncology research (Executive A). Development of 
a new cancer therapeutic differs from some other fields because of the terminal nature 
of cancer and the relatively small number of oncology clinicians. As a result clinical 
trials can be conducted at less expense and relatively quickly, which creates an 
opportunity for investors with a shorter investment horizon than other biotechnology 
fields. Opportunity exists for Australian biotechnology firms to leverage local expertise 
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in oncology research with investors seeing a return over a relatively short period of 
time. 
 
When compared with investors in the US, Australians seem to be more risk averse and 
have a reduced tolerance for failure (Executives C, D). Most biotechnology projects are 
doomed to failure, thus, over time, we will see an increasing number of managers with 
experience in managing a failed biotechnology firm. If investors are not willing to 
accept managers with experience in biotechnology failure, a valuable resource is left 
untapped. Failure provides valuable education and indeed an acceptance of this is 
necessary to encourage entrepreneurship in the industry (Executives C, D).  
4.6 CONCLUSION 
The overwhelming theme to emerge from this study is the significant challenge that 
Australian biotechnology firms face in attracting sufficient capital to fund their product 
development programs. Current funding mechanisms which encourage new ideas to be 
spun out into new entities, has created an industry comprised of small firms with few 
products in development.  
 
Given the risks associated with pharmaceutical product development, biotechnology 
firms without a sufficiently broad pipeline are poised for failure and as such face 
significant hurdles in attracting additional capital. The scarcity of development capital is 
exacerbated by the fierce competition for funding as a result of the capital intensive 
nature of biotechnology product development and the number of firms competing. 
 
The biotechnology sector has a high proportion of “mum-and-dad” type investors who 
are stakeholders in the industry without fully understanding the challenges facing the 
firms due to the complexity of the underlying products. As a result of this ‘uneducated’ 
money, there has not been a flow of funds away from the underperforming, lower 
potential firms to the more deserving ones. This has thwarted the Darwinian “survival 
of the fittest” mechanism and has meant that the underperforming firms continue to 
exist, consuming capital at the expense of the higher potential firms.  
 
Small unsustainable business models do little to inspire investor confidence and draw 
additional funds into the sector. As a result, firms are forced to prematurely sell their IP 
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to allow continued development of their product without capturing the optimal level of 
value growth along the development chain. This restricts the ability of the firm to fund 
additional research and development programs and dampens shareholder returns. 
 
Whilst the local industry faces significant challenges that must be overcome if it is to 
develop into a self-sustaining entity, careful management in these early stages should 
facilitate the desired outcome. To attract greater levels of investment into the sector the 
formation of sustainable business models with diverse product pipelines needs to be 
encouraged. Rather than encourage promising research to be spun off into new entities, 
the structure of early stage government funding should be revised to reduce the 
motivation to create start-ups. If closer links were fostered between industry and 
academia, new ideas could be out-licensed to existing firms with successful relevant 
histories. This would slow growth in the number of firms in the industry and at the same 
time diversify existing firms’ pipelines creating more sustainable business models with 
reduced risk profiles.  
 
Merger and acquisition activity between existing firms should also be encouraged to 
reduce the number of firms competing for development capital and diversify the firms’ 
product pipelines. Consolidating firms would increase the likelihood of successfully 
bringing a product to market and improving the sustainability of the business model. 
 
As the industry matures, successful firms will emerge, creating road maps for success to 
guide younger participants and investors. Investors will take confidence from successes 
in the industry and current concerns regarding the excessive risks associated with 
biotechnology investment will be mitigated through more diverse product pipelines. 
Improved investor confidence will see greater interest in the sector and capital flowing 
into the industry in all stages of development. 
 
Increased investor interest in the industry will create demand for investment analysts 
who over time will develop the expertise to effectively assess potential investments. 
This should allow a more educated distribution of investment capital, with funds 
flowing to the more deserving firms and away from the less deserving. This mechanism 
should improve the efficiency of the industry and encourage further growth of 
successful firms in the sector.  
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With greater levels of funding available to the sector, firms will be able to fund 
development of their products through a greater portion of the development process 
extracting more value as a result. Increased return to firms will allow them to divert 
funding back into their research and development programs. Through internal funding, 
the reliance on external capital providers is reduced, thus minimising their exposure to 
the risk of not being able to source sufficient capital. Reduced risk further enhances the 
sustainability of the firms’ business models and this similarly flows on to additional 
growth in the industry.  
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CHAPTER 5 MONEY LEFT AND UNDERPRICING IN 
AUSTRALIAN BIOTECHNOLOGY IPOS18 
5.1 INTRODUCTION 
The previous chapter described in detail the challenges that Australian biotechnology 
companies have in raising sufficient capital to fund their research and development 
programs. Australian firms have access to sufficient early stage start-up funds, however, 
subsequent development funding is significantly more difficult to source. In the US, 
venture capitalists are a significant source of funds for the biotechnology sector. In 
Australia the biotechnology industry has not had the same level of support from the 
venture capitalists with the result that companies are forced to find alternative sources 
of funds. This is evidenced by the relative immaturity of biotechnology firms raising 
capital via an IPO.  
 
An IPO is the process where a company first offers stock for sale to the public on the 
stock exchange. The process is managed by an investment bank and enables the issuing 
company to source an inflow of funds whilst the new shareholders receive potential 
profits in the form of future dividend returns and capital gains. “Underpricing” is a term 
used to describe the process in which the price of the listing company’s stock increases 
well above the issue price on the first day of listing, a phenomenon that has been 
reported consistently in studies around the world [see (Loughran, Ritter and Rydqvist 
1994)].  
 
Development of a viable and successful biotechnology industry is a key contributor to 
Australia’s economic growth, international competitiveness and quality of life 
                                                
18 The data presented in this chapter has been previously presented in two peer reviewed publications, for 
details, refer to Jens, P, Brooks, R, Nicoletti, G and Russell, R 2006, ‘Media Coverage and Biotechnology 
IPOs: Some Australian Evidence’, Journal of Commercial Biotechnology, vol. 13, no.1, pp. 43-47 and 
Jens, P, Brooks, R, Nicoletti, G and Russell, R 2006, ‘Capital Raising by Australian Biotechnology IPOs: 
Underpricing, Money Left and Proceeds Raised’, Accounting Research Journal, vol. 19, no. 1, pp. 31-45. 
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(Department of Education Science and Training 2004) and is supported through the 
Australian Federal government’s commitment of $8.3 billion in funding to science and 
innovation over the years from 2001-2011. Unfortunately, whilst Australia has 
relatively good levels of government-provided seed funding, subsequent research and 
product development, which is typically funded by venture capitalists and other sources 
of financial support, faces a shortfall in funding. As a result of this, Australian 
biotechnology companies are often prematurely forced to source finance from the public 
through an IPO (Herpin, Karuso and Foley 2005), increasing the importance of a 
successful listing for these businesses. 
 
The motivations for a company to raise capital via an IPO can be many and varied 
however a key concern will be the successful injection of a significant amount of capital 
into the business (Arkebauer and Schultz 1991). For biotechnology companies, which 
are inherently capital intensive businesses with long product lead times, the amount of 
capital raised that they can dedicate towards development of their product pipeline is a 
critical measure of the success of their IPO (Deeds, Decarolis and Coombs 1997). 
Stuart, Hoang and Hybels (1999) support this notion in their study [of venture capital-
backed biotechnology IPOs which used the total capital raised by venture capital-
backed biotechnology IPOs as a measure of listing success. Success of IPO capital 
raisings can be measured by the size of the capital raising, level of underpricing, and the 
performance of the issuing company in the years post-listing (Brau, Brown and 
Osteryoung 2004). A listing that raises less capital, is more underpriced and leaves more 
money on the table will have been less successful in meeting the primary requirement to 
inject significant capital into the business.  
 
This chapter analyses Biotechnology IPOs in Australia from 1994 to 2004 in three key 
dimensions related to their capital raising – underpricing returns, money left on the table 
and total proceeds raised. The analysis tests the relationship between the information 
provided to potential investors in the IPO prospectus and these key measures of listing 
success and performance. Three models have been used: first, using the amount of 
money left on the table (measured as the number of shares issued multiplied by the first 
day share price movement) as the dependent variable; second, using underpricing (the 
first day shareholder returns) as the dependent variable; and third, using total proceeds 
raised (measured as number of new shares issued multiplied by the issue price) as the 
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dependent variable. While all companies that list on the stock exchange are interested in 
these three measures, they are of particular concern for biotechnology companies given 
the high cost and long lead time in product development, and the uncertainties regarding 
the valuation of their intellectual assets (Schwartz 2004).  
 
The impact of market sentiment on the instantaneous values that the market assigns 
biotechnology assets at any time, is exacerbated by the uncertainty surrounding 
valuations of those assets. This chapter explores the impact of sentiment on IPO 
valuations using share market performance and popular press citations as proxy 
measures for sentiment levels. 
 
The plan of this chapter is as follows: Section 5.2 develops the base models following a 
similar study in the US by Deeds, Decarolis and Coombs (1997), Section 5.3 augments 
the base models to further explore the  impact of sentiment on IPO performance, and 
Section 5.4 concludes.  
5.2 BASE MODELS 
This research follows on from a similar study by Deeds, Decarolis and Coombs (1997) 
who studied 92 biotechnology company IPOs within the United States after 1982 to 
investigate the influence of factors endogenous and exogenous to the firm on the 
amount of capital raised.  
5.2.1 Data 
The models developed here test the relationship between data contained within 
Australian biotechnology company prospectuses and the success of their IPO, as 
measured by the amount of money left on the table, the amount of underpricing, and the 
total proceeds raised. Significant relationships identified in previous literature were used 
as the foundation from which the models were built and tested using an ordinary least 
squares regression framework. The data set used in this paper was constructed by 
extracting information from the prospectus documents of 34 biotechnology companies 
who listed on the Australian Stock Exchange between June 1994 and May 2004. Where 
possible, a copy of the prospectus was used in its original format (either electronic or 
hardcopy). In cases where this was not available, prospectus information was sourced 
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from the Connect4 Company Prospectus database. Market pricing data was sourced 
from Datastream.  
 
A subset of publicly listed biotechnology companies have been previously listed as 
technology development or mining exploration entities. These companies were 
excluded from this research which considered only those biotechnology firms coming to 
the market for the first time. During the time span, 34 biotechnology companies were 
listed on the ASX for the first time. Of these, twenty-nine focused their research effort 
on human therapeutics, four on medical devices and one on animal health. Due to the 
limited population size, all 34 listings were included in this analysis. 
 
Initially a large data set was constructed based on significant variables from previous 
studies. The independent variables included in the first cut models are shown in Table 
5-1. Note that no earnings data variables were included as the majority of companies in 
the sample were not generating revenues at time of IPO. 
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Table 5-1 Set of Potential Independent Variables 
This table provides details on the set of potential explanatory variables for the IPO models, including a 
brief description of the variable and its expected sign, as well as reference in the previous literature. 
Variable Expected 
Sign 
Citation Description 
Issue Price per 
Share 
Negative (Chalk and Peavy 1987; Tinic 
1988) 
Issue price per share as detailed in the 
prospectus 
Total Capital 
Raised 
Negative (Beatty and Ritter 1986; How, 
Izan and Monroe 1995; 
Michaely and Shaw 1994; 
Tinic 1988) 
Equals the number of new shares issued 
multiplied by the issue price per share 
Subscriber 
Options 
Negative (Jain 1997; Schultz 1993) Dummy variable, 1 where subscriber options 
offered, 0 otherwise 
Underwriter  Negative (Beatty and Ritter 1986; Tinic 
1988) 
Dummy variable, 1 where issue is underwritten, 
0 otherwise 
Underwriter 
Options 
Negative (Dunbar 1995) Dummy variable, 1 where underwriter receives 
options as payment (or part thereof), 0 otherwise 
Independent 
Accountant 
Reputation 
Negative (How, Izan and Monroe 1995; 
Michaely and Shaw 1995; 
Titman and Trueman 1986) 
Dummy variable, 1 for reputable independent 
accountant, 0 otherwise 
Age Negative (Ritter 1984) Company age measured as the number of days 
between incorporation and listing 
Location Negative (Deeds, Decarolis and 
Coombs 1997) 
Dummy variable, 1 head office location within a 
biotechnology hub, 0 otherwise 
Capital Retained Negative (Deeds, Decarolis and 
Coombs 1997) 
Amount of capital retained by the company after 
listing expenses and special dividends 
Research 
Projects 
Negative  Number of research projects yet to commence 
clinical trials  
Products in 
Development 
Negative (Deeds, Decarolis and 
Coombs 1997) 
Number of products in clinical trials 
Products Negative (Deeds, Decarolis and 
Coombs 1997) 
Number of fully developed products 
Services Negative  Number of revenue-generating services 
Health & Biotech 
Market 
Sentiment 
Positive  Movement in ASX Health and Biotechnology 
Index from the date of the independent 
accountants report to the day of listing 
Market 
Sentiment 
Positive (Dimovski and Brooks 2004a) Movement in ASX All Ordinaries Index 
(orthogonalised from the Health & Biotech index) 
from the date of the independent accountants 
report to the day of listing 
Momentum Positive  Underpricing of previous biotechnology listing 
divided by the number of days between the 
previous and current listing 
R&D Forecast 
Expenditure 
Negative  Future research and development forecast as 
per prospectus 
R&D Historical 
Expenditure 
Negative (Deeds, Decarolis and 
Coombs 1997) 
Historical research and development forecast as 
per prospectus 
%IPO Raisings 
for R&D 
Negative  % of total capital raised through the IPO to be 
allocated for research and development as per 
prospectus 
Total Citations Negative (Deeds, Decarolis and 
Coombs 1997) 
Total citation count for publications by staff listed 
in the prospectus (Web of Science database 
used to calculate for this sample) 
Patent Family Negative  Patent coverage measured as the number of 
patent families described in the prospectus 
Patents Negative (Deeds, Decarolis and 
Coombs 1997) 
Total number of awarded patents as per 
prospectus 
Patent 
Applications 
Negative  Total number of patent applications as per 
prospectus 
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A set of three full models was created where all of the independent variables listed in 
Table 5-1 were regressed against the three dependent variables with the White 
adjustment applied to manage heteroskedasticity problems impacting on the t-statistics. 
The models were then refined using a stepwise process where the least significant 
variable was removed from the regression framework and the parameters re-estimated. 
The process was systematically repeated until only those variables shown to be 
significant at the 10% level were retained19. With multicollinearity a potential problem 
(refer to Appendix A for a comprehensive correlation matrix) impacting on the 
reliability of this model, and to confirm that no significant variables were omitted, an F-
test for redundant variables was then conducted using all omitted variables. This model 
selection process was conducted for the ‘money left on the table’, ‘underpricing’ and 
‘log money raised’ models. Descriptive statistics for the dependent and significant 
independent variables are reported in Table 5-2.  
 
                                                
19 A 10% level of significance was chosen (in preference to the more common 5%) in order to reduce the 
likelihood of a type II error during the stepwise process. Type II error concerns were exacerbated by the 
potential impact of multicollinearity on the unrestricted model t-values. 
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Table 5-2 Descriptive Statistics 
This table reports measures of central tendency and variability for the dependent and independent 
explanatory variables. MoneyLeft is the amount of money left on the table (in $,000) which is equal to the 
number of shares issued * (price on close – issue price). Underpricing is the share price return on the first 
day of listing. MonRias is the amount of money raised (in $,000) in the capital raising which is equal to 
the number of shares on issue * issue price. Ln_MonRais is the natural logarithm of the amount of money 
raised by the IPO. CIT is the total number of citations of employees’ and members of the scientific 
advisory boards’ work as per the “web of science” database. INDACC is a dummy variable for the use of 
a reputable independent accountant. PRICE is the issue price of the listing. PROD is the number of fully 
developed products described in the prospectus. SENT_AO is the movement on the ASX all ordinaries 
index (orthogonalized to be independent of movement in the health and biotechnology index) from the 
date on the independent accountants report to date of listing. SENT_HB is the moment of the ASX health 
and biotechnology index) from the date on the independent accountants report to date of listing. 
TOT_APP is the total number of awarded patents and patents under application at the time of listing with 
each country treated as a separate application. TOT_PAT is the number of awarded patents at the time of 
listing. 
 Mean Median Maximum Minimum Std. Dev. 
Dependent Variables      
MoneyLeft 2,360 450 17,500 -2,700 4,781 
Underpricing 20.16% 2.67% 125.00% -50.00% 42.40% 
MonRais 23,419 7,025 312,000 1,606 55,912 
Ln_MonRais 16.09 15.76 19.56 14.29 1.07 
Significant Independent Variables     
CIT 10106 4465 66459 0 16174 
INDACC 0.47 0 1 0 0.51 
PRICE 0.68 0.50 2.50 0.20 0.62 
PROD 2.00 0.00 27.00 0.00 6.31 
SENT_AO 0.00 0.82 14.61 -14.62 6.14 
SENT_HB 3.20 1.24 24.34 -12.13 9.44 
TOT_APP 26 11 168 0 38 
TOT_PAT 6.88 1.00 42 0 11.09 
 
5.2.2 Results 
This research makes use of White (1980) standard errors even though the sample size is 
small. The properties of the White (1980) approach in finite samples has been the 
subject of some analysis in the literature, see inter alia MacKinnon and White (1985), 
Godfrey and Orme (1999), Cribari-Neto (2004) and Godfrey (2005). Godfrey (2005) 
uses a sample size of only 27 observations in his Monte Carlo analysis, and finds the 
conventional White (1980) test to be over-sized (that is, more likely to reject the null 
hypothesis of variable insignificance) in small samples, although the test is also found 
to have reasonable power relative to other available corrections to the test statistic. In 
the context of this research, the use of the conventional approach has a bias towards 
finding significant variables. Thus, the fact that these results did not show many 
variables to be significant can be seen as robust given that the nature of the bias in the 
test is in the opposite direction.  
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All three full models together with their final reduced forms are shown in Table 5-3. 
The table reports OLS parameter estimates and significant White corrected p-values are 
highlighted by asterisks. 
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Table 5-3 Regression Results 
This table reports the results of estimating the full and reduced form models for each of the three 
specifications of the dependent variables. The table reports OLS parameter estimates with significant 
White corrected p-values at the 10%, 5% and 1% level of significance shown by *, **, and *** 
respectively. The table also reports a range of regression diagnostics including the adjusted R squared, the 
White test, and the F test for the exclusion restrictions in the reduced for model. AGE is the age of 
company measured as the number of days between incorporation and listing. CAPRET is the amount of 
capital raised from the IPO allocated to the company (i.e. total raisings less brokerage fees and 
shareholder dividend). CIT is the total number of citations of employees’ and members of the scientific 
advisory boards’ work as per the “web of science” database. INDACC is a dummy variable for the use of 
a reputable independent accountant. LN_CAPRAIS is the amount of capital raised by the issue with the 
natural log taken to control for outliers (not that this variable is used as an independent variable for the 
money left and underpricing models but is used as the dependent variable for the log money raised 
model). LOC_METRO is a dummy variable for those companies whose head office is located in a 
metropolitan area of Adelaide, Brisbane, Melbourne, Perth or Sydney. MTUM is the amount of 
underpricing of the most recent previous listing divided by the number of days between that listing and 
the current listing. PRICE is the issue price of the listing. PAT_FAM is the number of patent families 
(includes patents granted and under application) identified in the prospectus. PROD is the number of fully 
developed products described in the prospectus. PROD_DEV is the number of products under 
development defined as the number of products in clinical trials. RD_FORC is the amount of research and 
development expenditure forecast in the prospectus. RD_HIST is the amount of historical research and 
development expenditure described in the prospectus. RDPERCENT is the percentage of capital raised 
from the IPO which will be allocated to research and development. RES_PROJ is the number of research 
projects defined as any research project still in pre-clinical development. SENT_AO is the movement on 
the ASX all ordinaries index (orthogonalized to be independent of movement in the health and 
biotechnology index) from the date on the independent accountants report to date of listing. SENT_HB is 
the movement of the ASX health and biotechnology index from the date on the independent accountants 
report to date of listing. SERV is the number of revenue generating services at the time of listing. 
SUBOPT is a dummy variable for the inclusion of subscriber options as part of a listing. TOT_APP is the 
total number of awarded patents and patents under application at the time of listing with each country 
treated as a separate application. TOT_PAT is the number of awarded patents at the time of listing. 
UNDOPT is a dummy variable where options are issued to underwriters. UWRIT is a dummy variable for 
those offerings that are underwritten. 
Variable Full Model Coefficients Stepwise Model Coefficients 
 MoneyLeft 
(,000) 
Underpricing Ln_CapRais MoneyLeft 
(,000) 
Underpricing Ln_CapRais 
Constant -28013.955 4.5563 15.7294*** -2269.752** 0.2016*** 15.1244*** 
AGE -0.158 -0.0001 -0.0001    
CAPRET 1245.876 1.1243 0.1242    
CIT 0.078 0.0000 0.0000 0.066***   
INDACC -3925.340 -0.1636 0.4503 -3839.288**  0.2795* 
LN_CAPRAIS 1474.904 -0.3417 --------   -------- 
LOC_METRO 2752.084 0.0219 -0.3071    
MTUM -9883.800 -0.5873 -0.8622    
PRICE 3656.250 0.4137 0.0512 8092.745***  1.3036*** 
PAT_FAM -313.240 0.0252 1.3288**    
PROD -770.867 -0.0272 0.0795 -356.160**  0.0308*** 
PROD_DEV 427.008 0.0528 0.0215    
RD_FORC 29.961 0.0452 0.0515*    
RD_HIST 213.260 0.0223 -0.0191    
RDPERCENT 5155.051 -0.0163 -0.6930    
RES_PROJ 28.645 -0.0294 -0.0374    
SENT_AO 26930.504 1.7644 -2.9983 23304.290***   
SENT_HB 2437.248 -1.4863 -2.2662   -1.3797* 
SERV 75.106 0.0807 0.0261    
SUBOPT -1782.948 -0.4853 -0.2072    
TOT_APP 36.042 0.0036 0.0034 38.152**  0.0060*** 
TOT_PAT 182.071 -0.0146 -0.0377***   -0.0319*** 
UNDOPT 2624.105 0.4302 0.0645    
UWRIT -486.492 0.0284 -0.0750    
Adjusted R2 -0.10 -1.03 0.80 0.43 0.00 0.87 
F-stat omitted 
variable (p-value) -------- -------- -------- 
0.227 
(0.995) 
0.271 
(0.995) 
0.435 
(0.937) 
Observations 34 34 34 34 34 34 
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5.2.2.1 Money Left Model 
Of the 34 biotechnology IPOs, the majority left money on the table. The market 
capitalisation of 21 offerings increased on the first day of listing, 9 saw a decrease in 
market capitalisation, and 4 offerings had no change in share price at close of the first 
day of trading from the issue price. The average amount of money left in the investors 
hands at the end of the first day’s trading was $2.36 million.  
 
The model selected at the end of the iterative estimation method described previously 
was: 
iAPPTOTAOSENT
PRODPRICEINDACCCITMoneyLeft
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++++=
__ 65
43210  
 
MoneyLeft is the amount of money left on the table which is equal to the number of 
shares issued * (price on close – issue price). CIT is the total number of citations of 
employees’ and members of the scientific advisory boards’ work as per the “web of 
science” database. INDACC is a dummy variable for the use of a reputable independent 
accountant. PRICE is the issue price of the listing. PROD is the number of fully 
developed products described in the prospectus. SENT_AO is the movement on the ASX 
All Ordinaries Index (orthogonalized to be independent of movement in the health and 
biotechnology index) from the date on the independent accountants report to date of 
listing. TOT_APP is the total number of awarded patents and patents under application 
at the time of listing with each country treated as a separate application.  
 
The number of times academic publications by employees and members of the scientific 
advisory board were cited was collected using the “web of science” database. The 
average number of citations for companies contained within this sample was 10,106 
ranging from 0 to 66,459. If it is assumed that a higher quality research team will have a 
greater number of citations of their academic work, then the positive and significant 
coefficient on the citation variable is counter to the argument that a biotechnology 
company with a quality research team has a greater chance of research success and 
offers relatively lower investment uncertainty. In support of Corolleur, Carrere and 
Mangematin (2004), the positive and significant coefficient for the CIT variable 
supports the notion that more qualified and senior research staff tend to become 
involved with projects at higher risk of failure albeit offering greater potential rewards.  
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Of the 34 companies included in the sample, 16 were deemed to have engaged a 
reputable independent accountant to verify the accounts presented in the prospectus. 
The negative significant coefficient for the INDACC variable supports the hypothesis 
that having a reputable independent accountant prepare the financial statements for an 
IPO prospectus reduces the uncertainty surrounding investment in that company and 
hence investors demand less capital gain on the first day of listing. 
 
The positive and significant PRICE variable is inconsistent with the hypothesis that 
higher priced offerings are associated with larger offerings which are more closely 
scrutinised by the investing community and as a result have reduced uncertainty of 
investment. This may be the result of sampling bias resulting from the focus of this 
research specifically on Australian Biotechnical companies. In this sample the range of 
asking prices for shares is from $0.20 to $2.50 with a mean of $0.68. This compares 
with Dimovski and Brooks’ (2004a) more general study of 358 Australian Industrial 
IPOs between 1994 and 1999 which had asking prices ranging from $0.20 to $4.70 with 
an average of $0.82.  
 
Those firms with products already fully developed and generating sales revenue 
obviously offer more certainty regarding future cash flows than those firms with no 
existing products which are wholly dependent on their ability to develop their 
proprietary intellectual property into a successful product. The greater the number of 
existing products a firm has on offer, the more diversified their revenue streams and the 
less uncertainty surrounding future cash flows (Amit and Livnat 1989). For an investor 
considering investment in a company with an established product, the greater certainty 
implies that they will rationally demand less underpricing return. Similarly the amount 
of capital that a firm could expect to raise will be greater if they can effectively 
demonstrate the value of their offering, such as with evidence of existing sales revenues. 
 
From the 34 companies in the sample, only 10 possessed fully developed products 
capable of generating revenues, with an average number of 2 products per company. 
The negative significant coefficient for the PROD variable indicates that the greater the 
number of fully developed products at time of listing, the less money was left on the 
table by the issuing company. This is consistent with the expectation that a pipeline of 
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products still in development offers less certainty of future cash flows than a firm which 
contains fully developed, revenue generating products. Lower uncertainty surrounding 
an IPO investment will reduce the amount of compensatory capital gain demanded by 
investors on the first day of listing. 
 
The SENT_AO variable is used as a proxy to capture investor sentiment in the period 
between the date of the release of the independent accountants report and the date of 
listing. As the movement in the ASX health and biotechnology index was also included 
in the full model, the SENT_AO variable was orthogonalised to remove any collinearity 
between the two measures. The proxy measures the return of the Australian All 
Ordinaries Index over this period and, where the independent accountant’s report was 
not provided or was not dated, the date of the independent expert’s report was used. 
Where no independent expert’s report was provided, the date of the prospectus was 
used. The average SENT_AO over the 34 observations was 0.00%, with the sample 
ranging from -14.62% to +14.61%. Based on the literature we would expect a positive 
co-efficient, that is, the greater the increase in the All Ordinaries in the period leading 
up to listing, the greater the first day movement in share price and money left on the 
table. The positive and significant coefficient supports this hypothesis. 
 
TOT_APP measures the total number of patent applications and awarded patents at the 
date of prospectus publications for each of the listing companies. An application for one 
innovation across two countries was considered as two applications. Of the 34 
companies in the sample, 7 had no awarded patents or patent applications, however, on 
average, companies had 26 awarded patents and patent applications (ranging from 0 to 
168). Successful patent protection is critical to controlling competitor risk and thus we 
would expect a negative coefficient, that is, a greater number of patents is negatively 
correlated to the amount of money left on the table. The positive and significant 
coefficient for the TOT_APP variable is inconsistent with this hypothesis and may be a 
result of investors demanding a research and development program which focuses its 
limited finances on fewer promising candidates. Patent protection is costly and the 
amount of funds available to Australian biotechnology companies is significantly less 
than that required to successfully bring a new drug to market. As a result, a company 
which is focused on fewer research and development activities is better able to finance 
these activities than one whose research and development program is more broadly 
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focused. Accordingly, investors may require greater first day returns to compensate for 
increased uncertainty regarding the ability of the company to adequately finance its 
research and development program. 
 
It should be noted that a firm focusing on one or few products has a greater exposure to 
development failure risk. An investor can mitigate this risk through diversification 
across multiple firms in order to efficiently minimise their portfolio exposure risk whilst 
maintaining their expected return. Managers of firms looking to minimise the amount of 
money left on the table at IPO should be wary of focusing on one or few products given 
the exposure to development risk that this creates. 
5.2.2.2 Underpricing Model 
From the 34 observations, 21 offerings were underpriced, 9 overpriced and for the 
remaining 4 offerings the share price at close of market on the first day of trading was 
equal to the issue price. Using the iterative procedure outlined earlier, the full model 
was incrementally condensed. However unlike the money left model, none of the 
independent variables were found to have a significant relationship with underpricing. 
For high intensity research and development firms (such as biotechnology firms) it is 
imperative that they raise as much capital as possible at their IPO. These results suggest 
that it is the amount of money left on the table and not underpricing returns that is more 
important (Habib and Ljungqvist 1998).  
5.2.2.3 Log Capital Raised Model 
The sample of 34 biotechnology IPOs raised an average of $23.4m, with the size of the 
capital raisings ranging from $1.6m to $312m. The natural log of the amount of capital 
raised at IPO was taken to control for large capital raisings in the sample of 
biotechnology IPOs. The stepwise procedure previously described produced the model 
outlined below and detailed in Table 5-3. 
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Where Ln_CapRais is the natural logarithm of the amount of money raised by the IPO. 
INDACC is a dummy variable for the use of a reputable independent accountant. PRICE 
is the issue price of the listing. PROD is the number of fully developed products 
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described in the prospectus. SENT_HB is the movement of the ASX health and 
biotechnology index measured from the date on the independent accountants report to 
date of listing. TOT_APP is the total number of awarded patents and patents under 
application at the time of listing with each country treated as a separate application. 
TOT_PAT is the number of awarded patents at the time of listing. 
 
The positive and significant INDACC variable supports the notion that larger offerings 
are more likely to afford the additional expense required to employ a reputable 
independent accountant to prepare their financial statements for presentation in the 
prospectus.  
 
Previous studies have found that IPOs with a larger issue price per share are generally 
less underpriced (Chalk and Peavy 1987; Tinic 1988). The explanation for this is based 
on the assumption that shares in larger issues are generally sold at a higher price per 
share (Tinic 1988). The positive and significant coefficient for the PRICE variable 
supports the notion that issues with larger issue price per share generally raise more 
capital.  
 
The time and resources required to successfully develop a product imply that those 
companies with fully developed products will generally be larger than those without a 
product on the market. This is supported by the positive and significant variable for the 
PROD variable indicating the greater the number of developed products a company 
owns, the greater the amount of capital they are likely to raise at their IPO. 
 
The insignificance of the SENT_AO indicates that there is no relationship between the 
amount of capital raised at IPO and the movement in the ASX All Ordinaries in the 
immediate period prior to listing. Interestingly, the negative significant coefficient of 
the SENT_HB indicates that the times when the ASX Health and Biotechnology Index is 
rising, there is an association with smaller capital raisings of Australian biotechnology 
companies. For this sample the ASX Health and Biotechnology share price index 
increased on average 3.2% in the period between the date on the independent 
accountants report and the day of listing, with the movement ranging between a fall of 
12.1% and a rise of 24.3%. 
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Those companies which had a greater number of patent approvals and patent 
applications were found to raise larger amounts of capital at their IPO, as demonstrated 
by the positive and significant coefficient for the TOT_APP variable. Conversely, those 
companies with fewer patent approvals were observed to raise more capital. On average, 
companies from the sample had 7 patent approvals with the total number ranging from 0 
to 42. 
5.2.3 Discussion 
A useful comparison can be made between the results of this study and the results 
obtained by Deeds, Decarolis and Coombs (1997) who studied 92 biotechnology 
company IPOs in the United States after 1982. They found significant relationships 
between the amount of capital raised at IPO and company location, number of products 
in development, and the number of citations of employee research publications. In their 
paper, Deeds, Decarolis and Coombs (1997) use the amount of capital raised (less 
listing expenses) as the dependent variable, and use the amount of assets reported in the 
prospectus to control for size of issuing company. The size control variable was not 
used in our analysis due to differences in the samples, as Australian biotechnology 
companies come to market at an earlier stage in their development and as such have few 
fixed assets on their balance sheet20.  
 
Deeds, Decarolis and Coombs (1997) found that the sum total number of developed 
products and products in development had a positive relationship with the amount of 
capital raised at IPO which was significant at the 0.1% level. Interestingly, contrary to 
Deeds, Decarolis and Coombs (1997) findings, this study found no significant 
relationship between the number of products in development and the amount of money 
left on the table, the level of underpricing, or the total capital raised. Perhaps the use  by 
Deeds, Decarolis and Coombs (1997) of total assets listed on the balance sheet as a 
control variable does not capture the size of the companies’ growth options, and thus 
this effect has therefore captured a positive significant relationship with the number of 
                                                
20 Deloitte Touche Tohmatsu (2002) found that by market capitalisation listed Australian biotechnology 
companies are on average 1/10, 1/24, 1/42 the size of listed biotechnology firms in Canada, the United 
States and the United Kingdom respectively (refer figure 1). The same report goes on to suggest that a 
lack of venture capitalists willing to invest in Australian biotechnology firms is resulting in those 
companies being forced into a premature listing. 
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products in development as a result of size effects. Whilst this study finds no significant 
impact from the number of products in development, the number of developed products 
in the market is shown to significantly increase the amount of capital raised and reduce 
the amount of money left on the table. This is likely a result of increased certainty 
surrounding future cash flows. 
 
The value of historical or forecast research and development expenditure was not found 
to be related to the amount of capital raised by Australian Biotechnology IPOs. This is a 
similar finding to that of Deeds, Decarolis and Coombs (1997). Additionally, no 
relationship was identified between the amount of money left on the table and research 
and development expenditures. In her study of 120 US pharmaceutical companies, 
Shortridge  (2004) found that the market provided a value premium to those companies 
with proven research and development success. The measure of total research and 
development expenditure fails to quantify the quality of the work undertaken and thus if 
this metric could be refined to measure quality as well as quantity of research and 
development, perhaps an improved insight could be obtained.  
 
This research found that the number of patents held had no significant relationship with 
the amount of money left on the table by Australian Biotechnology companies, however 
those companies with more approved patents were found to raise significantly less 
capital at their IPO. In their fully developed model, Deeds, Decarolis and Coombs 
(1997) found that the number of patents held by the listing company had no impact on 
the amount of money raised at IPO for United States Biotechnology companies. The 
positive significant coefficient on the sum total number of patents and patent 
applications variable indicates that firms with more patent applications will raise more 
capital at their IPO but leave more money on the table. More capital raised at IPO is 
likely a size effect, however the observation that more money is left on the table seems 
to highlight the need for Australian biotechnology companies to focus their limited 
amount of capital resources on a few core projects within their pipeline. This 
relationship was not captured by Deeds, Decarolis and Coombs (1997), however the 
greater volume of capital available to US biotechnology ventures may allow increased 
diversification in their research and development pipeline.  
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The citation index which Deeds, Decarolis and Coombs (1997) use as a measure of the 
firms scientific capabilities was found to have a positive relationship with the amount of 
capital raised at IPO which the authors propose is a result of  the better scientific teams 
engaging in more productive R&D. The negative and significant variable of the CIT 
coefficient presented in this thesis does not support the Deeds, Decarolis and Coombs 
(1997) hypothesis but instead supports recent research by Corolleur, Carrere and 
Mangematin (2004). If more senior and qualified scientific research people are engaging 
in riskier projects then the increased uncertainty surrounding the success of those 
projects would see investors requiring greater profits on the first day of listing. 
  
This research aimed to investigate in an Australian context the knowledge transfer effect 
found by Deeds, Decarolis and Coombs (1997) who showed a positive significant 
coefficient for the dummy variable to control for firms located within biotechnology 
clusters. They propose that the concentration of biotechnology firms in the geographical 
region surrounding a listing biotechnology company will have a positive impact on the 
amount of capital raised at IPO. Australian biotechnology companies are not clustered 
to the extent that they are in the US, thus having a head office located within a 
metropolitan region of a capital city was used as a proxy for a biotechnology cluster. 
The metropolitan location dummy variable used in this study was found to be 
insignificant suggesting that a metropolitan location is a poor proxy for a biotechnology 
cluster. Further refinement of this variable is necessary to determine if the effect 
captured by Deeds, Decarolis and Coombs (1997) is replicated in this set of Australian 
biotechnology IPOs. 
5.3 SENTIMENT AUGMENTATION 
The majority of explanations for the observed underpricing relate to uncertainty around 
the offering (see Rock (1986), Beatty and Ritter (1986)), although, since the work of 
Ibbotson and Jaffe (1975) and Ritter (1984), there are well known sentiment effects that 
produce hot issue periods in IPO markets. Hot issue periods are characterised by greater 
levels of IPO underpricing, with an increased volume of IPO capital raisings, and larger 
capital raisings (Helwege and Liang 2004). 
 
The key challenge is to find variables that capture the movements in market sentiment. 
Brailsford, Heaney and Shi (2001; 2004) conduct an analysis at the overall market level 
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and find a role for the number of new issues, the level of underpricing and general 
market conditions. The purpose of the present analysis is to explore this issue in the 
context of individual IPOs in the Australian biotechnology sector. Dimovski and Brooks 
(2004b; 2004a) find a significant role for variations in the market index as a sentiment 
variable for Australian IPOs in general which was shown to hold true for Australian 
biotechnology IPOs (refer Table 5-3).  
 
There are alternative variables that can be used to measure sentiment type effects. One 
possible alternative sentiment variable is media coverage during the issue period. 
Demers and Lewellen (2003) find that more underpriced offerings receive a greater 
number of media cites in the months post-IPO. They also show a relationship between 
media coverage in the month prior to listing and underpricing. With investor sentiment 
providing a significant contribution to underpricing, media coverage during the issue 
period and for high first day returns will encourage investment in subsequent listings. 
Conversely Pollock and Rindova (2003) found that a greater level of media coverage in 
the period one year prior to IPO was negatively related to the level of underpricing 
supporting their media legitimisation theory that increased media coverage provides a 
form of validation of a new firm’s legitimacy, hence reducing perceived investor risks 
associated with that firm.  
 
This section extends the previous analysis of market sentiment and media effects in the 
context of Australian biotechnology IPOs. The biotechnology sector provides an 
interesting analysis given the general uncertainty that applies to valuation in that sector. 
More specifically, market sentiment is explored through the addition to previous 
modelling of variables capturing media coverage during the issue period. Those 
companies with greater levels of direct (company name mentioned specifically) and 
indirect (for example discussions about the disease area the company hopes to treat) 
media coverage could expect to face differing levels of investor sentiment compared to 
more inconspicuous listings.  
5.3.1 Data 
The models developed in section 5.2 which follow the analysis in Deeds, Decarolis and 
Coombs (1997) are used as base models for this analysis, however, the underpricing 
model was excluded as none of the explanatory variables were found to have a 
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significant coefficient. In this section these models are augmented with additional 
variables to capture media coverage.  
 
Media coverage was measured as the number of media cites in major Australian 
publications in the period between the date specified on the independent accountant’s 
report and the day of listing. The Factiva database was used as the source to capture 
data on media coverage. To ensure consistency across the sample period, only those 
publications with electronic access over the entire sample period were included, 
specifically, The Age (a major Melbourne paper), The Sydney Morning Herald, The 
Australian Financial Review, and The Business Review Weekly. Media coverage data 
was collected at three levels: the industry level, the firm level, and the therapeutic 
impact level. “Biotech*” was used as the search term at the industry level, “<company 
name>” at the firm level, and at the therapeutic impact level, key words describing the 
areas of treatment and disease were selected from the prospectus. To control for 
variation in the length of the window of the issue period this information was 
standardised to produce a measure of media cites per day.  
 
Table 5-4 Media Coverage Descriptive Statistics 
This table reports measures of central tendency and variability for the media coverage explanatory 
variables. Where IND is the standardised count of daily media articles about biotechnology, DIS is the 
standardised count of daily media articles relating to the disease and treatment keywords and CO is the 
standardised count of daily media articles mentioning the company name.  
Variable Mean Median Maximum Minimum Std. Dev. 
IND 1.787 1.942 3.091 0.289 0.866 
DIS 2.052 0.636 17.200 0.000 3.468 
CO 0.144 0.096 1.196 0.012 0.214 
 
To control for outliers, the natural log was taken of all of the media coverage variables. 
Additionally, larger offerings are intuitively expected to attract a greater level of media 
attention. To control for this potential bias, the natural log of the total capital raised was 
also included in the money left model as an independent variable. 
 
Thus, the models augmented with the media coverage variables are: 
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LN_IND is the standardised count of daily media articles about biotechnology, LN_DIS 
is the standardised count of daily media articles relating to the disease and treatment 
keywords and LN_CO is the standardised count of daily media articles mentioning the 
company name. 
 
From the previous literature, there are two competing hypotheses about the impact of 
the media coverage variables. Following Demers and Lewellen (2003), one expects that 
increased media coverage in the period prior to the IPO results in improved investor 
sentiment towards the issue, resulting in more money being left on the table on the first 
day of listing. Conversely, following Pollock and Rindova (2003) one expects that 
increased media coverage provides investors with additional information regarding the 
nature of the company, thus reducing investor uncertainty resulting in less money being 
left on the table on the first day of listing. 
5.3.2 Results and Discussion 
The results of estimating the models, with and without the media coverage variables, are 
reported in Table 5-5. The table presents OLS parameter estimates and White-corrected 
p-values. The results in Table 5-5 reveal the following patterns. First, the introduction 
of the media citation variables has marginally increased the explanatory power of the 
MoneyLeft model, with the adjusted R squared of the model rising from 0.44 to 0.47. Of 
the three media variables, only the variable measuring the number of times the company 
has been named directly is found to have a significant impact on the amount of money 
left on the table. This positive and significant coefficient supports the Demers and 
Lewellen (2003) hypothesis that increased media exposure prior to listing has a positive 
influence on investor sentiment and thus increases the amount of money left on the 
table. In contrast, based on the “media legitimation” effect proposed by Pollock and 
Rindova (2003) one could expect some negative coefficients, especially in relation to 
direct media coverage of the company name. The positive and significant coefficient for 
the company media variable, combined with the insignificant coefficients for the disease 
target and industry citations leads to a conclusion against the media legitimation 
hypothesis for the underpricing of Australian biotechnology IPOs. Finally, the positive 
and significant coefficient for the market sentiment variable, shown in section 0 to 
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support research by Dimovski and Brooks (2004b; 2004a), retains its positive sign but 
loses its significance, suggesting that the media coverage variables might be a better 
measure of sentiment for Australian biotechnology IPOs. 
 
Augmentation of the Ln_CapRais with the media variables did not significantly increase 
the explanatory power of the model, with the adjusted R squared remaining at 0.87. The 
INDACC variable became insignificant, likely a result of a positive relationship between 
firm size, independent accountant quality and media coverage. The positive coefficient 
for the LN_IND variable indicates that periods with increased discussion of the 
biotechnology sector in the popular press were associated with larger IPOs. 
Interestingly, neither specific company references nor discussion of relevant therapeutic 
field was found to be significant, indicating that an awareness by readers of the popular 
press of the biotechnology sector as a whole is more influential on the magnitude of 
individual biotech company capital raisings.  
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Table 5-5 Sentiment Augmented Models 
MoneyLeft is the amount of money left on the table which is equal to the number of shares issued * (price 
on close – issue price). Ln_CapRais is the natural logarithm of the amount of capital raised by the IPO. 
CIT is the total number of citations of employees’ and members of the scientific advisory boards’ work as 
per the “web of science” database. INDACC is a dummy variable for the use of a reputable independent 
accountant. PRICE is the issue price of the listing. PROD is the number of fully developed products 
described in the prospectus. SENT_AO is the movement on the ASX all ordinaries index (orthogonalized 
to be independent of movement in the health and biotechnology index) from the date on the independent 
accountants report to date of listing. SENT_HB is the moment of the ASX health and biotechnology 
index) from the date on the independent accountants report to date of listing. TOT_APP is the total 
number of awarded patents and patents under application at the time of listing with each country treated 
as a separate application. TOT_PAT is the number of awarded patents at the time of listing. 
Variable Base Models Augmented Models 
 MoneyLeft (,000) Ln_CapRais MoneyLeft (,000) Ln_CapRais 
 Parameter 
estimates 
(p-value) 
Parameter 
estimates 
(p-value) 
Parameter 
estimates 
(p-value) 
Parameter 
estimates 
(p-value) 
Constant -2269.752 
(0.0116) 
15.1244 
(0.0000) 
14627.235 
(0.5635) 
15.11890 
(0.0000) 
CIT 0.066 
(0.0032)  
0.065 
(0.0106)  
INDACC -3839.288 
(0.0233) 
0.2795 
(0.0879) 
-3351.009 
(0.1582) 
0.164099 
(0.4566) 
PRICE 8092.745 
(0.0001) 
1.3036 
(0.0000) 
8858.387 
(0.0018) 
1.446753 
(0.0000) 
PROD -356.160 
(0.0266) 
0.0308 
(0.0004) 
-373.745 
(0.0294) 
0.029396 
(0.0166) 
SENT_AO 23304.290 
(0.0027)  
8867.474 
(0.5021)  
SENT_HB 
 
-1.3797 
(0.0788) 
 -2.289866 
(0.0239) 
TOT_APP 38.152 
(0.0143) 
0.0060 
(0.0008) 
32.267 
(0.0447) 
0.006231 
(0.0013) 
TOT_PAT 
 
-0.0319 
(0.0000) 
 -0.036517 
(0.0000) 
LN_CAPRAIS 
 -------- 
-851.360 
(0.6131) -------- 
LN_IND   -490.619 
(0.6130) 
0.171105 
(0.0993) 
LN_DIS   -246.312 
(0.5947) 
-0.065647 
(0.2907) 
LN_CO   1666.307 
(0.0046) 
0.016413 
(0.7841) 
Adjusted R2 0.43 0.87 0.47 0.87 
Observations 34 34 30 30 
5.4 CONCLUSION 
This chapter found evidence that during their IPO capital raising, Australian 
biotechnology companies leave significant amounts of money on the table. For 
Australian biotechnology companies, the amount of money left on the table was found 
to be more critical than the level of underpricing. This was evidenced by the significant 
relationships observed between the information contained within the prospectus and the 
amount of money left on the table, and the lack of significance with the level of 
underpricing.   
 
Australian biotechnology companies were able to reduce the amount of money left on 
the table at their IPO by having a fully developed product selling in the market prior to 
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listing, and by engaging the service of a reputable independent accountant to prepare 
their financial history for presentation in the prospectus. Interestingly, those companies 
possessing large numbers of patents and patent applications were found to leave more 
money on the table suggesting investors look for a narrower focus on one or few 
potential products. Companies with staff whose research work had been more 
frequently cited were found to leave more money on the table and this was interpreted 
as evidence of higher quality research staff being attracted by the reputation-enhancing 
and financial rewards that high risk projects offered.  
 
Similar to the findings of Deeds, Decarolis and Coombs (1997), information contained 
within the issuing prospectus was found to have an impact on the amount of funds 
retained by the floating company, however, some differences were found regarding the 
direction of influence of that information. As with Deeds, Decarolis and Coombs 
(1997), those companies with more developed products and a greater number of patent 
applications were found to raise more capital at IPO. Additionally, Australian 
biotechnology companies were found to raise more capital when they had engaged a 
reputable independent accountant and had a greater issue price per share. Conversely, 
no evidence of a reward for knowledge transfer orientation or research and development 
investment was observed.  
 
A large body of literature surrounds the question of IPO underpricing and the reasons 
for its persistent occurrence around the world, with a significant portion of that literature 
dedicated to examining the relationship between underpricing, hot issue periods and 
investor sentiment. This analysis of Australian biotechnology companies that went 
public between 1994 and 2004 provides an exploration of the role of hot issue 
conditions and market sentiment in underpricing. Hot issue periods are typically 
characterised by increased media coverage and greater levels of money left on the table 
by new issues. This research supports the proposition that increased media coverage in 
the lead up to IPO is positively related to the amount of money left on the table for 
Australian biotechnology IPOs. 
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CHAPTER 6 CRITICAL EVALUATION OF 
CONTEMPORARY VALUATION METHODOLOGIES 
6.1 INTRODUCTION 
Chapter 4 of this thesis described the challenge that Australian biotechnology 
companies face in raising sufficient capital to fund expensive research and development 
programs. As a result of the scarcity in development capital, Australian biotechnology 
firms are forced to consider a public sale through IPO and, as a result, the industry has a 
significant number of publicly listed firms which are still many years from successfully 
launching a product on the market. Whilst an IPO may provide a short term injection of 
funds to the company, these early stage firms often have difficulty with subsequent 
capital raisings due to the unattractive risk profile of an early stage biotechnology 
product.  
 
Chapter 5 investigated the phenomenon of IPO underpricing and found that the level of 
underpricing for biotechnology firms was greater than the average level of underpricing 
across all industrial sectors. Underpricing is also termed “money left on the table” as the 
new investors benefit from share price movement at the expense of the listing firm. If 
uncertainty surrounding biotechnology investment could be reduced, the amount of 
money left on the table by Australian biotechnology firms at their IPO might be 
reduced, providing additional capital towards product research and development. 
 
This chapter investigates the suitability of contemporary valuation methodologies for 
assessing biotechnology investments. If the uncertainty surrounding biotechnology 
investment can be reduced through modern investment tools, it is hoped that the 
industry should see an increase in the amount of funds directed into the sector.  
 
A model to analyse and compare contemporary valuation methodologies was developed 
following the process described in Chapter 3. The following discussion is subdivided 
into five areas: alternative valuation methodologies, biotechnology value drivers and 
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model input assumptions, valuation and the product development cycle, valuation 
model sensitivities and implications of valuation methodological choice for investors 
and management. 
6.2 ALTERNATIVE VALUATION METHODS 
Four valuation methods are analysed in this thesis. Two discounted cash flow (DCF) 
models were included, the standard DCF as well as an extension of this model called the 
expected discounted cash flow (eDCF). Two real option valuation models were also 
included, binomial option valuation and binomial lattice option valuation. 
6.2.1 Discounted Cash Flow 
Discounted cash flow (DCF) models are a commonly used tool to value investment 
opportunities that date back to early publications by Fisher (1930) and Williams (1938) 
who described the DCF method as a valuation tool accounting for the time value of 
money.  
 
Valuation using a DCF model requires that all cash flows associated with a prospective 
investment are forecast over the life of the project and are then discounted back to a 
present value using an appropriately chosen discount rate. The discount rate should be 
chosen to reflect the risks associated with the forecast cash flows, however this 
requirement can be problematic due to difficulties quantifying the risks upon which the 
discount rate is based.  
 
Modern financial theory uses the capital asset pricing model (CAPM) as a means for 
quantifying investment risk. This method quantifies firm sensitivity to systematic risk 
relative to the market as a whole. If an investment is more risky than “the market” then 
it should offer returns in excess of the market in order to compensate investors for that 
additional risk. To overcome difficulties in quantification of the risks and return 
characteristics of “the market”, the bundle of all publicly listed companies on the stock 
market is used as a proxy for “the market”. 
 
In addition to the underlying assumptions inherent in the CAPM, the use of this method 
to calculate the discount rate for a project assumes that the risks associated with the cash 
flows generated through the project are comparable to those of the firm for which a 
Chapter 6 – Critical Evaluation of Contemporary Valuation Methodologies 
- 133 - 
CAPM based discount rate is calculated. For a firm that is not publicly listed, a 
comparable publicly listed firm must be found in order to calculate a cost of capital 
using the CAPM. For an early stage biotechnology company this may pose some 
difficulty as there may be no listed firm with similar risk sensitivity which can be used 
as a basis for calculating a comparable discount rate. 
 
A DCF model was used to value a typical drug development project based on the inputs 
described in section 6.3.2 below. The DCF model does not incorporate the ability of 
management to respond flexibly to issues that arise throughout the project, and as such 
no flexibility is included in the cash flows forecast using this method. For this analysis, 
an average commercialisation outcome was assumed as the basis from which cash flows 
were estimated. No allowance was made for product development success risks as these 
are assumed to be diversifiable and quantified by selection of an appropriate discount 
rate.  
6.2.2 Expected Discounted Cash Flow  
The expected discounted cash flow model (eDCF) relies on the same principles as 
simple DCF models, however, it seeks to incorporate known project risk into cash flow 
forecasts. This is achieved by evaluating more than one cash flow outcome, best 
described in the form of an example. Let us say that a firm is deciding whether to invest 
in a project which requires an $80 investment and has two possible outcomes, A and B. 
A is more favourable than B with expected revenues one year from now of $100 whilst 
outcome B has expected revenues one year from now of $80. Additionally, each 
outcome has an equal likelihood of occurrence, that being 50% probability and the 
discount rate is assumed at 10%. This project is presented diagrammatically in Figure 
6-1. 
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Figure 6-1 eDCF Project Example Illustration of Cash Flows  
 
 
The present value of this investment is calculated as the probability weighted sum of the 
present values for all cash flows associated with the project. Thus the eDCF value for 
this project is equal to 100%*$(80) + 50%*$100/1.10 + 50%*$80/1.10 = $1.82. 
Therefore, on the basis of this calculation, the firm should choose to invest the required 
$80 in this project as it has a positive expected net present value. The input data 
required to compute this valuation were the discount rate, the cash flows (size, timing) 
and the probability of those cash flows occurring.  
 
This form of valuation is particularly suited to pharmaceutical investments due to the 
clearly defined hurdles that must be overcome during the product development phase. 
Once a product has undergone pre-clinical development and assessment, the product 
must undergo phase 1, 2, and 3 clinical trials prior to all documentation pertaining to the 
development being submitted to the regulator (for example the Therapeutic Goods 
Administration (TGA) in Australia) for approval. If the regulator is satisfied with the 
documentation and results of the clinical trials, then the product may be released on the 
market. This process is shown in decision tree form in Figure 6-2. 
 
$(80) 
$80
$100
50% 
50% 
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Figure 6-2 Typical Drug Development Decision Tree 
 
 
Factors such as the competitive landscape, efficacy of a treatment, side effect profiles, 
development cost (and drug pricing) and age of a product all have an impact on the 
revenues generated by a therapeutic. When conducting valuation of a pharmaceutical 
product in the early stages of development, great uncertainty exists around many of 
these factors hence significant uncertainty exists around the commercialisation stage 
cash flows that may be realised should the product pass all regulatory requirements and 
make it to a marketable product. To capture this uncertainty, Kellogg and Charnes 
(2000) propose that five separate commercialisation outcomes be included in valuation 
analysis. They labelled these outcomes as dog, below average, average, above average 
and breakthrough (or blockbuster). These outcomes can be simply added to the final 
branch of the decision tree in Figure 6-2 to produce the drug development and 
commercialisation decision tree shown in Figure 6-3.  
Figure 6-3 Drug Development and Commercialisation Decision Tree 
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The eDCF model in this chapter uses the decision tree shown in Figure 6-3 as the 
foundation for possible project outcomes. The method follows Kellogg and Charnes 
(2000), however, the input data has been updated to incorporate recent literature. 
Similar inputs to the simple example shown earlier are required to calculate an estimate 
of value: 
1. Probability of each outcome occurring (include probability of successfully 
completing each development phase as well as the probability of each of the 
commercialisation outcomes occurring). 
2. Commercialisation cash flow details (timings and size). 
3. Discount rate. 
The input values adopted for the model are described in greater detail in section 6.3.2.  
 
The eDCF valuation methodology allows the valuer to incorporate perceptions of 
project risk into the development model. With pharmaceutical products, a significant 
amount of information is available to help model the likelihood of each of the outcomes 
described in the decision tree. Use of this information enables the valuer to build a more 
powerful model which also allows a more quantitative description of the risks included 
in the model. Whilst the first cut of an eDCF valuation model may be based on industry 
wide data regarding the likelihood of success at each stage of clinical development, the 
specific manner in which this is incorporated into the model allows the valuer to easily 
adjust these risks to more accurately reflect the risks associated with the opportunity 
under assessment.   
 
Unfortunately, whilst the project risk can be specifically modelled with some accuracy, 
inclusion of this information in the model creates an inconsistency with the underlying 
valuation theory. As discussed, the discount rates should be chosen to reflect the risks 
associated with the project under assessment. This being the case, the addition of project 
risk estimates in the model effectively creates a double counting of this risk. To 
overcome this, the discount rate can be reduced to exclude project level risk, however, 
this requires knowledge of what portion of the discount rate reflects the specific project 
risk included in the decision tree. Calculation of the discount rate using the CAPM and 
weighted average cost of capital (WACC) does not allow the user to identify the 
components of risk included in the discount rate, thus, to estimate the portion 
attributable to project risk becomes a significant challenge. Fortunately, an underlying 
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assumption of the CAPM stipulates that the WACC only captures the impact of 
systematic risk. A biotechnology firm is able to reduce its exposure to project failure 
through diversification, hence a project risk contains at least some portion of 
unsystematic risk. The extent to which the project risk is systematic or unsystematic 
determines the extent to which the eDCF model incorporates a double counting of 
project risk. 
6.2.3 Binomial Option Valuation 
To overcome the problem of double counting of the project level risk in eDCF valuation 
models, Jagle (1999) proposes a solution based on binomial option valuation theory. 
Jagle provides a brief description of the methodological process, however, more detail 
can be found in Trigeorgis (1996) and Copeland and Antikarov (2001). 
A real option represents the right but not the obligation to undertake an action at a 
predetermined cost called the exercise price (Copeland and Antikarov 2001). 
A drug development project can be considered in the context of option valuation theory 
as a series of real options. The commercialisation cash flows are the underlying asset, 
and the discovery stage research and development costs represent the exercise price on 
call options to proceed to the next phase of development. If the drug development 
project is considered in this manner, then the value of the project at any stage in 
development is the value of the call option at that time. 
 
The underlying premise of option valuation is the concept of the risk neutral portfolio 
which forms the foundation for the following derivations. Consider an asset which has a 
present value, V, and two possible future values V+ and V - with the probability of these 
outcomes eventuating being a and b respectively. A call option on this asset also exists 
which has a present value of C, and two possible future values of C+ and C-. This 
scenario is diagrammatically shown below in Figure 6-4. 
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Figure 6-4 Simple Real Option Example 
 
 
By investing in a portfolio consisting of a long position in the underlying asset and 
selling short m call options on that asset, a risk neutral position can be held whereby the 
value of the portfolio is the same regardless of the eventual value of the underlying 
asset. That is to say that any increase in the value of the asset will be offset by the 
corresponding decrease in the value of the short call option(s), and visa versa.  
Thus: 
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As the value of the portfolio is the same regardless of the movement in the value of the 
underlying asset, the law of one price21 says that this portfolio must have returns equal 
to the risk free rate of return, r. Thus over a period of time, t, the change in portfolio 
value is: 
+
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Substituting the derived equation for m, above, and transposing for C gives: 
                                                
21 The law of one price states that in an efficient market two assets having identical returns, regardless of 
the state of nature, must have the same value (Copeland and Antikarov 2001). This makes intuitive sense 
as any variation between the prices of two assets having identical returns would create an arbitrage 
opportunity for risk free profits. 
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Thus if V, V+, V -, C+ and C- are known, then the concept of risk neutrality allows the 
calculation of the value of C. The estimate of p is known as the “risk neutral success 
probability” and is used (along with the risk free rate) to discount the future option 
values to calculate the present option value. 
 
To calculate C, the estimates of V, V+, and V - must first be calculated. V+ and V - are the 
values of the expected cash flows that would occur in favourable or unfavourable 
market conditions respectively. DCF can be used to calculate an estimate for the values 
of these inputs. Copeland and Antikarov (2001) assume that the present value of the 
expected cash flows is the best unbiased estimate for the value of the underlying asset. 
This assumes that management is without flexibility around project implementation and 
is called the Marketed Asset Disclaimer (MAD). This allows V to be calculated using 
the eDCF tools using a, the actual probability of a favourable outcome. 
 
Once all values in the underlying asset value tree are known, then the corresponding 
risk neutral success probability can be calculated. The next step is calculation of C+ and 
C-. At expiry, the value of a call option is entirely made up of its intrinsic value which 
equals the value of the underlying asset less the exercise price. In the case of a drug 
development project, the exercise price is research and development cost of that phase. 
On this basis C+ and C- can be estimated and the value for C can be calculated by 
discounting C+ and C- using the risk free rate and applying the risk neutral probabilities, 
p and 1-p to each outcome.  
 
The option of project abandonment can be incorporated into this model by specifying 
that C+ and C- are respectively equal to the maximum of V+ and V - less development 
costs or zero. That is to say, if the expected value dips below zero, the project would be 
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abandoned, hence the value of future cash flows will be zero. For the purposes of this 
study, and given the identical decision trees used for the binomial and eDCF models, 
the abandonment option was not incorporated into this model in order that a clearer 
comparison can be made with eDCF value estimates throughout the life of the project. 
This will also allow clearer exploration into the purported issue of double counting of 
project risk within the decision tree and discount rate. 
 
By expanding the binomial decision tree to incorporate each development phase as per 
Figure 6-2, a drug development project can be valued using this method. Whilst the size 
of the decision tree increases the computational workload, the process is the same as the 
simple example above. First, calculate the values in the underlying asset tree (similar to 
the eDCF model, however development costs are not included), then calculate the risk 
neutral probabilities, then calculate the option values at the end points, and finally, 
rolling back through the option tree (using the risk free rate and the risk neutral 
probabilities), calculate the present value of the option to invest in a drug development 
project.  
 
Following Jagle (1999), this model was built with each development phase representing 
one branch in the decision tree. For the purposes of this investigation, development 
costs incurred during each phase of development were assumed to occur at the 
commencement of that phase. This provides a conservative estimate of the actual 
development costs as in reality these costs would be spread throughout the phase. 
Allowing for the time value of money, the present value of actual development costs 
would be less than that assumed for this model. 
6.2.4 Binomial Lattice Option Valuation 
The binomial lattice option valuation method follows that described by Kellogg and 
Charnes (2000) which relies on the risk neutral valuation approach similar to the 
binomial option model described in section 6.2.3. In contrast to the previous methods, 
rather than a decision tree, a binomial lattice is used to model cash flows. The required 
inputs to value an asset with this methodology are: 
1. Current value of the asset, Va. 
2. The standard deviation of the asset value, σ . 
3. The risk free rate, r. 
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4. The exercise prices of the call options (these are the costs incurred in order to 
proceed to next stages in development).  
5. The probability of proceeding from one stage in development to the next. 
 
The project is broken up into a finite number of time increments, n, and the value of the 
asset is assumed to move either up or down through each of those increments. This 
allows construction of the binomial lattice shown below in Figure 6-5. 
 
Figure 6-5 Binomial Lattice Valuation Framework 
 
 
The asset is the final product, thus the current value, Va, is defined as the current value 
of the commercialisation cash flows at time zero. This is calculated by rolling the 
commercialisation cash flows through the decision tree in Figure 6-3. The development 
costs (i.e. the exercise prices), are ignored at this stage as we are only valuing “the 
asset”.   
 
In this case the value of Vaun is equal to the value of the commercialisation cash flows 
in the event of a blockbuster commercialisation outcome, CFblock. These cash flows are 
forecast in section 6.3.2.5, with the value of these cash flows at time n calculated using 
a DCF model of the blockbuster cash flows once the product is successfully launched. 
Following Amram and Kulatilaka (1999) as per Kellogg and Charnes (2000), u is set to 
eσ and d to e-σ. Thus: 
Vaun = Va eσn = CFblock 
Transposing gives: 
Va 
Vau 
Vad 
Vau2 
Vad2 
Vaud
Vau3
Vad3 
Vaud2
Vau2d
Vaun        = E1 
Vadn         = Ek 
Vad1un-1   = E2 
Vadn-1u1   = Ek-1 
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σ = (1/n)ln(CFblock /Va) 
With CFblock and Va calculated using a DCF model, σ  can easily be calculated allowing 
all of the asset values through the binomial lattice in Figure 6-5 to be computed.  
 
The next step is to calculate the risk neutral probabilities of success, p, and failure, 1-p, 
according to: 
p = 
du
de tr
−
−
∆
 
The actual probability of successfully completing a development stage is defined as θn. 
Where a development stage takes longer than one time period, the probability of 
successfully moving from one time period to the next is assumed as 1 for all but the last 
period, which is assumed to be θn. This allows the value of the call option, that being the 
value of the pharmaceutical development project, to be calculated by incrementally 
rolling back through the binomial lattice. The Ek values (for k = 1 to n+1) form the 
foundation of the calculation and subsequent values in the lattice are calculated 
according to: 
[ ]{ }0,)1(max 1,1,1, nntrknknkn DCFepVpVV −−+= ∆−+++ θ  
DCFn is equal to the value of development costs during time period n. It should be 
noted that according to this formula the value of the pharmaceutical project, Vn,k, can 
never be negative due to the max{X,0} statement. The theoretical basis for this is that if 
a negative number is expected in the next branch of the lattice, the project will be 
abandoned, and hence the value of future cash flows is zero. This is effectively 
capturing the value of abandonment of the project if the expected value of the 
underlying asset drops below that required to generate the necessary return for the given 
level of risk. Consistent with Kellogg and Charnes (2000), the abandonment option was 
incorporated in this model allowing some exploration of the value benefits of 
management flexibility around project abandonment.  
 
This model was constructed with each branch representing one month in development 
time. Development costs for each phase were assumed to be spread evenly over the 
duration of that phase and, as per Kellogg and Charnes (2000), the probability of an 
upward movement in the underlying asset value tree was assumed to be one for all 
branches other than the last month of development for each particular phase. For the last 
month the success probabilities are defined in Table 6-1. 
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6.3 MODEL INPUT ASSUMPTIONS 
6.3.1 Population Sampling Distributions 
To generate the model input data within a Monte Carlo simulation, a population 
distribution for each valuation input was estimated. The chosen distribution was based 
on the publicly available information describing the distribution for each of the input 
variables. The particular normal distribution was deemed to be unsuitable due to the 
skewed nature of the available sample data, together with the tendency for the variables 
to be contained within certain limits (for example development time cannot be less than 
zero). Data including development costs and development time were assumed to be 
clustered around a mode value, with fewer observations down (up) to a minimum 
(maximum) value. 
 
To model the input data, a version of the beta distribution was chosen for its attributes 
of being contained between an upper and lower limit and clustered around the mode. 
This distribution allows generation of more realistic input data as the tails are narrower 
than the triangular distribution, a similarity shared with the normal distribution.  
 
The beta distribution is defined by the probability density function: 
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Where B(v,w) is the beta function: 
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Where v and w are two shape parameters.  
 
A subset of the beta distribution called the betaPERT distribution allows the population 
mode to be used to generate the shape parameters. In the betaPERT distribution the 
mean µ is calculated: 
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Where λ is a scale parameter which determines the height of the distribution. 
 
The mean can then be used to calculate the shape parameters according to: 
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Thus, with a minimum, maximum, mode and scale parameter, the betaPERT 
distribution can be used to model input data for Monte Carlo scenario generation.  
 
Figure 6-6 below provides a graphical comparison of a normal, betaPERT and 
triangular distributions. The normal distribution has a mean of 1.5 with a standard 
deviation of 1. To represent data such as development time, the population distribution 
must be contained within a minimum parameter as negative (or very low) values are not 
possible. In this example, the standard deviation of the normal distribution was used as 
the basis for calculating the minimum and maximum values of the betaPERT and 
triangular distributions. For the minimum value, this was chosen as the mode less one 
standard deviation which equals 0.5. The maximum was chosen as 3.5 representing two 
normal distribution standard deviations greater than the mode.  
 
For the betaPERT distribution, a lambda (shape factor) of 4 was adopted. The graphical 
representation shows that the betaPERT distribution with lambda of 4 is similar to the 
triangular distribution, having a comparable mode expectation, however, as with the 
normal distribution, the extremes have narrow tails rather than straight lines.  
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Figure 6-6 Comparison of BetaPERT, Normal and Triangular Distribution Probability Mass 
Functions  
-2 -1 0 1 2 3 4 5
betaPERT normal triangular
 
6.3.2 Inputs Range Specification 
Table 6-1 below summarises all of the input data included in the valuation models and 
tested using Monte Carlo scenario analysis. The betaPERT distribution was adopted as 
the population sample for all inputs and the population descriptors of minimum, 
maximum and mode are shown. In all cases a shape factor (lambda) of 4 was chosen. 
Details regarding the selection of the population descriptors are provided in the 
subsequent subsections.  
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Table 6-1 Model Inputs and Population Descriptors 
Item  Population Descriptors* 
  Min Max Mode 
R&D Cost ($,000) Phase I -40,800 -2,400 -15,200 
 Phase II -67,700 -1,400 -23,500 
 Phase III -207,500 -25,700 -86,300 
 NDA Application -4,900 -1,000 -3,300 
R&D Time (months) Phase I 3.7 57.4 21.6 
 Phase II 4.4 68.3 25.7 
 Phase III 5.2 81.0 30.5 
 NDA Application 3.1 48.3 18.2 
 Post Approval 1.5 23.9 9 
Probability Development Success Phase I 53% 89% 71% 
 Phase II 33% 55% 44% 
 Phase III 57% 95% 76% 
 NDA Application 85% 95% 90% 
Salvage Value ($,000) Phase I 0 650 325 
 Phase II 0 800 400 
 Phase III 0 1000 500 
 NDA Application 0 1000 500 
Probability of Average Drug Sales  - 50% 70% 60% 
Post Approval R&D ($,000)  -371,908 -24,046 -140,000 
Revenues from Drug Sales ($,000) Dog 4,000 9,000 6,500 
 Below Average 9,000 20,000 14,500 
 Average 20,000 400,000 210,000 
 Above Average 400,000 1,500,000 950,000 
 Breakthrough 1,500,000 2,500,000 2,000,000 
Discount Rate (Real) Commercial 10.00% 12.00% 11.00% 
 R&D 7.00% 9.00% 8.00% 
Inflation - - - 2.82% 
Risk Free Rate - - - 5.50% 
* A shape factor (lambda) of 4 was adopted for all population distributions. 
6.3.2.1 Research and Development Costs 
Estimates for the research and development costs at each phase of product development 
prior to market launch were based on data provided in DiMasi, Hansen and Grabowski 
(2003). This paper has been widely cited and has also been the subject of extensive 
debate about the actual costs of drug development. The more recent analysis by Adams 
and Brantner (2006) uses data from an alternative source (the Pharmaprojects database 
which is a collation of data from publicly available sources assembled by the vendor, 
PJB Publications) and generally supports the findings of DiMasi, Hansen and 
Grabowski (2003). 
 
The sample used by DiMasi, Hansen and Grabowski (2003) included costs of 68 drugs 
in development by 10 pharmaceutical firms obtained from the proprietary Tufts Center 
for the Study of Drug Development (CSDD) database. The drug development programs 
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had begun between 1983 and 1994 and were in development though to 2000. Whilst 
they provide mean, median and standard deviation of the “out of pocket” drug 
development costs, no additional information was given regarding the distribution 
characteristics of the sample of costs. 
 
The mean costs were adopted as the mode for the purposes of this study and it was 
observed that, for all phases of product development, the mean cost was marginally 
greater than one standard deviation above zero. The minimum cost cannot be less than 
zero and the level of work required to develop a new drug implies that the cost cannot 
be near zero. For the purposes of this study, the mean cost of development in each phase 
less one standard deviation was adopted as the minimum cost boundary for our model.  
 
Greater possibility exists for costs being significantly higher than average depending on 
the particular characteristics of the drug in development. Some products with 
significantly increased development costs will be financed by drug development 
companies depending on the ultimate potential for commercial return of those products. 
To allow for this possibility of greater upwards variance in development costs, the mean 
cost plus two standard deviations was adopted as the maximum cost boundary for our 
model. 
6.3.2.2 Research and Development Time 
DiMasi, Hansen and Grabowski (2003) provide data regarding the mean time in each of 
the research and development phases prior to products being launched, however, no data 
is provided regarding the shape of the distribution of development times. In the absence 
of any additional descriptive data, the length of time taken in each development phase 
was assumed to be correlated to the cost incurred in that phase, with a similar shaped 
population distribution. The ratios of the standard deviations of phase one, two and 
three clinical trial costs compared with the mean costs for each are 0.84, 0.94 and 0.70 
respectively, with an average of 0.83.  
 
A ratio of 0.83 was assumed between the standard deviation and mean of development 
times. Applying this ratio enabled estimates of the standard deviation to be calculated, 
allowing calculation of minimum development times as one standard deviation less than 
the mean, and maximums of two standard deviations greater than the mean. 
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6.3.2.3 Research and Development Success Probabilities 
The probability of successful product development is a subject of much debate with a 
broad range of estimates depending on data source, drug characteristics and the time at 
which the data was collected. DiMasi, Hansen and Grabowski (2003) provide data 
regarding the probabilities of drugs moving from one phase to the next within their 
sample which was used as the basis for this study. Whilst not directly stated, their data 
implied that the probabilities of successfully moving from one development phase to the 
next were 0.71, 0.44 and 0.69 for phase one, two and three clinical trials respectively. 
The phase three success rate includes a successful new drug application (NDA) with the 
US Food and Drug Administration. In order to split this stage of the development 
process out from the phase three probabilities, a 0.90 success probability was assumed 
for a NDA after completion of phase 3 clinical trials. This implied a probability of 
successful completion of phase 3 clinical trials of 0.76.  
 
Due to the uncertainty surrounding actual success probabilities of specific drugs, a 
range of plus or minus 25% of the expected success rate was used as the maximum and 
minimum success probabilities for the clinical trial phases. Once a product has passed 
through clinical trials, the likelihood of successful NDA registration is high (DiMasi 
2001). Rather than apply a variation of plus or minus 25%, which would potentially 
generate excessively pessimistic success forecasts, the probability of successful new 
drug registration with the FDA was assumed to vary from a minimum of 0.85 to a 
maximum of 0.95. 
6.3.2.4 Salvage Values 
Salvage values represent the value of a research project in the event that a decision was 
made not to continue product development. The decision to terminate product 
development could be due to critical flaws in the product itself (such as efficacy or 
toxicity concerns), or for other matters such as the commercial viability of the final 
product or strategic decisions to withdraw from an area of product development.  
 
Whilst termination of a project will inevitably result in a significant revaluation of the 
associated intellectual property, potential remains for some value to be realised. For 
example the technology could be applied to a different product or the data generated in 
product development process may be valuable to a competitor. The value that can be 
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realised in the event of project termination is difficult to quantify, however, to test the 
sensitivity of the models for illustrative purposes, nominal figures for value were 
chosen. In his real option valuation example, Jagle (1999) adopted relatively large 
values for these termination values22, however, due to the uncertainty surrounding these 
salvage values, conservative numbers were chosen for this analysis. For each stage of 
development the termination values were generated based on a minimum value of $0 up 
to a maximum of $650,000, $800,000, $1,000,000, or $1,000,000 for products 
terminated after phase 1, 2, 3, and new drug registration respectively. The mode was 
chosen as the midpoint between the minimum and maximum values. 
6.3.2.5 Commercialisation Cash flows 
The commercialisation cash flows are dependant on a large number of underlying 
factors. The method for forecasting the commercialisation cash flows is based on the 
method outlined by Kellogg and Charnes (2000). For simplicity, costs are assumed as a 
percentage of sales and sales are forecast over a defined timeline. The operational costs 
assumed for this analysis is outlined below in Table 6-2. 
 
Table 6-2 Commercialisation Cash flow Cost Assumptions 
Cost Item % of Sales 
COGS 25.5% 
Sales & Marketing Expense Varies* 
General & Admin Expense 11.1% 
Tax 30.0% 
Working Capital 17.0% 
* Broadly in line with Kellogg and Charnes (2000), sales and marketing expenses are assumed as a 
percentage of revenues, decreasing from 100% in year 1, 50% in year 2, 25% in years 3 & 4, 20% in 
years 5-13, and 5% in years 14-20. 
 
Revenues are forecast over the entire life of the project with five possible revenue 
outcome expectations as defined by Myers and Howe (1997) and adopted by Kellogg 
and Charnes (2000). The quality of the revenue stream is defined by five possibilities: 
dog, below average, average, above average, breakthrough (blockbuster). The 
population descriptors for each of these revenue scenarios are shown in Table 6-1 and 
                                                
22 In his base case binomial option Jagle (1999) chose salvage values which were between 10% and 
22.5% of the value of forecast commercial cash flows generated if the development is assumed to be 
successful.  
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are based on current product revenue expectations23. However, it should be noted that 
these figures represent the maximum annual revenue realized over the life of the 
product. To forecast revenues over the product life cycle, the revenues for each year 
were estimated as a percentage of peak annual revenues based on the forecasts by 
Kellogg and Charnes (2000) and shown in Figure 6-7. These are forecast over 20 years 
to capture the impact of the Hatch-Waxman Act (1984) in the US which allowed patent 
holders to add a maximum of five years development and review time (to a total not 
longer than 14 years after FDA approval) to the length of the patent  (Chahine 2000). 
Whilst the patent will expire during the 20 year forecast period, lag between patent 
expiry and loss of market share moderates the rate revenue shrinkage (Grabowski, 
Vernon and DiMasi 2002). 
 
Figure 6-7 Revenue Forecast as a % of Peak Annual Revenue Estimates 
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Kellogg and Charnes (2000) assumed that the probability of a drug generating ‘average’ 
sales was 60% with a 10% chance of each of the other four revenue forecasts. To 
capture variation in the likelihood of each of these outcomes the probability of an 
average revenue outcome was allowed to vary as shown in Table 6-1 and with the other 
four outcomes assumed to have an equal probability of occurrence. Thus if the 
                                                
23 See for example Duggan and Morton (2004) who quote an average revenue for their sample of the top 
200 drugs in 2002 as USD $583m ranging from $117m up to $5.68b. A blockbuster drug has been 
defined as having annual revenues exceed USD $1b (Datamonitor 2003; Decision Resources 2005). 
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probability of average sales was 68%, then each of the other four outcomes would have 
an 8% chance of occurring. 
 
Post approval research and development costs are those associated with additional 
research and development after the product has been successfully launched on the 
market. This investment may be undertaken to investigate the potential for the drug to 
be used for alternative indications or to provide additional information to assist with 
product marketing. According to a report by the Tuft Centre for the Study of Drug 
Development (2003), the average amount spent on post approval research and 
development is $140m. This was used as the mode of the expected cost and, as with 
other research and development expenditures, the mode less 83% was used as the 
minimum bound, and the mode plus 166% was used as the upper bound. These 
expenses were assumed to form part of the commercialisation cash flows and, as per 
Kellogg and Charnes (2000), it was assumed that only products having ‘average’ or 
better commercial outcome were assumed to have had sufficient commercial return to 
warrant additional post approval expenditure. 
 
6.3.2.6 Discount Rate 
Following Myers and Howe (1997), separate discount rates were chosen for the 
development and commercialisation phases of the product cycle. Kellogg and Charnes 
(2000) adopted real discount rates of 6% for the development phase and 9% for the 
commercialisation phase of the product cycle. More recently, DiMasi, Hansen and 
Grabowski (2003) estimated that the cost of capital for pharmaceutical companies 
varied between 10.6% and 12% around a mean of 11% over the life of their study24.  
The discount rates chosen for this study were greater than those by Kellogg and Charnes 
(2000) in order to capture the estimates by DiMasi, Hansen and Grabowski (2003).  The 
real commercialisation discount rate and was allowed to vary between 10% and 12% 
around a mean of 11% and the real discount rate for development cash flows was also 
increased to vary between 7% and 9% around a mean of 8%. All discount rates were 
converted from real to nominal by adjusting for inflation (defined below). 
                                                
24 DiMasi, Hansen and Grabowski (2003) calculated the discount rate using the CAPM and compared the 
result with similar estimates by Myers and Howe (1999) and Myers and Shyam-Sunder (1996) to 
establish the appropriate discount rate for their study. 
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6.3.2.7 The Risk Free Rate and Inflation  
The risk free rate was chosen as the average yield on 10 year Commonwealth treasury 
bonds over the four years between 2002 through to 2005 as shown below in Table 6-3.  
 
Table 6-3 Risk Free Rate Source Data (Australian Bureau of Statistics 2006b) 
Year 10 Year Treasury Bond Yield 
2002 5.99% 
2003 5.01% 
2004 5.87% 
2005 5.11% 
Average 5.50% 
 
The inflation forecast was based on the average of the year on year annualised quarterly 
Australian Consumer Price Index (CPI) growth over the period from June 2005 through 
to March 2006 as shown in Table 6-4. There is research to suggest that drug 
development costs are increasing at a greater rate than CPI inflation (DiMasi, Hansen 
and Grabowski 2003), however, the issue is clouded by concerns that the increases are 
related to increasing complexity of the clinical trials process (Barnes 2006). For 
simplicity, this model assumes that the cash flows associated with development and 
commercialisation of drugs will increase with headline inflation.  
 
Table 6-4 Inflation Forecast Source Data (Australian Bureau of Statistics 2006a) 
Quarter Ending Year on Year Annualised CPI Increase 
Jun-2005 2.49% 
Sep-2005 3.03% 
Dec-2005 2.80% 
Mar-2006 2.98% 
Average 2.82% 
 
6.4 VALUATION AND THE PRODUCT DEVELOPMENT CYCLE 
In this section the alternative valuation methodologies were used to value a typical 
biotechnology product at four stages in the product development process, those being: 
after the product has completed all pre-clinical testing and is about to enter phase one 
clinical trials; as the product is about to enter phase two clinical trials; as the product is 
about to enter phase three clinical trials; and finally, at the point when all clinical trials 
are complete and a regulatory filing is being made. 
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Initially, the models were run using the expected mode of the inputs shown in Table 
6-1. The model outcomes for each of the valuation methods are shown in Table 6-5 and 
represent the expected valuations at each stage in product development in the absence of 
Monte Carlo scenario modelling. The DCF model consistently values this drug 
development project lower than each of the alternative valuation methods. As the DCF 
model does not quantify management flexibility and the potential for a commercial 
outcome greater than “average”, the difference in value is not unexpected. 
 
Table 6-5 Fixed Input Expected Valuations ($ ,000) 
Development Stage DCF eDCF Binomial Binomial Lattice 
Prior to Phase 1 -$2,247 $38 -$1,384 $0 
Prior to Phase 2 $18,963 $26,604 $23,378 $19,216 
Prior to Phase 3 $55,677 $140,854 $132,395 $134,989 
Prior to filing $175,048 $376,342 $376,142 $376,171 
 
The three remaining valuation methods allow for management flexibility throughout the 
project and have values that are similar and converge as the project moves towards 
commercialisation. The eDCF and binomial tree use the same decision tree through the 
development process, however the eDCF model consistently places a higher value on 
the project, particularly in the earlier stages of development. A contributing factor for 
this is that both methods incorporate the same levels of project risk into the same 
decision tree, however the eDCF uses the cost of capital to discount all cash flows back 
though the tree to the present. The binomial tree effectively discounts development 
costs (considered to be option exercise costs) at the risk free rate. As the cost of capital 
is greater than the risk free rate, the present value of development costs in the binomial 
tree is greater than for the eDCF model, thus producing consistently lower estimates of 
value.  
 
The binomial tree method uses the concept of a replicating portfolio to adjust the 
probabilities of success and failure at each decision node to represent “risk-free” 
probabilities which then enables all the cash flows to be discounted at the risk free rate. 
As the project moves from the early stages of development closer to the market launch, 
the differential between the eDCF and the binomial tree narrows. This is consistent with 
the notion that a project in later stages of development has less future development 
expenditure, hence the impact of the differential in discount rates applied to 
development stage costs is reduced.  
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Interestingly, whilst the binomial lattice method proposed by Kellogg and Charnes 
(2000) uses a unique lattice, it provides valuations broadly in line with the eDCF and 
binomial calculations. The zero valuation of the project prior to phase 1 clinical trials 
indicates that management should consider termination of the project unless motivations 
other than the cash flows directly associated with the project exist. This is a decision 
supported by the DCF and binomial valuations. 
 
Valuation analysis is useful to management in providing an estimate of project value at 
a specific point in time as well as providing data regarding the expected incremental 
changes in value throughout the project (see section 4.4.1). Table 6-6 shows the value 
accretion if each stage in the drug development process is successfully completed. 
Interestingly, the value accretion for the DCF model through phase one clinical trials is 
similar to those calculated using the alternative methods. However, the value accretion 
predicted using the DCF model through the remaining clinical trials is significantly less 
than that predicted with the alternative models. The DCF valuation assumes commercial 
cash flows in the event of an “average” outcome, whereas the remaining three methods 
allow for potential changes in the commercial success of the product. This difference in 
model structure seems to be less significant in the quantification of value accretion in 
the early stages of development. 
 
Table 6-6 Expected Value Accretion between Development Stages ($ ,000) 
 DCF eDCF Binomial Binomial Lattice 
Through Phase 1 $21,210 $26,566 $24,762 $19,216 
Through Phase 2 $36,714 $114,250 $109,017 $115,773 
Through Phase 3 $119,371 $235,488 $243,747 $241,182 
 
The value of the project prior to commencement of stage 1 clinical trials is low, and 
considering the risks associated with drug development, may lead management to 
abandon the project. However this decision should not be made without analysis of the 
expected value accretion if it were to go ahead. Whilst the expected cost of a phase one 
clinical trial is $15m (to be spent over 22 months), the expected increase in value if the 
trial is successful is between $19m and $27m depending on the valuation method that is 
adopted. This information may justify additional investigations into the likelihood of 
phase one clinical trials being successful before a decision is made to abandon the 
project. 
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6.4.1 Scenario Analysis Prior to Commencement of Clinical Trials 
In this section the valuation inputs are allowed to vary according to the population 
descriptions in Table 6-1. At each stage of product development, all of the model inputs 
were generated 1000 times, with the results then fed through the valuation models to 
produce 1000 corresponding estimates of value for each method.  
 
Figure 6-8 below shows the probability mass function for the estimates of value prior to 
commencement of phase one clinical trials. The DCF valuation model has the widest 
dispersion of valuation estimates in comparison with the decision tree valuation models. 
The DCF model requires less input data than the alternative valuation models, however 
this translates to a higher level of uncertainty surrounding the project valuation. 
 
Figure 6-8 Valuation at Commencement of Phase 1 Clinical Trials – Probability Mass Function 
Comparison between Alternative Valuation Methodologies 
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Table 6-7 below shows descriptive statistics for the sample of valuation estimates 
generated by each method and the binomial lattice is the only method that has an 
average valuation greater than zero. The binomial lattice incorporates the value of 
project abandonment at each node according to: 
 
{ }0,)(max nnkn DCFEV −= θ   (Kellogg and Charnes 2000) 
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Where Vn is the value at the node n, Ek is the value at the end branch k, θn is the 
probability of continuation from one node to the next and DCFn is the R&D payment 
that occurs in year n. Those cases where zero is chosen as the maximum represent value 
maximisation through project abandonment. 
 
In the early stages of development, zero was taken as the maximum value in the 
majority of cases, with only 15% of the simulations generating a value greater than zero 
using the binomial lattice method at the commencement of phase one clinical trials. 
Thus, whilst the average valuation of the project using this method was positive, the 
majority of simulations placed a zero value on the project, hence the positive value is 
misleading when compared with the output from the alternative valuation methods. 
Similarly, the standard deviation and inter quartile range provide misleading 
information regarding the certainty of the valuation when compared with alternative 
methods. 
 
The eDCF valuation provides the highest average value for the pre phase 1 product, 
however, it is also a negative value. Of the sample of 1000 simulations, 27% of the 
eDCF model outcomes were greater than zero. The eDCF valuation method also 
produced valuations with the lowest standard deviation and inter-quartile range.  
 
The DCF valuation provides the largest variation in valuation estimates with a standard 
deviation of close to $50m. This implies that any valuation derived using this method 
for an early stage drug development project should be viewed with caution due to the 
significant impact that the choice of input variables has on the estimate of value. The 
eDCF and binomial option methods provide valuation estimates that are less sensitive to 
assumptions regarding the underlying data and as such their outcomes provide a more 
robust foundation for management decisions. 
 
For a biotechnology firm looking to out-licence an early stage product, de novo 
valuation of the product provides an important tool for the negotiation of the terms of 
the deal. Razgaitis (2003) discusses this issue in detail and proposes that, in an open 
competitive market, the likely deal will be structured such that value (and the likelihood 
of value) will be split at around the 25th percentile. The actual terms will depend on the 
assumptions used by both sides in their financial models as well as market forces, thus, 
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there is often variation around the 25th percentile of the distribution of values. In this 
case the biotechnology company would argue for valuation using an eDCF method (the 
binomial lattice data provides misleading statistics as discussed above) whereas the 
licensor would argue for a valuation based on a DCF model. 
 
Table 6-7 Valuation Comparison at Commencement of Phase 1 Clinical Trials 
 DCF eDCF Binomial Binomial Lattice 
Mean -$23,273 -$9,420 -$10,954 $790 
Median -$23,246 -$9,164 -$11,336 $0 
Std Deviation $46,765 $14,165 $16,085 $3,207 
25th Percentile -$55,908 -$19,889 -$21,433 $0 
75th Percentile $8,156 $734 -$717 $0 
Prob V>0 31% 27% 23% 13% 
 
6.4.2 Scenario Analysis Prior to Commencement of Stage 2 Clinical Trials 
Figure 6-9 below shows the probability mass function for the estimates of value prior to 
commencement of phase two clinical trials. As with the valuation estimates prior to 
phase one, the DCF valuation model has the widest dispersion of valuation estimates in 
comparison with the decision tree valuation models. The binomial lattice output is still 
impacted by a high proportion of zero values, making inference of value of the project 
at this stage difficult. The eDCF values are consistently higher than those calculated 
using binomial option methods, however, both these methods give estimates that are 
strongly correlated and similar in magnitude.  
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Figure 6-9 Valuation at Commencement of Phase 2 Clinical Trials – Probability Mass Function 
Comparison between Alternative Valuation Methodologies 
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The data in Table 6-8 show that the eDCF valuation again provides the highest average 
value, that being $15m for a product about to enter phase two clinical trials. Of the 
sample of 1000 simulations, 75% of the eDCF model outcomes were greater than zero. 
Apart from the eDCF model, the binomial valuation method produced valuations with 
the lowest standard deviation and inter quartile range.  
 
The DCF valuation again provides the lowest average value, that being -$3.2m, with 
greatest uncertainty shown by a standard deviation of close to $58m and a larger inter 
quartile range. The standard deviation has increased from the earlier product stage, 
indicating that even though the product has overcome some of the risks associated with 
product development, there is no more certainty regarding value. Despite this, DCF 
valuation predicts that the project has a 47% chance of having a value greater than zero.  
 
Many Australian biotechnology firms require additional funding in order to commence 
phase two clinical trials. Based on valuations for this product, they will struggle to find 
a partner willing to licence in the product at this stage as the 25th percentile value 
remains less than zero. Valuation using the eDCF method gives a likely value to be 
realised in a licensing deal of around -$0.3m which is very low given the costs of 
developing a product to this stage.  
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Table 6-8 Valuation Comparison at Commencement of Phase 2 Clinical Trials 
 DCF eDCF Binomial Binomial Lattice 
Mean -$3,252 $15,265 $11,466 $13,671 
Median -$3,609 $15,178 $10,536 $6,982 
Std Deviation $58,357 $23,165 $25,845 $17,023 
25th Percentile -$44,883 -$263 -$5,621 $0 
75th Percentile $35,191 $30,162 $27,505 $22,803 
Prob V>0 47% 75% 66% 67% 
 
6.4.3 Scenario Analysis Prior to Commencement of Stage 3 Clinical Trials 
Valuation prior to the commencement of phase three clinical trials yields values which 
are significantly greater than those for products in earlier stages of development. The 
binomial lattice is no longer so affected by the high proportion of zero valuations and is 
shown in Figure 6-10 to produce similar results in terms of magnitude and dispersion as 
the eDCF and binomial methods. The eDCF model again estimates values that are 
consistently higher while the DCF valuation has a dispersion which is converging on the 
alternative methods, however values are consistently lower. 
  
Figure 6-10 Valuation at Commencement of Phase 3 Clinical Trials – Probability Mass Function 
Comparison between Alternative Valuation Methodologies 
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All four methods have an average value greater than zero, which is not unexpected 
given that the product has only one remaining clinical trial (albeit the largest and most 
expensive of the three) before NDA submission. The DCF method again has the largest 
uncertainty as indicated by the standard deviation and inter quartile range shown in 
Table 6-9 below. Valuation using the DCF model still only estimates the project value 
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to be positive in 68% of cases, a symptom of the inability of this method to capture the 
possibility of sales significantly higher (or lower) than ‘average’. 
 
Table 6-9 Valuation Comparison at Commencement of Phase 3 Clinical Trials 
 DCF eDCF Binomial Binomial Lattice 
Mean $37,000 $120,202 $110,614 $113,500 
Median $35,670 $117,724 $106,114 $109,362 
Std Deviation $69,796 $51,487 $62,430 $53,882 
25th Percentile -$16,282 $83,346 $69,103 $74,842 
75th Percentile $83,124 $156,490 $153,702 $151,063 
Prob V>0 68% 99% 97% 99% 
 
 
The eDCF and option valuation methods all estimate a 97-99% probability of having 
positive value. The eDCF method again produces the estimate which is least sensitive to 
the underlying input assumptions shown by the lowest standard deviation and inter 
quartile range.  
 
At the 25th percentile of valuation estimates, the eDCF model produces the highest 
estimate of value, followed by the binomial lattice then the binomial tree with the DCF 
model once again producing the lowest estimate. The difference between the outcomes 
of each of the valuation methods highlights the importance that participants in licensing 
negotiations should place on the methodologies used to generate value estimates as the 
foundation for deal terms.  
6.4.4 Scenario Analysis Prior to Regulatory Registration 
After the completion of clinical trials, the product is ready for filing with the regulator 
for NDA approval. Successful completion of the clinical trial process means that the 
project has overcome a significant portion of the risks inherent in the drug development 
pipeline, however, some risk still exists around the receipt of NDA approval. Figure 
6-11 below shows that the values determined using the decision tree models are closely 
correlated with the binomial model producing values with slightly greater positive 
variation.  
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Figure 6-11 Valuation Prior to Product Registration – Probability Mass Function Comparison 
between Alternative Valuation Methodologies 
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The standard deviations for value estimates produced by all methods increased with 
respect to valuations at earlier stages in the product development chain as shown below 
in Table 6-10. The eDCF and binomial lattice methods produced estimates that were 
least sensitive to the underlying input assumptions (shown by low standard deviations 
of value estimates). 
 
Table 6-10 Valuation at Commencement of New Drug Application  
 DCF eDCF Binomial Binomial Lattice 
Mean $166,570 $366,684 $366,611 $366,514 
Median $164,480 $363,099 $364,249 $362,838 
Std Deviation $82,358 $60,268 $64,957 $60,275 
25th Percentile $106,385 $323,886 $320,185 $324,013 
75th Percentile $225,448 $409,259 $411,002 $409,020 
Prob V>0 99% 100% 100% 100% 
 
All methods predict value to be positive with 99-100% probability. Predictably, as per 
earlier discussion, the DCF method again produced the lowest estimates of value. The 
25th percentile estimate of market valuation in the event of a sale of the product 
indicates that application of a decision tree method generates an expected deal price of 
around $320m, a significant increment from the similarly calculated values in the 
previous phase of development.   
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6.4.5 Value Accretion at the 25th Percentile 
Value accretion at the 25th percentile is weighted towards the later stages of the clinical 
trial process as shown below in Table 6-11. The significant acceleration in value 
accretion (at the 25th percentile) as a product moves through the development process 
provides motivation for biotechnology firms to endeavour to maintain ownership of the 
product as long as their resource levels allow. Unfortunately, the amount of capital 
available to Australian biotechnology firms means that few firms are able to fund 
development beyond phase 1 trials before out-licensing to a larger partner.  
 
Table 6-11 Value Accretion at the 25th Percentile between Development Stages ($ ,000) 
 DCF eDCF Binomial Binomial Lattice 
Through Phase 1 $11,025 $19,626 $15,812 $0 
Through Phase 2 $28,601 $83,609 $74,724 $74,842 
Through Phase 3 $122,667 $240,540 $251,082 $249,171 
 
Australian biotechnology companies will likely look to partner with a large 
pharmaceutical company with the experience and expertise to successfully bring the 
product to market. The largest pharmaceutical companies are based outside Australia 
and are foreign owned, thus, once a product is out-licensed from an Australian 
biotechnology firm, subsequent value accretion (resulting from successful development) 
is shared with the international partner. If more value could be retained by locally 
owned and based firms, the potential for these firms to subsequently reinvest in the local 
industry would be increased, improving the long term prospects of the industry. 
Australian shareholders would also benefit from not sharing the generated value with 
foreign listed firms. 
6.5 VALUATION MODEL SENSITIVITIES 
The standard deviations of the value estimates have been discussed in the earlier 
sections however Figure 6-12 provides a visual representation of the evolution of 
valuation uncertainty as the product moves through the development cycle. The DCF 
model generates values with much greater uncertainty, particularly in the earlier stages 
of development. All of the models exhibit greater uncertainty in value estimates of 
projects in the later stages of development when compared to those in earlier stages. 
This should be read in context, given that the value estimates themselves are much 
higher in the later stages of development, thus the level of uncertainty is not as critical. 
In the early stages, a $10m variation in valuation may mean the difference between 
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continuing or abandoning a project, whereas in the later stages $10m may represent less 
than 5% of the project value.  
 
The decision tree models generate estimates with similar levels of uncertainty 
throughout the project. The binomial lattice had the lowest levels of uncertainty in the 
early stages however this is a deceptive result due to the impact of the abandonment 
option (see section 6.4.1), hence reducing the standard deviation of value estimates. 
  
Figure 6-12 Valuation Standard Deviations for Unrestricted Models 
This figure shows the standard deviations of valuation estimates (expressed in $,000) allowing all input 
variables to vary according to the distribution characteristics defined in Table 6-1. 1000 simulations were 
used, generating estimates at four stages in the development cycle; prior to phase 1 clinical trials, prior to 
phase 2 clinical trials, prior to phase 3 clinical trials, and prior to regulatory registration.  
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In this section the four valuation models were tested for sensitivity to the variations in 
the values of the underlying inputs on an individual basis. The models were restricted 
by allowing one input group to vary in isolation for 1000 simulations and fixing all 
other inputs at the mode of their expected values (see Table 6-1). This process was 
repeated for each of the input groups (development time, development cost, salvage 
value, commercialisation cash flows, discount rate, development risk) in order to 
ascertain the influence that each input group has on the valuation estimates for each 
method. The standard deviation of values produced by each of the models was used as a 
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measurement of the influence that each input group had on value and the results are 
shown in graphical format in the subsequent sections.  
 
Generally, the sensitivity in value estimates to each of the specific inputs progressively 
increased as a project moved through the product development stages. Specifically, 
value estimate sensitivity increased for variations in: development time, development 
costs, commercialisation cash flows and discount rate. These results should be 
interpreted with consideration of to the magnitude of the value estimates at each stage. 
 
The values, V, produced by each of the models are a function of each of the specific 
input variables Xi. Thus the sensitivity of the value estimates to the input variables is 
represented by дV/дXi. Monte Carlo simulation was used to generate estimates for дV/дXi 
for each Xi across the range of possible values defined in Table 6-1. To estimate дV/дXi 
all inputs were set at the mode of their expected value, with one input allowed to vary. 
The model was then asked to incrementally vary the unrestricted input through the 
entire specified population for that input. For each data point, value estimates for each 
valuation model were calculated allowing the change in value to be calculated for each 
specified change in input, hence estimating дV/дXi.  
 
This method provides an estimate of дV/дXi for a two dimensional estimation of the 
response surface (as all inputs other than that under investigation were set at their 
expected mode value). This process was repeated for each input variable with the results 
presented in graphical format in the subsequent sections.  
6.5.1 Development Time 
Variation of the time spent developing the product contributes to the uncertainty in 
valuation estimates as shown in Figure 6-13. In the early stages of development, time 
had the greatest impact on estimates produced by the DCF model, with the standard 
deviation of restricted model value estimates greater than double that for early stage 
eDCF estimates. Interestingly, in the later stages of development, the alternative 
valuation models were more influenced by variation in estimates of development time. 
Time was most influential for valuations of projects entering phase 3 clinical trials for 
all valuation methods except eDCF. The binomial model was most affected by 
development time for projects entering or having finished phase 3 clinical trials. 
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Figure 6-13 Valuation Standard Deviations for Restricted Development Time Model 
This figure shows the standard deviations of the valuation estimates (expressed in $,000) for each 
methodology allowing development time to vary and holding all remaining inputs fixed. 1000 simulations 
were used to generate estimates at four stages in the development cycle; prior to phase 1 clinical trials, 
prior to phase 2 clinical trials, prior to phase 3 clinical trials, and prior to regulatory registration.  
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The sensitivity of estimates to time spent in phase 1 clinical trials is shown in Figure 
6-14. The sensitivity to this input reduces as the expected time to complete this stage of 
development increases and the impact of increased development time on values is 
negative. The DCF model is most sensitive to phase one development time with дV/дXi 
ranging from -$300,000 down to less than -$150,000. The alternative valuation methods 
were less sensitive to changes in phase 1 development time with sensitivities in the 
range -$190,000 down to -$80,000. The implication of this finding is that for an 
additional month spent in phase 1 clinical trials, the value estimate for the project was 
reduced by an amount between $80,000 and $300,000. 
 
Figure 6-15 shows the sensitivity of value estimates to time spent in phase 2 clinical 
trials. The sensitivity to this input reduces as the expected time to complete this stage of 
development increases and the impact of increased development time on values is 
negative. The DCF model is again more sensitive than the eDCF and binomial models, 
however, for valuations calculated immediately prior to phase 2 commencement, the 
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alternative methods are more sensitive when phase 2 development time is greater than 
around 51 months. The binomial lattice valuations are most sensitive to phase 2 
development times for values calculated immediately prior to phase 2 commencement. 
The time spent in phase 2 trials has a greater impact on valuations than that spent in 
phase 1 trials with дV/дXi ranging from -$700,000 down to around -$150,000 (excluding 
binomial lattice valuation for phase 1 projects),.  
 
The sensitivity of estimates to time spent in phase 3 clinical trials is shown in Figure 
6-16. The impact of increased development times on value estimates are negative with 
sensitivity reducing as time increases. As with earlier stage models, the DCF model is 
more sensitive than the eDCF and binomial models for valuations calculated 
immediately prior to commencement of phase 1 or phase 2 trials. Prior to the 
commencement of phase 3 clinical trials the DCF model is substantially less sensitive 
than the alternative methods with one additional month in phase 3 trials reducing DCF 
values by around half as much as the corresponding alternative valuation models. дV/дXi 
ranges from -$2500,000 down to around -$250,000 (excluding binomial lattice 
valuation for phase 1 projects), with the time spent in phase 3 trials having a greater 
impact on valuations than that spent in phase 1 or 2 trials. A project entering phase 3 
trials will face a reduction in value of between -$2,500,000 and -$500,000 for each 
additional month that the phase 3 trial is expected to run. 
 
 The sensitivity of estimates to time spent in regulatory assessment is shown in Figure 
6-17. The sensitivity to this input reduces as the expected time to complete this stage of 
development increases and the impact of increased development time on values is 
negative. The DCF model is again more sensitive than the eDCF and binomial models 
for valuations calculated immediately prior to commencement of phase 1 or phase 2 
trials. Prior to the commencement of phase 3 clinical trials and again prior to regulatory 
filing, the DCF model is substantially less sensitive than the alternative methods with 
one additional month in regulatory assessment reducing DCF values by around half as 
much as the corresponding alternative valuation models. The sensitivity of the value 
estimate, дV/дXi, ranges from -$3700,000 down to around -$250,000 (excluding 
binomial lattice valuation for phase 1 projects), with the valuations being more sensitive 
to movements in the time spent in NDA assessment than that in phase 1, 2, or 3 trials. A 
project entering phase 3 trials will face a reduction in value of between -$2,500,000 and 
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-$900,000 for each additional month that the regulatory assessment is expected to run. 
For a project that has finished phase 3 trials the impact of an additional month of 
assessment time jumps to between -$3,700,000 and -$1,200,000. 
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6.5.2 Development Costs 
The impact of variation in development costs on valuation uncertainty is shown in 
Figure 6-18. The DCF model was the most sensitive to variation in development costs 
for early stage projects with the standard deviation of restricted model value estimates 
greater than double that for early stage alternative model estimates. Upon completion of 
clinical trials, the impact of cost was significantly less as a result of the substantially 
reduced costs associated with regulatory assessment as compared with clinical trials 
(see Table 6-1). For all models, cost had the most influence on valuation estimates for 
values calculated prior to the commencement of phase 3 trials. 
 
Figure 6-18 Valuation Standard Deviations for Restricted Development Cost Model 
This figure shows the standard deviations of the valuation estimates (expressed in $,000) for each 
methodology allowing development costs to vary and holding all remaining inputs fixed. 1000 
simulations were used to generate estimates at four stages in the development cycle; prior to phase 1, 2 
and 3 clinical trials and prior to regulatory registration.  
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Figure 6-19 shows the sensitivity of valuation estimates to phase 1 clinical trial costs. 
The sensitivity to this input is constant for all expected values (excluding the binomial 
lattice valuations which are affected by the abandonment option). The binomial model 
is most sensitive to changes in expected phase 1 development costs with a $1 reduction 
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in cost increasing value by the same amount. The reason that the change in value is 
directly offset by the change in costs is due to the assumption in the binomial model that 
the development costs are incurred at the beginning of that phase, thus, the time value of 
money does not impact this cost. The DCF and eDCF models expect a reduction in 
value of around $0.90 for a $1 reduction in development cost.  
 
The sensitivity of estimates to phase 2 clinical trial costs is shown in Figure 6-20. As 
expected, the time value of money dictates that the greater the time between the point of 
valuation and the incurring of the cost, the less the cost impacts on expected value. For 
valuations conducted prior to the commencement of phase 1 trials, the DCF model is 
most sensitive to changes in the expected cost of phase 2 trials. DCF values reduced by 
around $0.80 for a $1 increase in costs versus eDCF and binomial values which reduced 
by slightly less than $0.60. Conversely, if costs are reduced the corresponding value 
gain is greatest for DCF valuation estimates.  
 
The sensitivity of estimates to phase 3 clinical trial costs is shown in Figure 6-21. For 
valuations conducted prior to the commencement of phase 1 trials, the DCF model is 
again most sensitive to changes in the expected cost of phase 3 trials. DCF values 
reduced by around $0.65 for a $1 increase in costs versus eDCF and binomial values 
which reduced by slightly more than $0.20. Prior to the commencement of phase 2 trials 
the difference remains substantial but is less pronounced, around $0.75 versus $0.35.  
 
The DCF model remains the most sensitive to changes in the expected regulatory 
registration costs for valuations prior to phase 1 trials, as shown in Figure 6-22. DCF 
values reduced by around $0.55 for a $1 increase in costs versus eDCF and binomial 
values which reduced by slightly more than $0.15. The binomial lattice model produced 
values with sensitivities greater than the eDCF and binomial models but less than the 
DCF for projects in all development stages excluding those directly due to commence 
regulatory registration.  
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6.5.3 Salvage Values 
Variation of salvage value, should the project be abandoned and sold, contributes to the 
uncertainty in valuation estimates as shown in Figure 6-23. The standard deviation in 
value estimates caused by variation in salvage values was greatest for projects having 
completed phase 1 and about to enter phase 2 clinical trials. The magnitude of variation 
is significantly less, with standard deviations between $10,000 and $80,000. In the later 
stages of development, the potential value of a fully developed drug grows significantly 
in relative terms compared with the potential salvage value, thus the influence of 
salvage value on project value reduces once the product moves in to phase 2 clinical 
trials. 
 
The DCF and binomial lattice methods do not incorporate salvage values as one of the 
model inputs, thus salvage values are therefore not relevant to value estimates for these 
methods. The impact on eDCF and binomial models was similar with the binomial 
model slightly more affected by variations in salvage values. 
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Figure 6-23 Valuation Standard Deviations for Restricted Salvage Value Model 
This figure shows the standard deviations of the valuation estimates (expressed in $,000) for each 
methodology allowing salvage value to vary and holding all remaining inputs fixed. 1000 simulations 
were used to generate estimates at four stages in the development cycle; prior to phase 1 clinical trials, 
prior to phase 2 clinical trials, prior to phase 3 clinical trials, and prior to regulatory registration.  
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The sensitivity of estimates to salvage value after phase 1 clinical trial failure is shown 
in Figure 6-24. Sensitivity to this input is constant for all phase 1 salvage values with 
the binomial model being more sensitive to changes in value. A $1 increase in the 
expected salvage value increases the expected valuation produced by the eDCF model 
by around $0.25 versus around $0.33 for the binomial model. As the expected salvage 
values are low, the expected impact of salvage value on product value is small. 
 
Value estimates are more impacted by salvage values after a phase 2 clinical trial failure 
than phase 1 as shown in Figure 6-25. Due to the time value of money, the impact of 
phase 2 salvage values is most influential on those estimates produced immediately 
prior to the commencement of phase 2 trials. The binomial model is again more 
sensitive to changes in the expected salvage value with дV/дXi for valuations prior to 
phase 2 commencement with a $1 increase in salvage value increasing value estimates 
by around $0.50 versus $0.45 for the eDCF model. Valuation prior to phase 1 
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commencement produces very similar sensitivities to phase 2 salvage values of around 
$0.30. 
 
The sensitivity of estimates to salvage value after phase 3 clinical trial failure is shown 
in Figure 6-26. Valuation estimates are less sensitive to changes in phase 3 salvage 
values than earlier salvage values. Interestingly, in contrast to phase 1 and 2 salvage 
values, the binomial model is less sensitive to changes in phase 3 salvage values than 
the eDCF model for valuations at all development stages.  
 
The probability of successful regulatory registration is assumed at 90% which reduces 
the impact that salvage value after regulatory assessment failure has on product value 
shown in Figure 6-27. As well as having reduced impact on product valuations, the 
differential in дV/дXi between the eDCF and binomial models are close to zero. 
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6.5.4 Commercialisation Cash Flows 
Variation of the commercialisation cash flows contributes to the uncertainty in valuation 
estimates as shown in Figure 6-28. In all stages of development, commercialisation cash 
flows had the greatest impact on estimates produced by the DCF model. The difference 
was most significant in the early stage valuations with standard deviations of around 
$40m for the DCF model compared with less than $10m for the alternatives. This 
difference is particularly relevant given that an early stage project will often have a 
value of less than $10m.  
 
For later stage valuations, the influence of commercialisation cash flows had a greater 
influence on the values for all methods as the impact of the time value discount 
diminished. All three alternative valuation methods were similarly influenced by the 
commercialisation cash flows throughout development, however, the binomial lattice 
was again less influenced for very early stage valuations due to the impact of the zero 
values predicted at project abandonment events. 
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Figure 6-28 Valuation Standard Deviations for Restricted Commercialisation Cash flows Model 
This figure shows the standard deviations of the valuation estimates (expressed in $,000) for each 
methodology allowing commercialisation cash flows to vary and holding all remaining inputs fixed. 1000 
simulations were used to generate estimates at four stages in the development cycle; prior to phase 1, 2 
and 3 clinical trials and prior to regulatory registration.  
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The DCF model does not take into consideration any commercial outcomes other than 
the “average” expectation, effectively assuming that the probability of this outcome is 
fixed at 100%, thus, this variable only influences the eDCF, binomial and binomial 
lattice models. The sensitivity of estimates to the expected likelihood that an “average” 
sales outcome will be achieved is shown in Figure 6-29. The instantaneous grade. 
дV/дXi, is constant for all probabilities and for all decision tree models at the same 
development phase. Sensitivity to this input is greatest for valuations immediately prior 
to regulatory registration, again due to the time value of money and the impact that this 
variable has on commercialisation cash flows. дV/дXi varies between -$500m and -
$100m implying that for a 1% increase in the probability of an “average” revenue 
outcome, the expected valuation is reduced by between $5m and $1m depending on 
project maturity.  
 
The sensitivity of estimates to the expected revenues for an “average” sales outcome is 
shown in Figure 6-30. As the DCF model is most sensitive to this input as it does not 
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consider any alternative commercialisation outcomes. As expected, the later stage 
valuations are most influenced by variation in this factor which influences expected 
commercialisation cash flows. For valuations immediately prior to regulatory 
registration, the DCF model forecasts that a $1 increase in expected “average” revenue 
created a $1.10 increase in value whilst the alternative models expect a more modest 
$0.60 increase in value.  
 
The sensitivity of estimates to the expected revenues for “non-average” sales outcomes 
are shown in Figure 6-31. The DCF model is not sensitive to changes in this input. As 
expected, for all decision tree models the later stage valuations are most influenced by 
variation in this factor which impacts expected commercialisation cash flows. 
Interestingly, despite the differing “non-average” commercialisation outcomes existing 
on different branches of the decision tree (see dog, below average, above average and 
blockbuster in Figure 6-3), дV/дXi is constant for all changes in revenue across each of 
these outcomes. The sensitivity to “non-average” revenue expectations is less than that 
for “average” revenue expectations for all three decision tree models. Despite this, the 
larger range in possible “non-average” revenues means that the range in values 
estimates produced is similar to the range produced by fluctuating “average” revenues.  
 
The DCF model is most sensitive to changes in post approval research and development 
time for valuations at all stages in development as shown in Figure 6-32. For all models 
дV/дXi is not constant, reducing as time increases although remaining positive across the 
range of times specified. The sensitivity of all models to changes in post approval time 
means that for a product about to commence regulatory filing, the expected impact of 
post approval research and development time is a decrease in value of between $0.7m 
and $3.5m for each additional month expected to be spent on this research.  
 
The sensitivity of estimates to the expected post approval research and development 
costs is shown in Figure 6-33. The DCF model is again most sensitive to changes in this 
input across all stages in development. For all models, дV/дXi is constant, hence 
regardless of the anticipated expenditure, the three alternative valuation methods have 
equal sensitivities. For a product about to submit for regulatory approval, the expected 
impact of this variable on value estimated by the alternative models is a decrease in 
value of $0.26 for each additional dollar of anticipated research and development 
Chapter 6 – Critical Evaluation of Contemporary Valuation Methodologies 
- 188 - 
expenditure. This compares with the DCF model which expects a decrease in value of 
$0.37 for each additional $1 of post approval research and development expenditure. 
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6.5.5 Discount Rate 
In the early stages of development, discount rates had the greatest impact on estimates 
produced by the DCF model, with the standard deviation of restricted model value 
estimates greater than double that for early stage alternative model estimates as shown 
in Figure 6-34. Interestingly, upon completion of phase 2 clinical trials, the impact of 
discount rates on valuations produced by the alternative valuation methods increased 
significantly to produce estimates with standard deviations greater than those produced 
by the DCF model. For all three alternative methods, the impact of discount rates was 
similar, however, the binomial lattice was again less influenced for very early stage 
valuations due to the impact of abandonment events.  
 
Figure 6-34 Valuation Standard Deviations for Restricted Discount Rate Model 
This figure shows the standard deviations of the valuation estimates (expressed in $,000) for each 
methodology allowing discount rates to vary and holding all remaining inputs fixed. 1000 simulations 
were used to generate estimates at four stages in the development cycle; prior to phase 1,2 and 3 clinical 
trials and prior to regulatory registration.  
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Only the DCF and eDCF models are sensitive to changes in this variable due to the 
manner in which the two option pricing models treat and discount expected 
development costs as shown in Figure 6-35. The option models treat development stage 
costs as the strike price of the option to continue research and development into the 
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subsequent stage (as discussed in section 6.2). These models rely on the principle of the 
risk neutral replicating portfolio which allows the option values to be discounted at the 
risk free rate. As a result, the exercise prices (development costs) are not discounted at 
the development stage discount rate, but instead at the lower risk free rate.  
 
The DCF and eDCF models both have a positive and reducing дV/дXi. As this discount 
rate is used to discount negative cash flows (costs), the greater the discount rate, the 
smaller the present value of costs, and hence the greater the expected value of the 
product. The DCF model is more sensitive to the development discount rate, 
particularly in the early stages of development. For a product entering in phase 1 
clinical trial a 1% increase in development phase discount rate equates to an increase in 
DCF expected value of between $3.3m and $3.8m, whereas the corresponding eDCF 
increase is between $1.3m and $1.5m. 
 
The sensitivity of estimates to commercialisation stage discount rates is shown in Figure 
6-36. All models are sensitive to changes in this variable with дV/дXi negative and 
reducing across the range of expected discount rates. In early stages of development 
(valuations prior to phase 1 or phase 2 clinical trials) the alternative models are less 
sensitive to the commercialisation discount rate than the DCF model, however, the 
situation is reversed for valuations of more mature products.  
 
The valuations are more sensitive to changes in the commercialisation discount rate than 
the development stage rate. For a product entering in phase 3 clinical trial a 1% increase 
in commercialisation phase discount rate equates to a decrease in DCF expected value 
of between $15m and $20m, whereas the corresponding alternative models expect a 
decrease of between $23m and $30m. 
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6.5.6 Development Risk 
The effects of variation in development risks on the standard deviation of value 
estimates are shown in Figure 6-37. The standard deviation in value estimates caused by 
variation in development risks were greatest for projects entering phase three clinical 
trials.  
 
The DCF model does not directly include the success probabilities as a valuation input. 
This risk is included indirectly as the discount rate is chosen to reflect all risks 
associated with the cash flows being forecast. For this reason, variation in the success 
probabilities had no impact on values produced by the DCF model. For all three 
alternative methods the impact of development risks were similar, however, the 
binomial lattice was again less influenced for very early stage valuations due to the 
impact of the zero values adopted in the modelled project abandonment events.   
 
Figure 6-37 Valuation Standard Deviations for Restricted Development Risk Model 
This figure shows the standard deviations of the valuation estimates (expressed in $,000) for each 
methodology allowing expected development risks to vary and holding all remaining inputs fixed. 1000 
simulations were used to generate estimates at four stages in the development cycle; prior to phase 1, 2 
and 3 clinical trials and prior to regulatory registration.  
$0
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The sensitivity of estimates to risk of phase 1 clinical trial failure is shown in Figure 
6-38. Sensitivity to this input is constant for all expected phase 1 success probabilities, 
with the eDCF being less sensitive to changes in success probability than the binomial 
model. The binomial lattice model is not influenced by variation in this input at this 
early stage due to the zero value adopted for the abandonment alternative. A 1% 
increase in the expected success probability increases the expected valuation produced 
by the eDCF model by around $190,000 versus around $195,000 for the binomial 
model. 
 
The дV/дXi values are higher (for X equals to the probability of phase 2 clinical trial 
success) than those for phase 1 as shown in Figure 6-39. The eDCF model is the most 
sensitive immediately before commencement of phase 2 clinical trials. The binomial 
lattice is least sensitive to changes in expected success probability, a 1% increase in the 
expected success probability increasing the expected valuation produced by the eDCF 
model by around $1.1m versus around $1.05m for the binomial model and $0.95m for 
the binomial lattice. 
 
The sensitivity of estimates to the expected phase 3 clinical trial success probabilities 
are shown in Figure 6-40. The дV/дXi values are higher than those for phase 1 or 2 
success probabilities and the alternative models are now equally sensitive to variation in 
expected success probability (where the binomial lattice is not impacted by zero value 
abandonment option). Variation in expected value for fluctuation in this variable is 
similar to that expected for the other stage development rates with 1% increase in the 
expected success probability increasing expected valuations by $0.6m, $1.0m and 
$2.9m for valuations prior to phase 1, 2, and 3 clinical trials respectively. 
 
Figure 6-41 shows the sensitivity of value estimates to variation in the expected 
probability of successful regulatory registration with дV/дXi values similar, but slightly 
less than, the previous development phase expectations. A 1% increase in the expected 
success probability of NDA filing increases expected valuations by $0.5m, $0.9m and 
$2.4m and $4.2m for valuations prior to phase 1, 2, 3 clinical trials and regulatory filing 
respectively. The impact of a 1% change in the expected success probability on the 
value of a project immediately prior to regulatory submission provides a clear signal 
regarding the importance of the quality of the regulatory submission. 
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6.6 VALUATION METHODOLOGY CHOICE IMPLICATIONS 
Reducing valuation uncertainty improves management’s ability to efficiently allocate 
resources and ensure shareholder returns are maximised. Similarly, reduced valuation 
uncertainty reduces a potential investor’s risk exposure, and with improving risk-return 
characteristics the amount of money being invested in drug development projects should 
increase. 
6.6.1 Management 
The reduced variation in the value estimates produced by the decision tree models offers 
management the opportunity to more effectively manage existing projects and assess 
potential new projects. With greater valuation certainty, management is less likely to 
misjudge the value of a potential project and miss an attractive investment opportunity. 
 
The eDCF model is easily constructed using commonly understood and applied DCF 
principles. The eDCF model produces value estimates with reduced uncertainty, and 
which equitably incorporates a wide variety of potential outcomes. Simple DCF 
analysis offers a useful tool for valuing opportunities, however, the benefits derived 
from incorporating a greater level of detail in to an eDCF model appear to more than 
outweigh the slight increase in workload required to construct this model.  
 
For early stage products, the option to abandon the project if unfavourable conditions 
eventuate may increase the expected value of the project. The option pricing models are 
able to incorporate the value benefits from abandonment and these tools may enable 
management to more effectively manage their product portfolio. 
 
The cash flows generated by the final product were the major driver of value for 
biotechnology products in all stages of development based on the results for four 
valuation methods included in this analysis. Thus management considering investment 
in biotechnology products need to carefully assess the commercial viability of the end 
product. Similarly, managers of a product under development need to carefully monitor 
the commercialisation landscape as a change in conditions may mean that value 
maximisation is achieved through project abandonment. This is particularly important 
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given that the sensitivity of value estimates to commercialisation cash flows increased 
as the product moved through the development process. 
 
Through the development process, management are able to directly influence value 
most through cost containment. However rather than embarking on substantial cost 
reduction strategies, management needs to be aware of the influence that development 
time also had on value estimates. Whilst cost had a greater impact on value, a reduction 
in expenditure may place the product at risk of increased time spent in development, 
offsetting the impact of reduced cost on value. 
 
For projects entering the regulatory registration, value estimates were significantly more 
influenced by the time under assessment than the cost of assessment. Thus it is 
important that firms have open communication with the regulator throughout 
development to ensure that the submission meets the regulators expectations. During the 
assessment period, firms should place a high priority on assisting the regulator, ensuring 
that any queries are addressed in a timely manner. 
 
The probability of successful development had less influence on value than commercial 
viability, development cost and development time. Thus when comparing two potential 
projects with similar commercial opportunities, management should focus their 
attention on the speed with which the product could be developed and at what cost 
rather than the probability of success. Whilst the probability of success may not be the 
most important driver of value, for cash strapped Australian biotechnology firms, the 
success of the firm often depends on the success of one or two lead products in their 
portfolio, thus, probability of successful development is of greater significance.  
6.6.2 Investors 
Improved value assessments by investors will allow investors to more accurately assess 
potential biotechnology investments and should facilitate a more efficient allocation of 
investment money. By shifting capital away from underperforming firms towards 
relatively undervalued higher potential firms, an increase in capital should be made 
available to those firms best able to apply those funds, successfully develop their 
portfolios and generate shareholder returns. 
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Considering the value of a biotechnology firm as the sum value of its portfolio of 
products allows investors to value a firm using “sum-of-parts” valuation. The eDCF 
model offers investors a simple mechanism to reduce the level of uncertainty in their 
investments compared with those assessed using simple DCF analysis.  
 
The value benefit from the incorporation of abandonment options into a valuation 
depends on management’s ability to identify those projects which would have their 
value maximised by abandoning or halting development. Investors should be wary of 
including the value benefits of abandonment options in their models as management 
may not possess the tools to allow continuous and efficient identification of those 
underperforming projects. This being the case, investors may overvalue abandonment 
options, thus investors should be wary of including abandonment value in their 
assessments without knowledge of management’s project evaluation and 
implementation practice. 
 
For investors analysing a biotechnology firm for potential investment, the ability of the 
management team to influence the primary value drivers should be assessed. If the final 
product is deemed to have strong commercial opportunities then investors should assess 
the likelihood that management will be able to cost effectively meet regulatory 
requirements in a timely manner. The majority of Australian firms do not have access to 
sufficient capital to fully develop a product, thus investors should also assess the 
potential development partners as part of their assessment. The major pharmaceutical 
companies likely to partner an Australian biotechnology firm have a track record of 
product development, providing investors with some insight into the ability of those 
firms to manage the development process.  
 
Throughout the development process the discount rate applied to the commercialisation 
cash flows had a greater impact on value than the development stage discount rate. It is 
important that investors test valuation models for sensitivity to discount rate 
assumptions prior to deciding on a choice of action.  
6.7 CONCLUSION 
The DCF valuation model is the simplest model to construct and is widely understood 
and applied by practitioners today. A simple DCF valuation can be expanded into an 
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eDCF model by incorporating alternative potential outcomes into the cash flow 
estimates. This process is relatively simple and does not require significant additional 
financial expertise. For biotechnology projects this has the potential to reduce 
investment uncertainty and, depending on the outcomes included in the model, can 
increase the estimated value of the project. 
 
The difference in standard deviations (see Figure 6-12) of the value estimates produced 
by the four unrestricted valuation models described in section 6.2 implies that the there 
is greater uncertainty in valuations produced by the traditional DCF model. By using 
alternative valuation methodologies, projects can be valued with greater precision, 
particularly in the early stages of development when Australian biotechnology firms 
battle for sufficient capital to fund necessary research and development costs. 
 
Through utilisation of the risk neutral valuation concept, the option pricing models were 
expected to estimate values consistently higher than those predicted by the eDCF 
model. The increase was expected due to the apparent “double counting” of risk in the 
eDCF model whereby project success rates were specifically modeled, whilst the 
discount rate was the same as those used for the DCF model which were based on 
CAPM analysis of drug development firms. The similarities between value estimates of 
the option models and the eDCF model suggest that the project success rates represent 
diversifiable risk which is not captured by the CAPM risk quantification. 
 
Whilst the option pricing models analysed in this thesis were not significantly more 
complex than the eDCF model, these models are less understood and applied by 
financial practitioners (Hartmann and Hassan 2006). These models require a greater 
understanding of financial instruments than the eDCF model however they may not 
produce valuation estimates providing any greater insight than the more recognised 
alternatives.  
 
By incorporating management ability to flexibly manage a project throughout its life, 
specifically the option to abort a project, value estimates for early stage projects are 
greater than would otherwise be the case. In later stage projects the abandonment option 
is less significant because the product is closer to market launch and the option to 
abandon is less likely to be of greater value than the option to continue development. 
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Value in biotechnology firms is driven by the commercial viability of the products 
under development. Managers and investors should be continuously focused on the 
likely commercial outcomes from the products in development. Development costs and 
times are also key drivers of value and the ability of management to control these 
elements with consideration of the relationship between these two elements is an 
important driver of value.  
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CHAPTER 7 CONCLUSION 
7.1 INTRODUCTION 
The Australian biotechnology industry must overcome significant challenges in order to 
fully capitalise on the competitive advantages of the local industry and successfully 
compete in a global market. Whilst biotechnology research and development is typified 
by long lead times and significant capital requirements, significant uncertainty also 
exists around investment returns. The underlying uncertainty of investment in 
biotechnology assets has acted as a deterrent to biotechnology investment in Australia, 
restricting our ability to compete with larger more mature markets.  
 
The three components of this research combine to describe the challenges and 
opportunities surrounding the Australian biotechnology industry. Insight into the drivers 
of value in biotechnology investments is provided through quantitative investigations 
into biotechnology value drivers at the firm and project level.  
7.2 SUMMARY OF THESIS 
The central focus of this investigation was an investigation into the value drivers for 
Australian biotechnology firms. This focus formed the nexus between the multiple 
research methods. The primary research question addressed in this thesis is:  
• What are the appropriate valuation models for Australian biotechnology firms? 
 
The focus of each of the discussion chapters addresses the following key secondary 
research questions:  
• What are the challenges and opportunities for Australian biotechnology firms? 
(Chapter 4) 
• What factors internal and external to the firm impact the amount of capital raised 
by Australian biotechnology companies through IPOs? (Chapter 5) 
• What is the appropriate methodology for valuation of biotechnology 
investments? And, what are the key drivers of value for Australian 
biotechnology companies? (Chapter 6) 
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First Chapter 2 introduces the Australian biotechnology industry in the context of a 
global competitive market via a review of the existing literature. One of the key barriers 
to success in the Australian industry is the inability of Australian firms to raise 
commercialisation capital, particularly when compared to our international competitors. 
As a result of the funding shortfall, Australian biotechnology firms have historically 
turned to the public markets for capital at an earlier stage than in other countries, 
particularly the US, whose biotechnology industry is the most successful in the world. 
For any company, an IPO is one of the most important capital raisings in that 
company’s life, however, for a biotechnology company, this is exacerbated by the 
capital intensive nature of biotechnology R&D and the difficulty in raising additional 
funds after IPO.  
 
The research methodology is discussed in Chapter 3 which describes a multi-method 
approach to investigate the multi-faceted aspects of the valuation challenges facing 
Australian biotechnology companies. A qualitative investigation of the issues facing 
Australian biotechnology companies formed a broad foundation, providing context for 
the two focused quantitative research components. The two quantitative components of 
this research delve into the issue of biotechnology valuation at the firm and project 
level. An analysis of biotechnology initial public offerings provides insights into the key 
value drivers for firms during this critical capital raising period. Additionally, Monte 
Carlo simulation of contemporary valuation models provides insight into the key value 
drivers for a biotechnology project with implications for both managers and investors. 
 
The first of three results and discussion chapters is presented in Chapter 4 which 
presents a broad qualitative investigation into challenges and opportunities facing the 
Australian biotechnology sector. The overwhelming theme to emerge from this analysis 
was the funding challenge that the Australian sector faces compared to larger 
international competitors. The structure of the industry was found to encourage creation 
of small firms with narrow pipelines, exacerbating the risk of company failure and 
acting as an impediment to sustainability and investment in the sector. Despite the 
challenges facing the Australian biotechnology industry, the nation possesses a 
competitive advantage in the strength of local science which, if fully leveraged, should 
see the development of an internationally competitive industry. Through improved 
funding mechanisms which encourage the creation of sustainable business models, 
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increased investor participation in the industry should see a greater portion of the value 
generated through biotechnology retained by local participants.  
 
An IPO is likely the largest single capital raising in a company’s history. Chapter 5 
provided a quantitative investigation into the factors which influence the amount of 
underpricing and money left on the table for Australian biotechnology IPOs and found 
that the amount of money left on the table was more critical than the level of 
underpricing. Additionally the impact of market sentiment on biotechnology IPOs was 
investigated and increased media coverage in the lead up to IPO was found to be 
positively related to the amount of money left on the table.  
 
Chapter 6 provided an additional exploration into the factors influencing biotechnology 
value. Using project valuation models the drivers of value over the life of a typical 
biotechnology project were identified. Value in biotechnology firms is driven by the 
commercial viability of the products under development. Managers and investors should 
be continuously focused on the likely commercial outcomes from the products in 
development. Development costs and times are key drivers of value and the ability of 
management to control these elements is crucial.  
 
Using alternative valuation methodologies for a typical biotechnology project, Chapter 
6 provided insight into the issue of value estimation and uncertainty. A traditional DCF 
model generated value estimates for a typical biotechnology project with a greater level 
of uncertainty than the more contemporary methods of decision trees analysis (eDCF 
and binomial real options) and binomial lattices. Additionally, DCF models are not able 
to quantify the benefits of management flexibility. Incorporation of management 
flexibility into the valuation assessment using real options techniques increased the 
perceived value of biotechnology projects, particularly for early stage projects where the 
option to abandon was found to greatly influence values generated.  
7.3 KEY CONTRIBUTIONS OF THESIS 
This thesis provides a clearer understanding of the challenges and opportunities facing 
the local industry and investigates the issue of valuation uncertainty in a quantitative 
framework. Biotechnology valuation is an issue that has been discussed at length in the 
literature however significant uncertainty continues to exist surrounding the most 
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appropriate valuation models and value drivers for biotechnology products. The major 
contribution of this thesis is the investigation into the value drivers for biotechnology 
products and those factors which significantly influence the valuation of biotechnology 
IPOs in an Australian context.  
 
Some of the specific findings presented in this thesis include: 
• The current structure of funding mechanisms in Australia encourages smaller 
firms with narrower product pipelines. 
• Australian biotechnology firms are often forced to raise capital via an IPO due to 
a lack of alternative funding sources.  
• Due to funding challenges Australian firms often sell a portion of their IP prior 
to development to a point that would allow an optimal risk return payoff.  
• Merger and acquisition activity between existing firms should be encouraged to 
improve firm survival prospects and reduce the risk of firm failure. 
• An excess of “uneducated” investment money in biotechnology exposes the 
industry to greater sentiment driven fluctuations in value and allows poorer 
performing firms to retain capital that would otherwise flow to higher potential 
firms. 
• Increased investor interest in the sector will drive improved analyst coverage 
leading to more efficient allocation of capital 
• Money left on the table at IPO is more critical than underpricing for Australian 
biotechnology companies 
• Australian biotechnology companies with a developed product leave less money 
on the table at IPO 
• Australian biotechnology companies who engage a reputable accountant to audit 
their prospectus financials leave less money on the table at IPO 
• Australian biotechnology companies with a larger number of patents and patent 
applications leave more money on the table at IPO 
• The more times Australian biotechnology company staff publications were cited, 
the greater the amount of money on the table at IPO 
• In times of rising investor sentiment more money is left on the table by 
Australian biotechnology IPOs 
• Media exposure is a superior proxy for sentiment for Australian biotechnology 
IPOs 
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• Valuation estimates incorporating decision tree analysis have lower levels of 
uncertainty for assessment of biotechnology project value than standard DCF 
models. 
• Real option analysis captures the value of management flexibility and increases 
perceived project value, particularly for early stage biotechnology projects. 
• Commercialisation cash flows are the major driver of value for a biotechnology 
project. 
• The sensitivity of valuation estimates to commercialisation cash flows increases 
as the project moves through the development process 
• Development time, costs and project success are important drivers of value 
which should be considered by biotechnology project investors and managers 
alike. 
7.4 DIRECTIONS FOR FUTURE RESEARCH 
By definition the biotechnology sector covers a diverse range of business sectors. Due 
to the breadth of this definition and the relatively small size of the Australian 
biotechnology industry this study focuses on the drug development sub-sector which 
comprises the majority of Australian biotechnology companies. Despite the size of the 
drug discovery sub-sector, other sub-sectors within the biotechnology definition such as 
agbio and biomechanics provide an important contribution to the Australian economy 
and warrant further study into their specific challenges, opportunities and value drivers.  
 
To control costs, interview participants for the qualitative component of this study were 
chosen from biotechnology firms based in Victoria, home to the greatest number of 
biotechnology firms in Australia. Additional interviews with biotechnology firms based 
in alternative locations would provide a broader sample set and enable a comparison of 
the difference (if any) commercial environments for biotechnology across Australia. 
 
The quantitative analysis of Australian biotechnology company IPOs gathered data for 
all the reasonably available biotechnology listing data up to 2004 which gave a total of 
34 companies. Additional data points to include recently listed biotechnology firms 
would add to the robustness of conclusions drawn from this stage of the research. 
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The quantitative analysis of contemporary valuation techniques relies on publicly 
available data relating to the probability of successfully negotiating the clinical trials 
and regulatory approval. This information is predominantly US based due to the lack of 
Australian data available. A useful extension to this study would be collection of 
Australian drug development data for comparison with the international figures. 
Currently the Australian biotechnology industry has not generated a sufficient volume 
of data for consideration in isolation however this will change as the industry evolves. 
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